{
    "data_version": "master",
    "facets": {
        "unique_drugs": 41,
        "associated_targets": 1,
        "associated_diseases": 140,
        "clinical_trials": {
            "Phase 0": 9,
            "Phase IV": 59,
            "Phase I": 816,
            "Phase II": 1438,
            "Phase III": 304
        },
        "drug_type_activity": {
            "Small molecule": {
                "drug_negative_modulator": 1802
            },
            "Antibody": {
                "drug_negative_modulator": 817,
                "up_or_down": 700
            }
        }
    },
    "data": [
        {
            "status": "Active, not recruiting",
            "count": 1,
            "drug_type": "Small molecule",
            "drug_label": "LAPATINIB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 0,
            "disease_id": "EFO_0000305",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase 0",
            "disease_name": "breast carcinoma",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00331630%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL554"
        },
        {
            "status": "Completed",
            "count": 1,
            "drug_type": "Small molecule",
            "drug_label": "ERLOTINIB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 0,
            "disease_id": "EFO_0006859",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase 0",
            "disease_name": "head and neck malignant neoplasia",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00601913%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL553"
        },
        {
            "status": "Recruiting",
            "count": 1,
            "drug_type": "Small molecule",
            "drug_label": "BRIGATINIB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 0,
            "disease_id": "EFO_0003060",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase 0",
            "disease_name": "non-small cell lung carcinoma",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT03707938%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL3545311"
        },
        {
            "status": "Recruiting",
            "count": 2,
            "drug_type": "Small molecule",
            "drug_label": "DACOMITINIB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 0,
            "disease_id": "EFO_0001071",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor",
                "Epidermal growth factor receptor inhibitor"
            ],
            "clinical_trial_phase_label": "Phase 0",
            "disease_name": "lung carcinoma",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT03755102%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT03755102%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL2110732"
        },
        {
            "status": "Recruiting",
            "count": 1,
            "drug_type": "Small molecule",
            "drug_label": "ERLOTINIB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 0,
            "disease_id": "EFO_0003060",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase 0",
            "disease_name": "non-small cell lung carcinoma",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT02468661%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL553"
        },
        {
            "status": "Terminated",
            "count": 1,
            "drug_type": "Small molecule",
            "drug_label": "LAPATINIB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 0,
            "disease_id": "EFO_0000292",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase 0",
            "disease_name": "bladder carcinoma",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT01245660%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL554"
        },
        {
            "status": "Terminated",
            "count": 1,
            "drug_type": "Small molecule",
            "drug_label": "LAPATINIB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 0,
            "disease_id": "EFO_0000311",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase 0",
            "disease_name": "cancer",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT01427322%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL554"
        },
        {
            "status": "Withdrawn",
            "count": 1,
            "drug_type": "Small molecule",
            "drug_label": "ERLOTINIB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 0,
            "disease_id": "EFO_0003060",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase 0",
            "disease_name": "non-small cell lung carcinoma",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT02277457%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL553"
        },
        {
            "status": "Active, not recruiting",
            "count": 1,
            "drug_type": "Small molecule",
            "drug_label": "AFATINIB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 1,
            "disease_id": "EFO_0000181",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase I",
            "disease_name": "head and neck squamous cell carcinoma",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT01783587%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL1173655"
        },
        {
            "status": "Active, not recruiting",
            "count": 1,
            "drug_type": "Small molecule",
            "drug_label": "AFATINIB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 1,
            "disease_id": "EFO_0002618",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase I",
            "disease_name": "pancreatic carcinoma",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT02975141%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL1173655"
        },
        {
            "status": "Active, not recruiting",
            "count": 2,
            "drug_type": "Small molecule",
            "drug_label": "AFATINIB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 1,
            "disease_id": "EFO_0003060",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase I",
            "disease_name": "non-small cell lung carcinoma",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT01999985%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT02364609%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL1173655"
        },
        {
            "status": "Active, not recruiting",
            "count": 4,
            "drug_type": "Antibody",
            "drug_label": "CETUXIMAB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 1,
            "disease_id": "EFO_0000181",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase I",
            "disease_name": "head and neck squamous cell carcinoma",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT01468896%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT01716416%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT02277197%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT02764593%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL1201577"
        },
        {
            "status": "Active, not recruiting",
            "count": 3,
            "drug_type": "Antibody",
            "drug_label": "CETUXIMAB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 1,
            "disease_id": "EFO_0000311",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase I",
            "disease_name": "cancer",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00543504%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT01787500%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT02095054%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL1201577"
        },
        {
            "status": "Active, not recruiting",
            "count": 2,
            "drug_type": "Antibody",
            "drug_label": "CETUXIMAB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 1,
            "disease_id": "EFO_0000707",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase I",
            "disease_name": "squamous cell carcinoma",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT02282371%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT03109158%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL1201577"
        },
        {
            "status": "Active, not recruiting",
            "count": 1,
            "drug_type": "Antibody",
            "drug_label": "CETUXIMAB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 1,
            "disease_id": "EFO_0003835",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase I",
            "disease_name": "anal neoplasm",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT01621217%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL1201577"
        },
        {
            "status": "Active, not recruiting",
            "count": 1,
            "drug_type": "Antibody",
            "drug_label": "CETUXIMAB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 1,
            "disease_id": "EFO_0004142",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase I",
            "disease_name": "colorectal neoplasm",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT02124148%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL1201577"
        },
        {
            "status": "Active, not recruiting",
            "count": 1,
            "drug_type": "Antibody",
            "drug_label": "CETUXIMAB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 1,
            "disease_id": "EFO_0006859",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase I",
            "disease_name": "head and neck malignant neoplasia",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT01860430%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL1201577"
        },
        {
            "status": "Active, not recruiting",
            "count": 1,
            "drug_type": "Antibody",
            "drug_label": "CETUXIMAB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 1,
            "disease_id": "EFO_0009708",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase I",
            "disease_name": "metastasis",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT02124148%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL1201577"
        },
        {
            "status": "Active, not recruiting",
            "count": 1,
            "drug_type": "Antibody",
            "drug_label": "CETUXIMAB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 1,
            "disease_id": "EFO_1001951",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase I",
            "disease_name": "colorectal carcinoma",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT01719380%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL1201577"
        },
        {
            "status": "Active, not recruiting",
            "count": 1,
            "drug_type": "Small molecule",
            "drug_label": "EGF816",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 1,
            "disease_id": "EFO_0003060",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase I",
            "disease_name": "non-small cell lung carcinoma",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT02108964%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL3545234"
        },
        {
            "status": "Active, not recruiting",
            "count": 1,
            "drug_type": "Small molecule",
            "drug_label": "EPITINIB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 1,
            "disease_id": "EFO_0000616",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase I",
            "disease_name": "neoplasm",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT02590952%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL3545121"
        },
        {
            "status": "Active, not recruiting",
            "count": 1,
            "drug_type": "Small molecule",
            "drug_label": "ERLOTINIB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 1,
            "disease_id": "EFO_0000305",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase I",
            "disease_name": "breast carcinoma",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00600496%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL553"
        },
        {
            "status": "Active, not recruiting",
            "count": 2,
            "drug_type": "Small molecule",
            "drug_label": "ERLOTINIB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 1,
            "disease_id": "EFO_0000311",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase I",
            "disease_name": "cancer",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00543504%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT01197170%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL553"
        },
        {
            "status": "Active, not recruiting",
            "count": 1,
            "drug_type": "Small molecule",
            "drug_label": "ERLOTINIB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 1,
            "disease_id": "EFO_0000616",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase I",
            "disease_name": "neoplasm",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00045201%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL553"
        },
        {
            "status": "Active, not recruiting",
            "count": 1,
            "drug_type": "Small molecule",
            "drug_label": "ERLOTINIB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 1,
            "disease_id": "EFO_0000756",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase I",
            "disease_name": "melanoma",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00600496%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL553"
        },
        {
            "status": "Active, not recruiting",
            "count": 2,
            "drug_type": "Small molecule",
            "drug_label": "ERLOTINIB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 1,
            "disease_id": "EFO_0001071",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase I",
            "disease_name": "lung carcinoma",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00600496%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT01455389%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL553"
        },
        {
            "status": "Active, not recruiting",
            "count": 1,
            "drug_type": "Small molecule",
            "drug_label": "ERLOTINIB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 1,
            "disease_id": "EFO_0002890",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase I",
            "disease_name": "renal carcinoma",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00600496%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL553"
        },
        {
            "status": "Active, not recruiting",
            "count": 5,
            "drug_type": "Small molecule",
            "drug_label": "ERLOTINIB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 1,
            "disease_id": "EFO_0003060",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase I",
            "disease_name": "non-small cell lung carcinoma",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT01454102%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT02013219%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT02039674%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT02535338%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT02574078%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL553"
        },
        {
            "status": "Active, not recruiting",
            "count": 1,
            "drug_type": "Small molecule",
            "drug_label": "ERLOTINIB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 1,
            "disease_id": "EFO_0003869",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase I",
            "disease_name": "breast neoplasm",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00600496%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL553"
        },
        {
            "status": "Active, not recruiting",
            "count": 1,
            "drug_type": "Small molecule",
            "drug_label": "ERLOTINIB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 1,
            "disease_id": "EFO_0006859",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase I",
            "disease_name": "head and neck malignant neoplasia",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00954226%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL553"
        },
        {
            "status": "Active, not recruiting",
            "count": 2,
            "drug_type": "Small molecule",
            "drug_label": "ERLOTINIB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 1,
            "disease_id": "EFO_1000044",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase I",
            "disease_name": "pancreatic adenocarcinoma",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00769483%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT01660971%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL553"
        },
        {
            "status": "Active, not recruiting",
            "count": 1,
            "drug_type": "Small molecule",
            "drug_label": "ERLOTINIB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 1,
            "disease_id": "EFO_1001950",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase I",
            "disease_name": "colon carcinoma",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00600496%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL553"
        },
        {
            "status": "Active, not recruiting",
            "count": 1,
            "drug_type": "Small molecule",
            "drug_label": "GEFITINIB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 1,
            "disease_id": "EFO_0001075",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase I",
            "disease_name": "ovarian carcinoma",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00317772%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL939"
        },
        {
            "status": "Active, not recruiting",
            "count": 6,
            "drug_type": "Small molecule",
            "drug_label": "GEFITINIB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 1,
            "disease_id": "EFO_0003060",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase I",
            "disease_name": "non-small cell lung carcinoma",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT01570296%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT01982955%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT02039674%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT02088112%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT02151721%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT02374645%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL939"
        },
        {
            "status": "Active, not recruiting",
            "count": 1,
            "drug_type": "Small molecule",
            "drug_label": "GEFITINIB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 1,
            "disease_id": "EFO_1000251",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase I",
            "disease_name": "Fallopian Tube Carcinoma",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00317772%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL939"
        },
        {
            "status": "Active, not recruiting",
            "count": 1,
            "drug_type": "Small molecule",
            "drug_label": "GEFITINIB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 1,
            "disease_id": "EFO_1001100",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase I",
            "disease_name": "peritoneal neoplasm",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00317772%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL939"
        },
        {
            "status": "Active, not recruiting",
            "count": 5,
            "drug_type": "Small molecule",
            "drug_label": "LAPATINIB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 1,
            "disease_id": "EFO_0000305",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase I",
            "disease_name": "breast carcinoma",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT01300962%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT01434303%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT02073916%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT02422199%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT02650752%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL554"
        },
        {
            "status": "Active, not recruiting",
            "count": 1,
            "drug_type": "Small molecule",
            "drug_label": "LAPATINIB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 1,
            "disease_id": "EFO_0000311",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase I",
            "disease_name": "cancer",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00543504%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL554"
        },
        {
            "status": "Active, not recruiting",
            "count": 1,
            "drug_type": "Small molecule",
            "drug_label": "LAPATINIB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 1,
            "disease_id": "EFO_0002892",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase I",
            "disease_name": "thyroid carcinoma",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT01947023%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL554"
        },
        {
            "status": "Active, not recruiting",
            "count": 2,
            "drug_type": "Small molecule",
            "drug_label": "LAPATINIB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 1,
            "disease_id": "EFO_0003869",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase I",
            "disease_name": "breast neoplasm",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00251433%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00367471%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL554"
        },
        {
            "status": "Active, not recruiting",
            "count": 1,
            "drug_type": "Small molecule",
            "drug_label": "LAPATINIB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 1,
            "disease_id": "EFO_0006861",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase I",
            "disease_name": "male breast carcinoma",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT01783756%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL554"
        },
        {
            "status": "Active, not recruiting",
            "count": 4,
            "drug_type": "Antibody",
            "drug_label": "NECITUMUMAB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 1,
            "disease_id": "EFO_0003060",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase I",
            "disease_name": "non-small cell lung carcinoma",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT01763788%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT02411591%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT02451930%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT02789345%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL1743047"
        },
        {
            "status": "Active, not recruiting",
            "count": 1,
            "drug_type": "Antibody",
            "drug_label": "NECITUMUMAB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 1,
            "disease_id": "EFO_0009708",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase I",
            "disease_name": "metastasis",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT02411591%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL1743047"
        },
        {
            "status": "Active, not recruiting",
            "count": 2,
            "drug_type": "Small molecule",
            "drug_label": "OSIMERTINIB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 1,
            "disease_id": "EFO_0000616",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor",
                "Epidermal growth factor receptor inhibitor"
            ],
            "clinical_trial_phase_label": "Phase I",
            "disease_name": "neoplasm",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT02923947%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT02923947%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL3353410"
        },
        {
            "status": "Active, not recruiting",
            "count": 18,
            "drug_type": "Small molecule",
            "drug_label": "OSIMERTINIB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 1,
            "disease_id": "EFO_0003060",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor",
                "Epidermal growth factor receptor inhibitor"
            ],
            "clinical_trial_phase_label": "Phase I",
            "disease_name": "non-small cell lung carcinoma",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT01802632%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT01802632%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT02157883%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT02157883%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT02163733%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT02163733%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT02197234%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT02197234%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT02197247%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT02197247%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT02228369%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT02228369%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT02529995%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT02529995%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT02789345%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT02789345%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT02954523%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT02954523%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL3353410"
        },
        {
            "status": "Active, not recruiting",
            "count": 1,
            "drug_type": "Antibody",
            "drug_label": "PANITUMUMAB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 1,
            "disease_id": "EFO_0000707",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase I",
            "disease_name": "squamous cell carcinoma",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT01581840%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL1201827"
        },
        {
            "status": "Active, not recruiting",
            "count": 1,
            "drug_type": "Antibody",
            "drug_label": "PANITUMUMAB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 1,
            "disease_id": "EFO_0003060",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase I",
            "disease_name": "non-small cell lung carcinoma",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT01061788%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL1201827"
        },
        {
            "status": "Active, not recruiting",
            "count": 1,
            "drug_type": "Antibody",
            "drug_label": "PANITUMUMAB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 1,
            "disease_id": "EFO_1001480",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase I",
            "disease_name": "metastatic colorectal cancer",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT01591421%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL1201827"
        },
        {
            "status": "Active, not recruiting",
            "count": 1,
            "drug_type": "Small molecule",
            "drug_label": "POZIOTINIB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 1,
            "disease_id": "EFO_0000305",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor inhibitor"
            ],
            "clinical_trial_phase_label": "Phase I",
            "disease_name": "breast carcinoma",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT03429101%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL3545154"
        },
        {
            "status": "Active, not recruiting",
            "count": 1,
            "drug_type": "Small molecule",
            "drug_label": "PYROTINIB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 1,
            "disease_id": "EFO_0000305",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase I",
            "disease_name": "breast carcinoma",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT02422199%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL3544956"
        },
        {
            "status": "Active, not recruiting",
            "count": 1,
            "drug_type": "Small molecule",
            "drug_label": "ROCILETINIB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 1,
            "disease_id": "EFO_0003060",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase I",
            "disease_name": "non-small cell lung carcinoma",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT01526928%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL3545308"
        },
        {
            "status": "Active, not recruiting",
            "count": 1,
            "drug_type": "Small molecule",
            "drug_label": "TESEVATINIB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 1,
            "disease_id": "EFO_1001496",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase I",
            "disease_name": "Autosomal dominant polycystic kidney disease",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT01559363%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL3544983"
        },
        {
            "status": "Active, not recruiting",
            "count": 1,
            "drug_type": "Small molecule",
            "drug_label": "VANDETANIB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 1,
            "disease_id": "EFO_0003060",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor inhibitor"
            ],
            "clinical_trial_phase_label": "Phase I",
            "disease_name": "non-small cell lung carcinoma",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT01586624%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL24828"
        },
        {
            "status": "Completed",
            "count": 2,
            "drug_type": "Small molecule",
            "drug_label": "AC-480",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 1,
            "disease_id": "EFO_0000311",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase I",
            "disease_name": "cancer",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00095537%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00207012%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL1645462"
        },
        {
            "status": "Completed",
            "count": 1,
            "drug_type": "Small molecule",
            "drug_label": "AC-480",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 1,
            "disease_id": "EFO_0000326",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase I",
            "disease_name": "central nervous system cancer",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00979173%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL1645462"
        },
        {
            "status": "Completed",
            "count": 1,
            "drug_type": "Small molecule",
            "drug_label": "AC-480",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 1,
            "disease_id": "EFO_0000616",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase I",
            "disease_name": "neoplasm",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00093730%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL1645462"
        },
        {
            "status": "Completed",
            "count": 1,
            "drug_type": "Small molecule",
            "drug_label": "AEE-788",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 1,
            "disease_id": "EFO_0000311",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase I",
            "disease_name": "cancer",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00118456%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL587723"
        },
        {
            "status": "Completed",
            "count": 1,
            "drug_type": "Small molecule",
            "drug_label": "AEE-788",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 1,
            "disease_id": "EFO_0000326",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase I",
            "disease_name": "central nervous system cancer",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00107237%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL587723"
        },
        {
            "status": "Completed",
            "count": 1,
            "drug_type": "Small molecule",
            "drug_label": "AEE-788",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 1,
            "disease_id": "EFO_0000519",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase I",
            "disease_name": "glioblastoma multiforme",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00116376%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL587723"
        },
        {
            "status": "Completed",
            "count": 1,
            "drug_type": "Small molecule",
            "drug_label": "AFATINIB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 1,
            "disease_id": "EFO_0000519",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase I",
            "disease_name": "glioblastoma multiforme",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00977431%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL1173655"
        },
        {
            "status": "Completed",
            "count": 16,
            "drug_type": "Small molecule",
            "drug_label": "AFATINIB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 1,
            "disease_id": "EFO_0000616",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase I",
            "disease_name": "neoplasm",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00716417%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00730821%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00809133%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00906698%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00998296%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT01169675%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT01206816%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT01214616%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT02020577%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT02171637%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT02171650%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT02171663%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT02171676%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT02171702%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT02171728%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT02171741%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL1173655"
        },
        {
            "status": "Completed",
            "count": 1,
            "drug_type": "Small molecule",
            "drug_label": "AFATINIB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 1,
            "disease_id": "EFO_0001421",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase I",
            "disease_name": "liver disease",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT01298063%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL1173655"
        },
        {
            "status": "Completed",
            "count": 3,
            "drug_type": "Small molecule",
            "drug_label": "AFATINIB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 1,
            "disease_id": "EFO_0003060",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase I",
            "disease_name": "non-small cell lung carcinoma",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00993499%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT01090011%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT02191891%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL1173655"
        },
        {
            "status": "Completed",
            "count": 1,
            "drug_type": "Small molecule",
            "drug_label": "AFATINIB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 1,
            "disease_id": "EFO_0003869",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase I",
            "disease_name": "breast neoplasm",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00950742%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL1173655"
        },
        {
            "status": "Completed",
            "count": 4,
            "drug_type": "Small molecule",
            "drug_label": "BMS-690514",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 1,
            "disease_id": "EFO_0000311",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase I",
            "disease_name": "cancer",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00329004%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00420186%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00516451%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00578916%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL3545396"
        },
        {
            "status": "Completed",
            "count": 1,
            "drug_type": "Small molecule",
            "drug_label": "CANERTINIB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 1,
            "disease_id": "EFO_0003060",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase I",
            "disease_name": "non-small cell lung carcinoma",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00174356%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL31965"
        },
        {
            "status": "Completed",
            "count": 1,
            "drug_type": "Small molecule",
            "drug_label": "CEP-32496",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 1,
            "disease_id": "EFO_0000616",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase I",
            "disease_name": "neoplasm",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT01877811%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL2029988"
        },
        {
            "status": "Completed",
            "count": 1,
            "drug_type": "Antibody",
            "drug_label": "CETUXIMAB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 1,
            "disease_id": "EFO_0000178",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase I",
            "disease_name": "gastric carcinoma",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00477880%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL1201577"
        },
        {
            "status": "Completed",
            "count": 3,
            "drug_type": "Antibody",
            "drug_label": "CETUXIMAB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 1,
            "disease_id": "EFO_0000181",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase I",
            "disease_name": "head and neck squamous cell carcinoma",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT01332266%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT01758731%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT02350712%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL1201577"
        },
        {
            "status": "Completed",
            "count": 1,
            "drug_type": "Antibody",
            "drug_label": "CETUXIMAB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 1,
            "disease_id": "EFO_0000182",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase I",
            "disease_name": "hepatocellular carcinoma",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00980239%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL1201577"
        },
        {
            "status": "Completed",
            "count": 6,
            "drug_type": "Antibody",
            "drug_label": "CETUXIMAB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 1,
            "disease_id": "EFO_0000311",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase I",
            "disease_name": "cancer",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00895362%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00940381%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00941499%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT01285037%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT01727869%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT02327169%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL1201577"
        },
        {
            "status": "Completed",
            "count": 4,
            "drug_type": "Antibody",
            "drug_label": "CETUXIMAB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 1,
            "disease_id": "EFO_0000365",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase I",
            "disease_name": "colorectal adenocarcinoma",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00478634%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00540943%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00593060%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT01294826%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL1201577"
        },
        {
            "status": "Completed",
            "count": 1,
            "drug_type": "Antibody",
            "drug_label": "CETUXIMAB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 1,
            "disease_id": "EFO_0000519",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase I",
            "disease_name": "glioblastoma multiforme",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT01238237%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL1201577"
        },
        {
            "status": "Completed",
            "count": 1,
            "drug_type": "Antibody",
            "drug_label": "CETUXIMAB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 1,
            "disease_id": "EFO_0000571",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase I",
            "disease_name": "lung adenocarcinoma",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00716456%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL1201577"
        },
        {
            "status": "Completed",
            "count": 8,
            "drug_type": "Antibody",
            "drug_label": "CETUXIMAB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 1,
            "disease_id": "EFO_0000616",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase I",
            "disease_name": "neoplasm",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00207077%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00376727%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00388427%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00502567%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT01472016%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT01482377%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT01973868%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT02020577%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL1201577"
        },
        {
            "status": "Completed",
            "count": 2,
            "drug_type": "Antibody",
            "drug_label": "CETUXIMAB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 1,
            "disease_id": "EFO_0000707",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase I",
            "disease_name": "squamous cell carcinoma",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00705016%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00815295%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL1201577"
        },
        {
            "status": "Completed",
            "count": 1,
            "drug_type": "Antibody",
            "drug_label": "CETUXIMAB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 1,
            "disease_id": "EFO_0001071",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase I",
            "disease_name": "lung carcinoma",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00408499%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL1201577"
        },
        {
            "status": "Completed",
            "count": 1,
            "drug_type": "Antibody",
            "drug_label": "CETUXIMAB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 1,
            "disease_id": "EFO_0002499",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase I",
            "disease_name": "anaplastic astrocytoma",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT01238237%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL1201577"
        },
        {
            "status": "Completed",
            "count": 2,
            "drug_type": "Antibody",
            "drug_label": "CETUXIMAB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 1,
            "disease_id": "EFO_0002618",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase I",
            "disease_name": "pancreatic carcinoma",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00467116%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT01077986%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL1201577"
        },
        {
            "status": "Completed",
            "count": 2,
            "drug_type": "Antibody",
            "drug_label": "CETUXIMAB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 1,
            "disease_id": "EFO_0002916",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase I",
            "disease_name": "esophageal carcinoma",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00445861%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00544362%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL1201577"
        },
        {
            "status": "Completed",
            "count": 1,
            "drug_type": "Antibody",
            "drug_label": "CETUXIMAB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 1,
            "disease_id": "EFO_0002938",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase I",
            "disease_name": "hypopharyngeal carcinoma",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT01334177%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL1201577"
        },
        {
            "status": "Completed",
            "count": 6,
            "drug_type": "Antibody",
            "drug_label": "CETUXIMAB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 1,
            "disease_id": "EFO_0003060",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase I",
            "disease_name": "non-small cell lung carcinoma",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00034541%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00162318%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00216203%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00522886%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT01004731%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT01090011%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL1201577"
        },
        {
            "status": "Completed",
            "count": 1,
            "drug_type": "Antibody",
            "drug_label": "CETUXIMAB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 1,
            "disease_id": "EFO_0003871",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase I",
            "disease_name": "tongue neoplasm",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT01334177%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL1201577"
        },
        {
            "status": "Completed",
            "count": 1,
            "drug_type": "Antibody",
            "drug_label": "CETUXIMAB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 1,
            "disease_id": "EFO_0004252",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase I",
            "disease_name": "nasopharyngeal neoplasm",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT01712919%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL1201577"
        },
        {
            "status": "Completed",
            "count": 2,
            "drug_type": "Antibody",
            "drug_label": "CETUXIMAB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 1,
            "disease_id": "EFO_0004284",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase I",
            "disease_name": "upper aerodigestive tract neoplasm",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00402545%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT02555644%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL1201577"
        },
        {
            "status": "Completed",
            "count": 1,
            "drug_type": "Antibody",
            "drug_label": "CETUXIMAB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 1,
            "disease_id": "EFO_0006352",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase I",
            "disease_name": "laryngeal squamous cell carcinoma",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT01334177%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL1201577"
        },
        {
            "status": "Completed",
            "count": 8,
            "drug_type": "Antibody",
            "drug_label": "CETUXIMAB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 1,
            "disease_id": "EFO_0006859",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase I",
            "disease_name": "head and neck malignant neoplasia",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00291707%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00629226%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00704639%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00714649%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00851877%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT01046266%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT01255800%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT01540682%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL1201577"
        },
        {
            "status": "Completed",
            "count": 1,
            "drug_type": "Antibody",
            "drug_label": "CETUXIMAB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 1,
            "disease_id": "EFO_0007535",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase I",
            "disease_name": "verrucous carcinoma",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT01334177%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL1201577"
        },
        {
            "status": "Completed",
            "count": 1,
            "drug_type": "Antibody",
            "drug_label": "CETUXIMAB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 1,
            "disease_id": "EFO_1000218",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase I",
            "disease_name": "Digestive System Carcinoma",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT02845999%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL1201577"
        },
        {
            "status": "Completed",
            "count": 2,
            "drug_type": "Antibody",
            "drug_label": "CETUXIMAB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 1,
            "disease_id": "EFO_1000657",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase I",
            "disease_name": "rectum cancer",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00972881%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT01294826%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL1201577"
        },
        {
            "status": "Completed",
            "count": 7,
            "drug_type": "Antibody",
            "drug_label": "CETUXIMAB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 1,
            "disease_id": "EFO_1001480",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase I",
            "disease_name": "metastatic colorectal cancer",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00207155%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00422773%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00594984%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00778830%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT01008475%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT01075048%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT02278133%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL1201577"
        },
        {
            "status": "Completed",
            "count": 1,
            "drug_type": "Antibody",
            "drug_label": "CETUXIMAB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 1,
            "disease_id": "EFO_1001950",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase I",
            "disease_name": "colon carcinoma",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT01287130%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL1201577"
        },
        {
            "status": "Completed",
            "count": 10,
            "drug_type": "Antibody",
            "drug_label": "CETUXIMAB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 1,
            "disease_id": "EFO_1001951",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase I",
            "disease_name": "colorectal carcinoma",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00207051%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00436072%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00478634%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00497497%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00501410%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00522665%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00593060%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00671372%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00925015%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT01086267%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL1201577"
        },
        {
            "status": "Completed",
            "count": 1,
            "drug_type": "Antibody",
            "drug_label": "CETUXIMAB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 1,
            "disease_id": "EFO_1001967",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase I",
            "disease_name": "salivary gland squamous cell carcinoma",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT01334177%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL1201577"
        },
        {
            "status": "Completed",
            "count": 1,
            "drug_type": "Small molecule",
            "drug_label": "CUDC-101",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 1,
            "disease_id": "EFO_0000178",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase I",
            "disease_name": "gastric carcinoma",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT01171924%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL598797"
        },
        {
            "status": "Completed",
            "count": 1,
            "drug_type": "Small molecule",
            "drug_label": "CUDC-101",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 1,
            "disease_id": "EFO_0000182",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase I",
            "disease_name": "hepatocellular carcinoma",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT01171924%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL598797"
        },
        {
            "status": "Completed",
            "count": 1,
            "drug_type": "Small molecule",
            "drug_label": "CUDC-101",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 1,
            "disease_id": "EFO_0000305",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase I",
            "disease_name": "breast carcinoma",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT01171924%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL598797"
        },
        {
            "status": "Completed",
            "count": 1,
            "drug_type": "Small molecule",
            "drug_label": "CUDC-101",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 1,
            "disease_id": "EFO_0000616",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase I",
            "disease_name": "neoplasm",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00728793%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL598797"
        },
        {
            "status": "Completed",
            "count": 1,
            "drug_type": "Small molecule",
            "drug_label": "CUDC-101",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 1,
            "disease_id": "EFO_0003060",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase I",
            "disease_name": "non-small cell lung carcinoma",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT01171924%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL598797"
        },
        {
            "status": "Completed",
            "count": 2,
            "drug_type": "Small molecule",
            "drug_label": "CUDC-101",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 1,
            "disease_id": "EFO_0006859",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase I",
            "disease_name": "head and neck malignant neoplasia",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT01171924%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT01384799%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL598797"
        },
        {
            "status": "Completed",
            "count": 2,
            "drug_type": "Small molecule",
            "drug_label": "DACOMITINIB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 1,
            "disease_id": "EFO_0000181",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor",
                "Epidermal growth factor receptor inhibitor"
            ],
            "clinical_trial_phase_label": "Phase I",
            "disease_name": "head and neck squamous cell carcinoma",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT01737008%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT01737008%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL2110732"
        },
        {
            "status": "Completed",
            "count": 2,
            "drug_type": "Small molecule",
            "drug_label": "DACOMITINIB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 1,
            "disease_id": "EFO_0000313",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor",
                "Epidermal growth factor receptor inhibitor"
            ],
            "clinical_trial_phase_label": "Phase I",
            "disease_name": "carcinoma",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00728390%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00728390%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL2110732"
        },
        {
            "status": "Completed",
            "count": 6,
            "drug_type": "Small molecule",
            "drug_label": "DACOMITINIB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 1,
            "disease_id": "EFO_0000616",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor",
                "Epidermal growth factor receptor inhibitor"
            ],
            "clinical_trial_phase_label": "Phase I",
            "disease_name": "neoplasm",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00225121%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00225121%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00728468%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00728468%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00783328%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00783328%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL2110732"
        },
        {
            "status": "Completed",
            "count": 4,
            "drug_type": "Small molecule",
            "drug_label": "DACOMITINIB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 1,
            "disease_id": "EFO_0003060",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor",
                "Epidermal growth factor receptor inhibitor"
            ],
            "clinical_trial_phase_label": "Phase I",
            "disease_name": "non-small cell lung carcinoma",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00553254%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00553254%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT01121575%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT01121575%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL2110732"
        },
        {
            "status": "Completed",
            "count": 2,
            "drug_type": "Small molecule",
            "drug_label": "DACOMITINIB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 1,
            "disease_id": "EFO_0005570",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor",
                "Epidermal growth factor receptor inhibitor"
            ],
            "clinical_trial_phase_label": "Phase I",
            "disease_name": "oral cavity cancer",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT01116843%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT01116843%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL2110732"
        },
        {
            "status": "Completed",
            "count": 2,
            "drug_type": "Small molecule",
            "drug_label": "DACOMITINIB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 1,
            "disease_id": "EFO_0009708",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor",
                "Epidermal growth factor receptor inhibitor"
            ],
            "clinical_trial_phase_label": "Phase I",
            "disease_name": "metastasis",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00728390%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00728390%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL2110732"
        },
        {
            "status": "Completed",
            "count": 1,
            "drug_type": "Antibody",
            "drug_label": "DEPATUXIZUMAB MAFODOTIN",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 1,
            "disease_id": "EFO_0000519",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 binding agent"
            ],
            "clinical_trial_phase_label": "Phase I",
            "disease_name": "glioblastoma multiforme",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT01800695%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "up_or_down",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL3707277"
        },
        {
            "status": "Completed",
            "count": 1,
            "drug_type": "Antibody",
            "drug_label": "DEPATUXIZUMAB MAFODOTIN",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 1,
            "disease_id": "EFO_0000616",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 binding agent"
            ],
            "clinical_trial_phase_label": "Phase I",
            "disease_name": "neoplasm",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT01741727%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "up_or_down",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL3707277"
        },
        {
            "status": "Completed",
            "count": 2,
            "drug_type": "Antibody",
            "drug_label": "DULIGOTUZUMAB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 1,
            "disease_id": "EFO_0000616",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase I",
            "disease_name": "neoplasm",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT01207323%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT01986166%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL3137345"
        },
        {
            "status": "Completed",
            "count": 1,
            "drug_type": "Antibody",
            "drug_label": "DULIGOTUZUMAB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 1,
            "disease_id": "EFO_0006859",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase I",
            "disease_name": "head and neck malignant neoplasia",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT01911598%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL3137345"
        },
        {
            "status": "Completed",
            "count": 2,
            "drug_type": "Small molecule",
            "drug_label": "ERLOTINIB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 1,
            "disease_id": "EFO_0000181",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase I",
            "disease_name": "head and neck squamous cell carcinoma",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00049166%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT01515137%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL553"
        },
        {
            "status": "Completed",
            "count": 1,
            "drug_type": "Small molecule",
            "drug_label": "ERLOTINIB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 1,
            "disease_id": "EFO_0000182",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase I",
            "disease_name": "hepatocellular carcinoma",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00047346%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL553"
        },
        {
            "status": "Completed",
            "count": 1,
            "drug_type": "Small molecule",
            "drug_label": "ERLOTINIB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 1,
            "disease_id": "EFO_0000198",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase I",
            "disease_name": "myelodysplastic syndrome",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT01085838%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL553"
        },
        {
            "status": "Completed",
            "count": 5,
            "drug_type": "Small molecule",
            "drug_label": "ERLOTINIB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 1,
            "disease_id": "EFO_0000305",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase I",
            "disease_name": "breast carcinoma",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00033514%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00574366%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00834678%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00998036%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT01650506%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL553"
        },
        {
            "status": "Completed",
            "count": 9,
            "drug_type": "Small molecule",
            "drug_label": "ERLOTINIB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 1,
            "disease_id": "EFO_0000311",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase I",
            "disease_name": "cancer",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00705874%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00895128%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00895362%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00895687%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00903734%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT01192165%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT01287546%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT01532011%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT01727869%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL553"
        },
        {
            "status": "Completed",
            "count": 3,
            "drug_type": "Small molecule",
            "drug_label": "ERLOTINIB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 1,
            "disease_id": "EFO_0000326",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase I",
            "disease_name": "central nervous system cancer",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00124657%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00509431%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00901849%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL553"
        },
        {
            "status": "Completed",
            "count": 1,
            "drug_type": "Small molecule",
            "drug_label": "ERLOTINIB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 1,
            "disease_id": "EFO_0000349",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase I",
            "disease_name": "clear cell renal carcinoma",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00193258%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL553"
        },
        {
            "status": "Completed",
            "count": 1,
            "drug_type": "Small molecule",
            "drug_label": "ERLOTINIB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 1,
            "disease_id": "EFO_0000519",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase I",
            "disease_name": "glioblastoma multiforme",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00301418%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL553"
        },
        {
            "status": "Completed",
            "count": 2,
            "drug_type": "Small molecule",
            "drug_label": "ERLOTINIB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 1,
            "disease_id": "EFO_0000571",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase I",
            "disease_name": "lung adenocarcinoma",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00716456%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT01259089%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL553"
        },
        {
            "status": "Completed",
            "count": 20,
            "drug_type": "Small molecule",
            "drug_label": "ERLOTINIB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 1,
            "disease_id": "EFO_0000616",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase I",
            "disease_name": "neoplasm",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00042809%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00085553%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00126620%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00139620%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00207077%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00276575%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00320073%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00495872%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00603356%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00611468%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00739453%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00759928%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00770263%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00848718%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00884845%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00996515%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT01009073%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT01116622%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT01472016%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT01482377%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL553"
        },
        {
            "status": "Completed",
            "count": 1,
            "drug_type": "Small molecule",
            "drug_label": "ERLOTINIB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 1,
            "disease_id": "EFO_0000630",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase I",
            "disease_name": "oligoastrocytoma",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00112736%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL553"
        },
        {
            "status": "Completed",
            "count": 10,
            "drug_type": "Small molecule",
            "drug_label": "ERLOTINIB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 1,
            "disease_id": "EFO_0001071",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase I",
            "disease_name": "lung carcinoma",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00043823%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00072072%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00280150%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00387322%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00390429%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00408499%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT01068587%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT01302808%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT01967095%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT02155465%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL553"
        },
        {
            "status": "Completed",
            "count": 1,
            "drug_type": "Small molecule",
            "drug_label": "ERLOTINIB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 1,
            "disease_id": "EFO_0001075",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase I",
            "disease_name": "ovarian carcinoma",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00217529%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL553"
        },
        {
            "status": "Completed",
            "count": 3,
            "drug_type": "Small molecule",
            "drug_label": "ERLOTINIB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 1,
            "disease_id": "EFO_0002499",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase I",
            "disease_name": "anaplastic astrocytoma",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00045110%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00112736%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00301418%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL553"
        },
        {
            "status": "Completed",
            "count": 2,
            "drug_type": "Small molecule",
            "drug_label": "ERLOTINIB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 1,
            "disease_id": "EFO_0002501",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase I",
            "disease_name": "anaplastic oligodendroglioma",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00045110%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00112736%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL553"
        },
        {
            "status": "Completed",
            "count": 12,
            "drug_type": "Small molecule",
            "drug_label": "ERLOTINIB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 1,
            "disease_id": "EFO_0002618",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase I",
            "disease_name": "pancreatic carcinoma",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00033241%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00243854%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00260364%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00480584%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00614653%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00617708%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00735306%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00761345%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00885066%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00925769%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00954525%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT01010945%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL553"
        },
        {
            "status": "Completed",
            "count": 31,
            "drug_type": "Small molecule",
            "drug_label": "ERLOTINIB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 1,
            "disease_id": "EFO_0003060",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase I",
            "disease_name": "non-small cell lung carcinoma",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00088959%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00147537%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00294736%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00444015%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00452413%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00453362%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00456833%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00581789%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00596648%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00602030%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00619424%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00692640%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00702182%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00729742%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00777699%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00778167%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00826449%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00965731%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00975182%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00994123%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT01069757%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT01199068%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT01211483%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT01233687%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT01251796%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT01259089%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT01545947%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT01801111%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT01839955%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT01998126%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT02507375%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL553"
        },
        {
            "status": "Completed",
            "count": 5,
            "drug_type": "Small molecule",
            "drug_label": "ERLOTINIB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 1,
            "disease_id": "EFO_0006859",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase I",
            "disease_name": "head and neck malignant neoplasia",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00030576%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00079053%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00113347%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00400374%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT01116336%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL553"
        },
        {
            "status": "Completed",
            "count": 1,
            "drug_type": "Small molecule",
            "drug_label": "ERLOTINIB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 1,
            "disease_id": "EFO_1000044",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase I",
            "disease_name": "pancreatic adenocarcinoma",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00063947%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL553"
        },
        {
            "status": "Completed",
            "count": 1,
            "drug_type": "Small molecule",
            "drug_label": "ERLOTINIB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 1,
            "disease_id": "EFO_1000142",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase I",
            "disease_name": "Brain Stem Glioma",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00418327%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL553"
        },
        {
            "status": "Completed",
            "count": 1,
            "drug_type": "Small molecule",
            "drug_label": "ERLOTINIB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 1,
            "disease_id": "EFO_1000251",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase I",
            "disease_name": "Fallopian Tube Carcinoma",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00217529%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL553"
        },
        {
            "status": "Completed",
            "count": 2,
            "drug_type": "Small molecule",
            "drug_label": "ERLOTINIB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 1,
            "disease_id": "EFO_1000657",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase I",
            "disease_name": "rectum cancer",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00307736%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00543842%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL553"
        },
        {
            "status": "Completed",
            "count": 1,
            "drug_type": "Small molecule",
            "drug_label": "ERLOTINIB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 1,
            "disease_id": "EFO_1001100",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase I",
            "disease_name": "peritoneal neoplasm",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00217529%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL553"
        },
        {
            "status": "Completed",
            "count": 4,
            "drug_type": "Small molecule",
            "drug_label": "ERLOTINIB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 1,
            "disease_id": "EFO_1001465",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase I",
            "disease_name": "gliosarcoma",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00045110%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00112736%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00335764%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00609999%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL553"
        },
        {
            "status": "Completed",
            "count": 3,
            "drug_type": "Small molecule",
            "drug_label": "ERLOTINIB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 1,
            "disease_id": "EFO_1001951",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase I",
            "disease_name": "colorectal carcinoma",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00047762%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00049101%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00118261%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL553"
        },
        {
            "status": "Completed",
            "count": 1,
            "drug_type": "Small molecule",
            "drug_label": "ERLOTINIB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 1,
            "disease_id": "Orphanet_2495",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase I",
            "disease_name": "Meningioma",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00045110%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL553"
        },
        {
            "status": "Completed",
            "count": 1,
            "drug_type": "Antibody",
            "drug_label": "FUTUXIMAB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 1,
            "disease_id": "EFO_0000616",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 antagonist"
            ],
            "clinical_trial_phase_label": "Phase I",
            "disease_name": "neoplasm",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT01955473%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL2109388"
        },
        {
            "status": "Completed",
            "count": 1,
            "drug_type": "Antibody",
            "drug_label": "FUTUXIMAB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 1,
            "disease_id": "EFO_1001480",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 antagonist"
            ],
            "clinical_trial_phase_label": "Phase I",
            "disease_name": "metastatic colorectal cancer",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT01117428%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL2109388"
        },
        {
            "status": "Completed",
            "count": 1,
            "drug_type": "Small molecule",
            "drug_label": "GEFITINIB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 1,
            "disease_id": "EFO_0000196",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase I",
            "disease_name": "metastatic prostate cancer",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00239291%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL939"
        },
        {
            "status": "Completed",
            "count": 1,
            "drug_type": "Small molecule",
            "drug_label": "GEFITINIB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 1,
            "disease_id": "EFO_0000305",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase I",
            "disease_name": "breast carcinoma",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00086957%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL939"
        },
        {
            "status": "Completed",
            "count": 1,
            "drug_type": "Small molecule",
            "drug_label": "GEFITINIB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 1,
            "disease_id": "EFO_0000326",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase I",
            "disease_name": "central nervous system cancer",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00027625%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL939"
        },
        {
            "status": "Completed",
            "count": 7,
            "drug_type": "Small molecule",
            "drug_label": "GEFITINIB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 1,
            "disease_id": "EFO_0000616",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase I",
            "disease_name": "neoplasm",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00039390%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00040781%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00084708%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00084786%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00127829%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00186979%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00502060%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL939"
        },
        {
            "status": "Completed",
            "count": 1,
            "drug_type": "Small molecule",
            "drug_label": "GEFITINIB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 1,
            "disease_id": "EFO_0000681",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase I",
            "disease_name": "renal cell carcinoma",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00113529%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL939"
        },
        {
            "status": "Completed",
            "count": 6,
            "drug_type": "Small molecule",
            "drug_label": "GEFITINIB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 1,
            "disease_id": "EFO_0001071",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase I",
            "disease_name": "lung carcinoma",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00005806%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00062270%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00096486%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00238628%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00310154%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT01039948%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL939"
        },
        {
            "status": "Completed",
            "count": 1,
            "drug_type": "Small molecule",
            "drug_label": "GEFITINIB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 1,
            "disease_id": "EFO_0002618",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase I",
            "disease_name": "pancreatic carcinoma",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00234416%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL939"
        },
        {
            "status": "Completed",
            "count": 7,
            "drug_type": "Small molecule",
            "drug_label": "GEFITINIB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 1,
            "disease_id": "EFO_0003060",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase I",
            "disease_name": "non-small cell lung carcinoma",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00162318%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00252798%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00255489%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00328562%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00372515%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT01513174%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT02040064%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL939"
        },
        {
            "status": "Completed",
            "count": 1,
            "drug_type": "Small molecule",
            "drug_label": "GEFITINIB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 1,
            "disease_id": "EFO_0004252",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase I",
            "disease_name": "nasopharyngeal neoplasm",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00212108%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL939"
        },
        {
            "status": "Completed",
            "count": 1,
            "drug_type": "Small molecule",
            "drug_label": "GEFITINIB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 1,
            "disease_id": "EFO_0004284",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase I",
            "disease_name": "upper aerodigestive tract neoplasm",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00239304%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL939"
        },
        {
            "status": "Completed",
            "count": 3,
            "drug_type": "Small molecule",
            "drug_label": "GEFITINIB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 1,
            "disease_id": "EFO_0006859",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase I",
            "disease_name": "head and neck malignant neoplasia",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00083057%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00352105%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00681967%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL939"
        },
        {
            "status": "Completed",
            "count": 1,
            "drug_type": "Small molecule",
            "drug_label": "GEFITINIB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 1,
            "disease_id": "EFO_1001465",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase I",
            "disease_name": "gliosarcoma",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00052208%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL939"
        },
        {
            "status": "Completed",
            "count": 3,
            "drug_type": "Small molecule",
            "drug_label": "GEFITINIB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 1,
            "disease_id": "EFO_1001951",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase I",
            "disease_name": "colorectal carcinoma",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00026299%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00026364%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00242788%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL939"
        },
        {
            "status": "Completed",
            "count": 1,
            "drug_type": "Antibody",
            "drug_label": "IMGATUZUMAB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 1,
            "disease_id": "EFO_0000616",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase I",
            "disease_name": "neoplasm",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00721266%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL2109389"
        },
        {
            "status": "Completed",
            "count": 1,
            "drug_type": "Antibody",
            "drug_label": "IMGATUZUMAB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 1,
            "disease_id": "EFO_0006859",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase I",
            "disease_name": "head and neck malignant neoplasia",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT01046266%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL2109389"
        },
        {
            "status": "Completed",
            "count": 1,
            "drug_type": "Small molecule",
            "drug_label": "JNJ-26483327",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 1,
            "disease_id": "EFO_0000311",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase I",
            "disease_name": "cancer",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00676299%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL3545133"
        },
        {
            "status": "Completed",
            "count": 1,
            "drug_type": "Small molecule",
            "drug_label": "LAPATINIB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 1,
            "disease_id": "EFO_0000292",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase I",
            "disease_name": "bladder carcinoma",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00623064%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL554"
        },
        {
            "status": "Completed",
            "count": 15,
            "drug_type": "Small molecule",
            "drug_label": "LAPATINIB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 1,
            "disease_id": "EFO_0000305",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase I",
            "disease_name": "breast carcinoma",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00085020%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00316875%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00379509%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00450892%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00513058%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00544804%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00632489%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00753207%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00807859%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00952692%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT01044485%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT01133912%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT01138384%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT01172223%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT01471847%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL554"
        },
        {
            "status": "Completed",
            "count": 3,
            "drug_type": "Small molecule",
            "drug_label": "LAPATINIB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 1,
            "disease_id": "EFO_0000311",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase I",
            "disease_name": "cancer",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT01087983%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT01290354%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT01454804%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL554"
        },
        {
            "status": "Completed",
            "count": 1,
            "drug_type": "Small molecule",
            "drug_label": "LAPATINIB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 1,
            "disease_id": "EFO_0000326",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase I",
            "disease_name": "central nervous system cancer",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00099060%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL554"
        },
        {
            "status": "Completed",
            "count": 1,
            "drug_type": "Small molecule",
            "drug_label": "LAPATINIB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 1,
            "disease_id": "EFO_0000365",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase I",
            "disease_name": "colorectal adenocarcinoma",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00536809%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL554"
        },
        {
            "status": "Completed",
            "count": 1,
            "drug_type": "Small molecule",
            "drug_label": "LAPATINIB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 1,
            "disease_id": "EFO_0000574",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase I",
            "disease_name": "lymphoma",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00352443%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL554"
        },
        {
            "status": "Completed",
            "count": 4,
            "drug_type": "Small molecule",
            "drug_label": "LAPATINIB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 1,
            "disease_id": "EFO_0000616",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase I",
            "disease_name": "neoplasm",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00389922%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00495872%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00662636%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00984425%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL554"
        },
        {
            "status": "Completed",
            "count": 2,
            "drug_type": "Small molecule",
            "drug_label": "LAPATINIB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 1,
            "disease_id": "EFO_0000681",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase I",
            "disease_name": "renal cell carcinoma",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00158782%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00516672%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL554"
        },
        {
            "status": "Completed",
            "count": 1,
            "drug_type": "Small molecule",
            "drug_label": "LAPATINIB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 1,
            "disease_id": "EFO_0003017",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase I",
            "disease_name": "transitional cell carcinoma of kidney",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00623064%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL554"
        },
        {
            "status": "Completed",
            "count": 1,
            "drug_type": "Small molecule",
            "drug_label": "LAPATINIB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 1,
            "disease_id": "EFO_0003060",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase I",
            "disease_name": "non-small cell lung carcinoma",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00528281%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL554"
        },
        {
            "status": "Completed",
            "count": 11,
            "drug_type": "Small molecule",
            "drug_label": "LAPATINIB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 1,
            "disease_id": "EFO_0003869",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase I",
            "disease_name": "breast neoplasm",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00148902%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00258050%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00359190%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00388076%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00462956%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00650910%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00790816%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00807859%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00821054%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00849329%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00996762%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL554"
        },
        {
            "status": "Completed",
            "count": 1,
            "drug_type": "Small molecule",
            "drug_label": "LAPATINIB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 1,
            "disease_id": "EFO_0003884",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase I",
            "disease_name": "chronic kidney disease",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT02581124%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL554"
        },
        {
            "status": "Completed",
            "count": 1,
            "drug_type": "Small molecule",
            "drug_label": "LAPATINIB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 1,
            "disease_id": "EFO_0006859",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase I",
            "disease_name": "head and neck malignant neoplasia",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00498953%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL554"
        },
        {
            "status": "Completed",
            "count": 1,
            "drug_type": "Small molecule",
            "drug_label": "LAPATINIB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 1,
            "disease_id": "EFO_0006861",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase I",
            "disease_name": "male breast carcinoma",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT01245205%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL554"
        },
        {
            "status": "Completed",
            "count": 1,
            "drug_type": "Antibody",
            "drug_label": "MDX-447",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 1,
            "disease_id": "EFO_0000326",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 other"
            ],
            "clinical_trial_phase_label": "Phase I",
            "disease_name": "central nervous system cancer",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00005813%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "up_or_down",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL2109391"
        },
        {
            "status": "Completed",
            "count": 1,
            "drug_type": "Small molecule",
            "drug_label": "MP-412",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 1,
            "disease_id": "EFO_0000311",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase I",
            "disease_name": "cancer",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00551850%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL3545002"
        },
        {
            "status": "Completed",
            "count": 2,
            "drug_type": "Antibody",
            "drug_label": "NECITUMUMAB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 1,
            "disease_id": "EFO_0000616",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase I",
            "disease_name": "neoplasm",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00801177%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT01088464%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL1743047"
        },
        {
            "status": "Completed",
            "count": 14,
            "drug_type": "Small molecule",
            "drug_label": "NERATINIB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 1,
            "disease_id": "EFO_0000305",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor",
                "Epidermal growth factor receptor inhibitor"
            ],
            "clinical_trial_phase_label": "Phase I",
            "disease_name": "breast carcinoma",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00398567%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00398567%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00445458%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00445458%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00706030%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00706030%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00708903%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00708903%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00741260%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00741260%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT01111825%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT01111825%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT01423123%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT01423123%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL180022"
        },
        {
            "status": "Completed",
            "count": 2,
            "drug_type": "Small molecule",
            "drug_label": "NERATINIB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 1,
            "disease_id": "EFO_0000313",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor",
                "Epidermal growth factor receptor inhibitor"
            ],
            "clinical_trial_phase_label": "Phase I",
            "disease_name": "carcinoma",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00838539%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00838539%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL180022"
        },
        {
            "status": "Completed",
            "count": 8,
            "drug_type": "Small molecule",
            "drug_label": "NERATINIB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 1,
            "disease_id": "EFO_0000616",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor",
                "Epidermal growth factor receptor inhibitor"
            ],
            "clinical_trial_phase_label": "Phase I",
            "disease_name": "neoplasm",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00397046%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00397046%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00768469%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00768469%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00958724%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00958724%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT01128842%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT01128842%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL180022"
        },
        {
            "status": "Completed",
            "count": 4,
            "drug_type": "Small molecule",
            "drug_label": "NERATINIB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 1,
            "disease_id": "EFO_0003869",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor",
                "Epidermal growth factor receptor inhibitor"
            ],
            "clinical_trial_phase_label": "Phase I",
            "disease_name": "breast neoplasm",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00146172%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00146172%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00445458%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00445458%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL180022"
        },
        {
            "status": "Completed",
            "count": 1,
            "drug_type": "Antibody",
            "drug_label": "NIMOTUZUMAB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 1,
            "disease_id": "EFO_0000616",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase I",
            "disease_name": "neoplasm",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00369252%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL2108359"
        },
        {
            "status": "Completed",
            "count": 1,
            "drug_type": "Antibody",
            "drug_label": "NIMOTUZUMAB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 1,
            "disease_id": "EFO_0001416",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase I",
            "disease_name": "cervical adenocarcinoma",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT02095119%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL2108359"
        },
        {
            "status": "Completed",
            "count": 1,
            "drug_type": "Antibody",
            "drug_label": "NIMOTUZUMAB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 1,
            "disease_id": "EFO_0002916",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase I",
            "disease_name": "esophageal carcinoma",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00950417%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL2108359"
        },
        {
            "status": "Completed",
            "count": 1,
            "drug_type": "Small molecule",
            "drug_label": "OLMUTINIB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 1,
            "disease_id": "EFO_0003060",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase I",
            "disease_name": "non-small cell lung carcinoma",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT01588145%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL3786343"
        },
        {
            "status": "Completed",
            "count": 2,
            "drug_type": "Small molecule",
            "drug_label": "OSIMERTINIB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 1,
            "disease_id": "EFO_0000616",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor",
                "Epidermal growth factor receptor inhibitor"
            ],
            "clinical_trial_phase_label": "Phase I",
            "disease_name": "neoplasm",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT02161770%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT02161770%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL3353410"
        },
        {
            "status": "Completed",
            "count": 2,
            "drug_type": "Small molecule",
            "drug_label": "OSIMERTINIB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 1,
            "disease_id": "EFO_0003060",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor",
                "Epidermal growth factor receptor inhibitor"
            ],
            "clinical_trial_phase_label": "Phase I",
            "disease_name": "non-small cell lung carcinoma",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT02317016%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT02317016%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL3353410"
        },
        {
            "status": "Completed",
            "count": 1,
            "drug_type": "Antibody",
            "drug_label": "PANITUMUMAB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 1,
            "disease_id": "EFO_0000181",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase I",
            "disease_name": "head and neck squamous cell carcinoma",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00513383%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL1201827"
        },
        {
            "status": "Completed",
            "count": 1,
            "drug_type": "Antibody",
            "drug_label": "PANITUMUMAB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 1,
            "disease_id": "EFO_0000365",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase I",
            "disease_name": "colorectal adenocarcinoma",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT01139138%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL1201827"
        },
        {
            "status": "Completed",
            "count": 4,
            "drug_type": "Antibody",
            "drug_label": "PANITUMUMAB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 1,
            "disease_id": "EFO_0000616",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase I",
            "disease_name": "neoplasm",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00091806%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00586443%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00610948%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00658658%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL1201827"
        },
        {
            "status": "Completed",
            "count": 1,
            "drug_type": "Antibody",
            "drug_label": "PANITUMUMAB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 1,
            "disease_id": "EFO_0001071",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase I",
            "disease_name": "lung carcinoma",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00004879%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL1201827"
        },
        {
            "status": "Completed",
            "count": 1,
            "drug_type": "Antibody",
            "drug_label": "PANITUMUMAB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 1,
            "disease_id": "EFO_0001663",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase I",
            "disease_name": "prostate carcinoma",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00004879%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL1201827"
        },
        {
            "status": "Completed",
            "count": 2,
            "drug_type": "Antibody",
            "drug_label": "PANITUMUMAB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 1,
            "disease_id": "EFO_0002618",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase I",
            "disease_name": "pancreatic carcinoma",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00004879%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT01175733%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL1201827"
        },
        {
            "status": "Completed",
            "count": 1,
            "drug_type": "Antibody",
            "drug_label": "PANITUMUMAB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 1,
            "disease_id": "EFO_0002890",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase I",
            "disease_name": "renal carcinoma",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00004879%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL1201827"
        },
        {
            "status": "Completed",
            "count": 2,
            "drug_type": "Antibody",
            "drug_label": "PANITUMUMAB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 1,
            "disease_id": "EFO_0002916",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase I",
            "disease_name": "esophageal carcinoma",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00004879%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00578071%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL1201827"
        },
        {
            "status": "Completed",
            "count": 1,
            "drug_type": "Antibody",
            "drug_label": "PANITUMUMAB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 1,
            "disease_id": "EFO_0003060",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase I",
            "disease_name": "non-small cell lung carcinoma",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00094835%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL1201827"
        },
        {
            "status": "Completed",
            "count": 1,
            "drug_type": "Antibody",
            "drug_label": "PANITUMUMAB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 1,
            "disease_id": "EFO_1000657",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase I",
            "disease_name": "rectum cancer",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00101894%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL1201827"
        },
        {
            "status": "Completed",
            "count": 3,
            "drug_type": "Antibody",
            "drug_label": "PANITUMUMAB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 1,
            "disease_id": "EFO_1001480",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase I",
            "disease_name": "metastatic colorectal cancer",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00563316%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT01791309%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT01927341%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL1201827"
        },
        {
            "status": "Completed",
            "count": 1,
            "drug_type": "Antibody",
            "drug_label": "PANITUMUMAB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 1,
            "disease_id": "EFO_1001950",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase I",
            "disease_name": "colon carcinoma",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00101894%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL1201827"
        },
        {
            "status": "Completed",
            "count": 6,
            "drug_type": "Antibody",
            "drug_label": "PANITUMUMAB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 1,
            "disease_id": "EFO_1001951",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase I",
            "disease_name": "colorectal carcinoma",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00004879%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00867334%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00879385%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT01139138%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT02008383%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT02613221%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL1201827"
        },
        {
            "status": "Completed",
            "count": 1,
            "drug_type": "Small molecule",
            "drug_label": "PELITINIB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 1,
            "disease_id": "EFO_0000616",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase I",
            "disease_name": "neoplasm",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00098501%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL607707"
        },
        {
            "status": "Completed",
            "count": 1,
            "drug_type": "Small molecule",
            "drug_label": "POZIOTINIB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 1,
            "disease_id": "EFO_0000178",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor inhibitor"
            ],
            "clinical_trial_phase_label": "Phase I",
            "disease_name": "gastric carcinoma",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT01746771%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL3545154"
        },
        {
            "status": "Completed",
            "count": 1,
            "drug_type": "Small molecule",
            "drug_label": "POZIOTINIB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 1,
            "disease_id": "EFO_0000311",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor inhibitor"
            ],
            "clinical_trial_phase_label": "Phase I",
            "disease_name": "cancer",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT01455584%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL3545154"
        },
        {
            "status": "Completed",
            "count": 1,
            "drug_type": "Small molecule",
            "drug_label": "POZIOTINIB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 1,
            "disease_id": "EFO_0000616",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor inhibitor"
            ],
            "clinical_trial_phase_label": "Phase I",
            "disease_name": "neoplasm",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT01455571%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL3545154"
        },
        {
            "status": "Completed",
            "count": 2,
            "drug_type": "Small molecule",
            "drug_label": "PYROTINIB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 1,
            "disease_id": "EFO_0000305",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase I",
            "disease_name": "breast carcinoma",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT01937689%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT02361112%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL3544956"
        },
        {
            "status": "Completed",
            "count": 1,
            "drug_type": "Small molecule",
            "drug_label": "ROCILETINIB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 1,
            "disease_id": "EFO_0003060",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase I",
            "disease_name": "non-small cell lung carcinoma",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT02630186%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL3545308"
        },
        {
            "status": "Completed",
            "count": 1,
            "drug_type": "Small molecule",
            "drug_label": "TAK-285",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 1,
            "disease_id": "EFO_0000311",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase I",
            "disease_name": "cancer",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00535522%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL1614725"
        },
        {
            "status": "Completed",
            "count": 1,
            "drug_type": "Small molecule",
            "drug_label": "THELIATINIB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 1,
            "disease_id": "EFO_0000311",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase I",
            "disease_name": "cancer",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT02601248%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL3545180"
        },
        {
            "status": "Completed",
            "count": 1,
            "drug_type": "Small molecule",
            "drug_label": "VANDETANIB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 1,
            "disease_id": "EFO_0000305",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor inhibitor"
            ],
            "clinical_trial_phase_label": "Phase I",
            "disease_name": "breast carcinoma",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00496665%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL24828"
        },
        {
            "status": "Completed",
            "count": 2,
            "drug_type": "Small molecule",
            "drug_label": "VANDETANIB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 1,
            "disease_id": "EFO_0000311",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor inhibitor"
            ],
            "clinical_trial_phase_label": "Phase I",
            "disease_name": "cancer",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00503711%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00660725%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL24828"
        },
        {
            "status": "Completed",
            "count": 3,
            "drug_type": "Small molecule",
            "drug_label": "VANDETANIB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 1,
            "disease_id": "EFO_0000326",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor inhibitor"
            ],
            "clinical_trial_phase_label": "Phase I",
            "disease_name": "central nervous system cancer",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00272350%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00472017%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00822887%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL24828"
        },
        {
            "status": "Completed",
            "count": 2,
            "drug_type": "Small molecule",
            "drug_label": "VANDETANIB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 1,
            "disease_id": "EFO_0000365",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor inhibitor"
            ],
            "clinical_trial_phase_label": "Phase I",
            "disease_name": "colorectal adenocarcinoma",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00499850%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00507091%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL24828"
        },
        {
            "status": "Completed",
            "count": 1,
            "drug_type": "Small molecule",
            "drug_label": "VANDETANIB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 1,
            "disease_id": "EFO_0000519",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor inhibitor"
            ],
            "clinical_trial_phase_label": "Phase I",
            "disease_name": "glioblastoma multiforme",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00821080%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL24828"
        },
        {
            "status": "Completed",
            "count": 1,
            "drug_type": "Small molecule",
            "drug_label": "VANDETANIB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 1,
            "disease_id": "EFO_0000616",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor inhibitor"
            ],
            "clinical_trial_phase_label": "Phase I",
            "disease_name": "neoplasm",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00667147%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL24828"
        },
        {
            "status": "Completed",
            "count": 1,
            "drug_type": "Small molecule",
            "drug_label": "VANDETANIB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 1,
            "disease_id": "EFO_0002618",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor inhibitor"
            ],
            "clinical_trial_phase_label": "Phase I",
            "disease_name": "pancreatic carcinoma",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00681798%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL24828"
        },
        {
            "status": "Completed",
            "count": 2,
            "drug_type": "Small molecule",
            "drug_label": "VANDETANIB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 1,
            "disease_id": "EFO_0002892",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor inhibitor"
            ],
            "clinical_trial_phase_label": "Phase I",
            "disease_name": "thyroid carcinoma",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT01539655%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT01661179%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL24828"
        },
        {
            "status": "Completed",
            "count": 2,
            "drug_type": "Small molecule",
            "drug_label": "VANDETANIB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 1,
            "disease_id": "EFO_0003060",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor inhibitor"
            ],
            "clinical_trial_phase_label": "Phase I",
            "disease_name": "non-small cell lung carcinoma",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00496275%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00506051%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL24828"
        },
        {
            "status": "Completed",
            "count": 1,
            "drug_type": "Small molecule",
            "drug_label": "VANDETANIB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 1,
            "disease_id": "EFO_0006859",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor inhibitor"
            ],
            "clinical_trial_phase_label": "Phase I",
            "disease_name": "head and neck malignant neoplasia",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00450138%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL24828"
        },
        {
            "status": "Completed",
            "count": 1,
            "drug_type": "Small molecule",
            "drug_label": "VANDETANIB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 1,
            "disease_id": "EFO_1000026",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor inhibitor"
            ],
            "clinical_trial_phase_label": "Phase I",
            "disease_name": "diffuse intrinsic pontine glioma",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00996723%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL24828"
        },
        {
            "status": "Completed",
            "count": 2,
            "drug_type": "Small molecule",
            "drug_label": "VANDETANIB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 1,
            "disease_id": "EFO_1001465",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor inhibitor"
            ],
            "clinical_trial_phase_label": "Phase I",
            "disease_name": "gliosarcoma",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00441142%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00613223%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL24828"
        },
        {
            "status": "Completed",
            "count": 2,
            "drug_type": "Small molecule",
            "drug_label": "VANDETANIB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 1,
            "disease_id": "EFO_1001951",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor inhibitor"
            ],
            "clinical_trial_phase_label": "Phase I",
            "disease_name": "colorectal carcinoma",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00436072%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00496509%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL24828"
        },
        {
            "status": "Completed",
            "count": 4,
            "drug_type": "Small molecule",
            "drug_label": "VARLITINIB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 1,
            "disease_id": "EFO_0000311",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase I",
            "disease_name": "cancer",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00278902%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00637702%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00710736%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00833326%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL2103842"
        },
        {
            "status": "Completed",
            "count": 1,
            "drug_type": "Small molecule",
            "drug_label": "VARLITINIB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 1,
            "disease_id": "EFO_0002618",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase I",
            "disease_name": "pancreatic carcinoma",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00862524%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL2103842"
        },
        {
            "status": "Completed",
            "count": 1,
            "drug_type": "Small molecule",
            "drug_label": "VARLITINIB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 1,
            "disease_id": "EFO_0003891",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase I",
            "disease_name": "biliary tract neoplasm",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT03082053%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL2103842"
        },
        {
            "status": "Completed",
            "count": 1,
            "drug_type": "Antibody",
            "drug_label": "ZALUTUMUMAB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 1,
            "disease_id": "EFO_0004284",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 antagonist"
            ],
            "clinical_trial_phase_label": "Phase I",
            "disease_name": "upper aerodigestive tract neoplasm",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00093041%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL2107861"
        },
        {
            "status": "Completed",
            "count": 1,
            "drug_type": "Antibody",
            "drug_label": "ZALUTUMUMAB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 1,
            "disease_id": "EFO_0006859",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 antagonist"
            ],
            "clinical_trial_phase_label": "Phase I",
            "disease_name": "head and neck malignant neoplasia",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT01054625%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL2107861"
        },
        {
            "status": "Not yet recruiting",
            "count": 1,
            "drug_type": "Small molecule",
            "drug_label": "AFATINIB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 1,
            "disease_id": "EFO_0001065",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase I",
            "disease_name": "endometriosis",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT03481842%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL1173655"
        },
        {
            "status": "Not yet recruiting",
            "count": 1,
            "drug_type": "Small molecule",
            "drug_label": "AFATINIB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 1,
            "disease_id": "EFO_0003060",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase I",
            "disease_name": "non-small cell lung carcinoma",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT03827070%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL1173655"
        },
        {
            "status": "Not yet recruiting",
            "count": 1,
            "drug_type": "Small molecule",
            "drug_label": "BRIGATINIB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 1,
            "disease_id": "EFO_0003060",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase I",
            "disease_name": "non-small cell lung carcinoma",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT03420742%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL3545311"
        },
        {
            "status": "Not yet recruiting",
            "count": 1,
            "drug_type": "Antibody",
            "drug_label": "CETUXIMAB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 1,
            "disease_id": "EFO_0000181",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase I",
            "disease_name": "head and neck squamous cell carcinoma",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT03169764%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL1201577"
        },
        {
            "status": "Not yet recruiting",
            "count": 1,
            "drug_type": "Antibody",
            "drug_label": "CETUXIMAB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 1,
            "disease_id": "EFO_0000616",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase I",
            "disease_name": "neoplasm",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT03783403%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL1201577"
        },
        {
            "status": "Not yet recruiting",
            "count": 1,
            "drug_type": "Antibody",
            "drug_label": "CETUXIMAB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 1,
            "disease_id": "EFO_0004284",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase I",
            "disease_name": "upper aerodigestive tract neoplasm",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT03051906%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL1201577"
        },
        {
            "status": "Not yet recruiting",
            "count": 1,
            "drug_type": "Antibody",
            "drug_label": "CETUXIMAB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 1,
            "disease_id": "EFO_0005842",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase I",
            "disease_name": "colorectal cancer",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT02826837%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL1201577"
        },
        {
            "status": "Not yet recruiting",
            "count": 2,
            "drug_type": "Antibody",
            "drug_label": "CETUXIMAB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 1,
            "disease_id": "EFO_1001951",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase I",
            "disease_name": "colorectal carcinoma",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT03169777%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT03491709%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL1201577"
        },
        {
            "status": "Not yet recruiting",
            "count": 1,
            "drug_type": "Antibody",
            "drug_label": "CETUXIMAB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 1,
            "disease_id": "Orphanet_178",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase I",
            "disease_name": "Chordoma",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT03647423%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL1201577"
        },
        {
            "status": "Not yet recruiting",
            "count": 2,
            "drug_type": "Small molecule",
            "drug_label": "DACOMITINIB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 1,
            "disease_id": "EFO_0001421",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor",
                "Epidermal growth factor receptor inhibitor"
            ],
            "clinical_trial_phase_label": "Phase I",
            "disease_name": "liver disease",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT03865446%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT03865446%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL2110732"
        },
        {
            "status": "Not yet recruiting",
            "count": 1,
            "drug_type": "Antibody",
            "drug_label": "NIMOTUZUMAB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 1,
            "disease_id": "EFO_0000311",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase I",
            "disease_name": "cancer",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT03554889%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL2108359"
        },
        {
            "status": "Not yet recruiting",
            "count": 2,
            "drug_type": "Small molecule",
            "drug_label": "OSIMERTINIB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 1,
            "disease_id": "EFO_0003060",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor",
                "Epidermal growth factor receptor inhibitor"
            ],
            "clinical_trial_phase_label": "Phase I",
            "disease_name": "non-small cell lung carcinoma",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT03831932%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT03831932%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL3353410"
        },
        {
            "status": "Not yet recruiting",
            "count": 1,
            "drug_type": "Small molecule",
            "drug_label": "POZIOTINIB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 1,
            "disease_id": "EFO_0000616",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor inhibitor"
            ],
            "clinical_trial_phase_label": "Phase I",
            "disease_name": "neoplasm",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT03804515%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL3545154"
        },
        {
            "status": "Recruiting",
            "count": 1,
            "drug_type": "Small molecule",
            "drug_label": "AFATINIB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 1,
            "disease_id": "EFO_0000707",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase I",
            "disease_name": "squamous cell carcinoma",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT03652233%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL1173655"
        },
        {
            "status": "Recruiting",
            "count": 1,
            "drug_type": "Small molecule",
            "drug_label": "AFATINIB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 1,
            "disease_id": "EFO_0003060",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase I",
            "disease_name": "non-small cell lung carcinoma",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT03054038%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL1173655"
        },
        {
            "status": "Recruiting",
            "count": 1,
            "drug_type": "Small molecule",
            "drug_label": "AFATINIB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 1,
            "disease_id": "EFO_0003833",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase I",
            "disease_name": "brain neoplasm",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT02423525%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL1173655"
        },
        {
            "status": "Recruiting",
            "count": 2,
            "drug_type": "Antibody",
            "drug_label": "CETUXIMAB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 1,
            "disease_id": "EFO_0000181",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase I",
            "disease_name": "head and neck squamous cell carcinoma",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT02054442%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT03498378%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL1201577"
        },
        {
            "status": "Recruiting",
            "count": 1,
            "drug_type": "Antibody",
            "drug_label": "CETUXIMAB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 1,
            "disease_id": "EFO_0000182",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase I",
            "disease_name": "hepatocellular carcinoma",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT03563170%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL1201577"
        },
        {
            "status": "Recruiting",
            "count": 1,
            "drug_type": "Antibody",
            "drug_label": "CETUXIMAB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 1,
            "disease_id": "EFO_0000519",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase I",
            "disease_name": "glioblastoma multiforme",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT02861898%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL1201577"
        },
        {
            "status": "Recruiting",
            "count": 1,
            "drug_type": "Antibody",
            "drug_label": "CETUXIMAB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 1,
            "disease_id": "EFO_0000616",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase I",
            "disease_name": "neoplasm",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT03693612%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL1201577"
        },
        {
            "status": "Recruiting",
            "count": 5,
            "drug_type": "Antibody",
            "drug_label": "CETUXIMAB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 1,
            "disease_id": "EFO_0000707",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase I",
            "disease_name": "squamous cell carcinoma",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT02101034%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT02438995%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT02822482%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT03387111%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT03667482%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL1201577"
        },
        {
            "status": "Recruiting",
            "count": 1,
            "drug_type": "Antibody",
            "drug_label": "CETUXIMAB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 1,
            "disease_id": "EFO_0003060",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase I",
            "disease_name": "non-small cell lung carcinoma",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT02845856%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL1201577"
        },
        {
            "status": "Recruiting",
            "count": 1,
            "drug_type": "Antibody",
            "drug_label": "CETUXIMAB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 1,
            "disease_id": "EFO_0004142",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase I",
            "disease_name": "colorectal neoplasm",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT02953782%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL1201577"
        },
        {
            "status": "Recruiting",
            "count": 1,
            "drug_type": "Antibody",
            "drug_label": "CETUXIMAB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 1,
            "disease_id": "EFO_0004284",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase I",
            "disease_name": "upper aerodigestive tract neoplasm",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT02643550%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL1201577"
        },
        {
            "status": "Recruiting",
            "count": 1,
            "drug_type": "Antibody",
            "drug_label": "CETUXIMAB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 1,
            "disease_id": "EFO_0006859",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase I",
            "disease_name": "head and neck malignant neoplasia",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT03024489%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL1201577"
        },
        {
            "status": "Recruiting",
            "count": 3,
            "drug_type": "Antibody",
            "drug_label": "CETUXIMAB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 1,
            "disease_id": "EFO_1001480",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase I",
            "disease_name": "metastatic colorectal cancer",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT02117466%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT03356158%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT03563157%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL1201577"
        },
        {
            "status": "Recruiting",
            "count": 2,
            "drug_type": "Small molecule",
            "drug_label": "DACOMITINIB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 1,
            "disease_id": "EFO_0000616",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor",
                "Epidermal growth factor receptor inhibitor"
            ],
            "clinical_trial_phase_label": "Phase I",
            "disease_name": "neoplasm",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT01920061%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT01920061%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL2110732"
        },
        {
            "status": "Recruiting",
            "count": 2,
            "drug_type": "Small molecule",
            "drug_label": "DACOMITINIB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 1,
            "disease_id": "EFO_0003060",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor",
                "Epidermal growth factor receptor inhibitor"
            ],
            "clinical_trial_phase_label": "Phase I",
            "disease_name": "non-small cell lung carcinoma",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT03810807%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT03810807%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL2110732"
        },
        {
            "status": "Recruiting",
            "count": 2,
            "drug_type": "Small molecule",
            "drug_label": "DACOMITINIB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 1,
            "disease_id": "EFO_1001951",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor",
                "Epidermal growth factor receptor inhibitor"
            ],
            "clinical_trial_phase_label": "Phase I",
            "disease_name": "colorectal carcinoma",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT02039336%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT02039336%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL2110732"
        },
        {
            "status": "Recruiting",
            "count": 1,
            "drug_type": "Antibody",
            "drug_label": "DEPATUXIZUMAB MAFODOTIN",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 1,
            "disease_id": "EFO_0000519",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 binding agent"
            ],
            "clinical_trial_phase_label": "Phase I",
            "disease_name": "glioblastoma multiforme",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT02590263%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "up_or_down",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL3707277"
        },
        {
            "status": "Recruiting",
            "count": 2,
            "drug_type": "Small molecule",
            "drug_label": "EGF816",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 1,
            "disease_id": "EFO_0003060",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase I",
            "disease_name": "non-small cell lung carcinoma",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT02335944%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT03333343%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL3545234"
        },
        {
            "status": "Recruiting",
            "count": 1,
            "drug_type": "Small molecule",
            "drug_label": "EGF816",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 1,
            "disease_id": "EFO_1000849",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase I",
            "disease_name": "bronchial neoplasm",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT03516214%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL3545234"
        },
        {
            "status": "Recruiting",
            "count": 1,
            "drug_type": "Small molecule",
            "drug_label": "EPITINIB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 1,
            "disease_id": "EFO_0000519",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase I",
            "disease_name": "glioblastoma multiforme",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT03231501%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL3545121"
        },
        {
            "status": "Recruiting",
            "count": 1,
            "drug_type": "Small molecule",
            "drug_label": "ERLOTINIB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 1,
            "disease_id": "EFO_0000311",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase I",
            "disease_name": "cancer",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT02099058%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL553"
        },
        {
            "status": "Recruiting",
            "count": 1,
            "drug_type": "Small molecule",
            "drug_label": "ERLOTINIB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 1,
            "disease_id": "EFO_0000571",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase I",
            "disease_name": "lung adenocarcinoma",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT03076164%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL553"
        },
        {
            "status": "Recruiting",
            "count": 1,
            "drug_type": "Small molecule",
            "drug_label": "ERLOTINIB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 1,
            "disease_id": "EFO_0000616",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase I",
            "disease_name": "neoplasm",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT02942095%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL553"
        },
        {
            "status": "Recruiting",
            "count": 1,
            "drug_type": "Small molecule",
            "drug_label": "ERLOTINIB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 1,
            "disease_id": "EFO_0002618",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase I",
            "disease_name": "pancreatic carcinoma",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT03403049%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL553"
        },
        {
            "status": "Recruiting",
            "count": 4,
            "drug_type": "Small molecule",
            "drug_label": "ERLOTINIB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 1,
            "disease_id": "EFO_0003060",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase I",
            "disease_name": "non-small cell lung carcinoma",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT01859026%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT01911507%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT02991651%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT03050411%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL553"
        },
        {
            "status": "Recruiting",
            "count": 1,
            "drug_type": "Small molecule",
            "drug_label": "ERLOTINIB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 1,
            "disease_id": "EFO_0003860",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase I",
            "disease_name": "pancreatic neoplasm",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT02737228%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL553"
        },
        {
            "status": "Recruiting",
            "count": 5,
            "drug_type": "Small molecule",
            "drug_label": "GEFITINIB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 1,
            "disease_id": "EFO_0003060",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase I",
            "disease_name": "non-small cell lung carcinoma",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT03050411%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT03122717%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT03333343%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT03599518%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT03758287%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL939"
        },
        {
            "status": "Recruiting",
            "count": 1,
            "drug_type": "Small molecule",
            "drug_label": "LAPATINIB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 1,
            "disease_id": "EFO_0000305",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase I",
            "disease_name": "breast carcinoma",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT03052634%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL554"
        },
        {
            "status": "Recruiting",
            "count": 1,
            "drug_type": "Small molecule",
            "drug_label": "LAPATINIB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 1,
            "disease_id": "EFO_1001951",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase I",
            "disease_name": "colorectal carcinoma",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT02230553%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL554"
        },
        {
            "status": "Recruiting",
            "count": 1,
            "drug_type": "Antibody",
            "drug_label": "NECITUMUMAB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 1,
            "disease_id": "EFO_0000707",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase I",
            "disease_name": "squamous cell carcinoma",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT03387111%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL1743047"
        },
        {
            "status": "Recruiting",
            "count": 2,
            "drug_type": "Antibody",
            "drug_label": "NECITUMUMAB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 1,
            "disease_id": "EFO_0003060",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase I",
            "disease_name": "non-small cell lung carcinoma",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT02496663%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT03054038%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL1743047"
        },
        {
            "status": "Recruiting",
            "count": 4,
            "drug_type": "Small molecule",
            "drug_label": "NERATINIB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 1,
            "disease_id": "EFO_0000305",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor",
                "Epidermal growth factor receptor inhibitor"
            ],
            "clinical_trial_phase_label": "Phase I",
            "disease_name": "breast carcinoma",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT02236000%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT02236000%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT03377387%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT03377387%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL180022"
        },
        {
            "status": "Recruiting",
            "count": 2,
            "drug_type": "Small molecule",
            "drug_label": "NERATINIB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 1,
            "disease_id": "EFO_0003869",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor",
                "Epidermal growth factor receptor inhibitor"
            ],
            "clinical_trial_phase_label": "Phase I",
            "disease_name": "breast neoplasm",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT03101748%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT03101748%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL180022"
        },
        {
            "status": "Recruiting",
            "count": 1,
            "drug_type": "Antibody",
            "drug_label": "NIMOTUZUMAB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 1,
            "disease_id": "EFO_0003060",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase I",
            "disease_name": "non-small cell lung carcinoma",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT02947386%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL2108359"
        },
        {
            "status": "Recruiting",
            "count": 4,
            "drug_type": "Small molecule",
            "drug_label": "OSIMERTINIB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 1,
            "disease_id": "EFO_0001071",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor",
                "Epidermal growth factor receptor inhibitor"
            ],
            "clinical_trial_phase_label": "Phase I",
            "disease_name": "lung carcinoma",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT02917993%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT02917993%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT03567642%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT03567642%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL3353410"
        },
        {
            "status": "Recruiting",
            "count": 28,
            "drug_type": "Small molecule",
            "drug_label": "OSIMERTINIB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 1,
            "disease_id": "EFO_0003060",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor",
                "Epidermal growth factor receptor inhibitor"
            ],
            "clinical_trial_phase_label": "Phase I",
            "disease_name": "non-small cell lung carcinoma",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT02143466%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT02143466%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT02496663%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT02496663%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT02503722%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT02503722%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT02520778%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT02520778%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT02803203%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT02803203%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT03050411%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT03050411%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT03122717%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT03122717%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT03255083%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT03255083%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT03381274%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT03381274%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT03418532%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT03418532%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT03455829%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT03455829%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT03463525%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT03463525%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT03535363%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT03535363%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT03810807%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT03810807%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL3353410"
        },
        {
            "status": "Recruiting",
            "count": 1,
            "drug_type": "Small molecule",
            "drug_label": "PYROTINIB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 1,
            "disease_id": "EFO_0000178",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase I",
            "disease_name": "gastric carcinoma",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT02500199%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL3544956"
        },
        {
            "status": "Recruiting",
            "count": 2,
            "drug_type": "Small molecule",
            "drug_label": "PYROTINIB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 1,
            "disease_id": "EFO_0000305",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase I",
            "disease_name": "breast carcinoma",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT02500199%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT03772353%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL3544956"
        },
        {
            "status": "Recruiting",
            "count": 1,
            "drug_type": "Small molecule",
            "drug_label": "PYROTINIB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 1,
            "disease_id": "EFO_0003060",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase I",
            "disease_name": "non-small cell lung carcinoma",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT02500199%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL3544956"
        },
        {
            "status": "Recruiting",
            "count": 1,
            "drug_type": "Small molecule",
            "drug_label": "PYROTINIB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 1,
            "disease_id": "EFO_0005537",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase I",
            "disease_name": "triple-negative breast cancer",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT03805399%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL3544956"
        },
        {
            "status": "Recruiting",
            "count": 1,
            "drug_type": "Small molecule",
            "drug_label": "VANDETANIB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 1,
            "disease_id": "EFO_0000311",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor inhibitor"
            ],
            "clinical_trial_phase_label": "Phase I",
            "disease_name": "cancer",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT01582191%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL24828"
        },
        {
            "status": "Recruiting",
            "count": 1,
            "drug_type": "Small molecule",
            "drug_label": "VARLITINIB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 1,
            "disease_id": "EFO_0003891",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase I",
            "disease_name": "biliary tract neoplasm",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT02992340%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL2103842"
        },
        {
            "status": "Suspended",
            "count": 2,
            "drug_type": "Small molecule",
            "drug_label": "DACOMITINIB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 1,
            "disease_id": "EFO_0003060",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor",
                "Epidermal growth factor receptor inhibitor"
            ],
            "clinical_trial_phase_label": "Phase I",
            "disease_name": "non-small cell lung carcinoma",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT01918761%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT01918761%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL2110732"
        },
        {
            "status": "Suspended",
            "count": 1,
            "drug_type": "Small molecule",
            "drug_label": "LAPATINIB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 1,
            "disease_id": "EFO_0000305",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase I",
            "disease_name": "breast carcinoma",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT01589861%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL554"
        },
        {
            "status": "Terminated",
            "count": 1,
            "drug_type": "Small molecule",
            "drug_label": "AFATINIB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 1,
            "disease_id": "EFO_0000181",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase I",
            "disease_name": "head and neck squamous cell carcinoma",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT01732640%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL1173655"
        },
        {
            "status": "Terminated",
            "count": 1,
            "drug_type": "Small molecule",
            "drug_label": "AFATINIB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 1,
            "disease_id": "EFO_0009709",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase I",
            "disease_name": "metastatic neoplasm",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT01679405%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL1173655"
        },
        {
            "status": "Terminated",
            "count": 1,
            "drug_type": "Antibody",
            "drug_label": "CETUXIMAB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 1,
            "disease_id": "EFO_0000178",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase I",
            "disease_name": "gastric carcinoma",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT01611506%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL1201577"
        },
        {
            "status": "Terminated",
            "count": 3,
            "drug_type": "Antibody",
            "drug_label": "CETUXIMAB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 1,
            "disease_id": "EFO_0000181",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase I",
            "disease_name": "head and neck squamous cell carcinoma",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT01015664%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT01360827%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT01602315%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL1201577"
        },
        {
            "status": "Terminated",
            "count": 1,
            "drug_type": "Antibody",
            "drug_label": "CETUXIMAB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 1,
            "disease_id": "EFO_0000311",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase I",
            "disease_name": "cancer",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT03009058%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL1201577"
        },
        {
            "status": "Terminated",
            "count": 2,
            "drug_type": "Antibody",
            "drug_label": "CETUXIMAB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 1,
            "disease_id": "EFO_0000616",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase I",
            "disease_name": "neoplasm",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00811993%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00954512%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL1201577"
        },
        {
            "status": "Terminated",
            "count": 1,
            "drug_type": "Antibody",
            "drug_label": "CETUXIMAB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 1,
            "disease_id": "EFO_0001071",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase I",
            "disease_name": "lung carcinoma",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00288054%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL1201577"
        },
        {
            "status": "Terminated",
            "count": 1,
            "drug_type": "Antibody",
            "drug_label": "CETUXIMAB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 1,
            "disease_id": "EFO_0002618",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase I",
            "disease_name": "pancreatic carcinoma",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT01042028%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL1201577"
        },
        {
            "status": "Terminated",
            "count": 3,
            "drug_type": "Antibody",
            "drug_label": "CETUXIMAB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 1,
            "disease_id": "EFO_0006859",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase I",
            "disease_name": "head and neck malignant neoplasia",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00882583%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00927147%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT01009346%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL1201577"
        },
        {
            "status": "Terminated",
            "count": 1,
            "drug_type": "Antibody",
            "drug_label": "CETUXIMAB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 1,
            "disease_id": "EFO_1000657",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase I",
            "disease_name": "rectum cancer",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00226941%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL1201577"
        },
        {
            "status": "Terminated",
            "count": 1,
            "drug_type": "Antibody",
            "drug_label": "CETUXIMAB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 1,
            "disease_id": "EFO_1001950",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase I",
            "disease_name": "colon carcinoma",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00494611%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL1201577"
        },
        {
            "status": "Terminated",
            "count": 2,
            "drug_type": "Antibody",
            "drug_label": "CETUXIMAB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 1,
            "disease_id": "EFO_1001951",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase I",
            "disease_name": "colorectal carcinoma",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00361244%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00719199%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL1201577"
        },
        {
            "status": "Terminated",
            "count": 1,
            "drug_type": "Small molecule",
            "drug_label": "CUDC-101",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 1,
            "disease_id": "EFO_0000311",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase I",
            "disease_name": "cancer",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT01702285%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL598797"
        },
        {
            "status": "Terminated",
            "count": 2,
            "drug_type": "Small molecule",
            "drug_label": "DACOMITINIB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 1,
            "disease_id": "EFO_0003060",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor",
                "Epidermal growth factor receptor inhibitor"
            ],
            "clinical_trial_phase_label": "Phase I",
            "disease_name": "non-small cell lung carcinoma",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00971191%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00971191%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL2110732"
        },
        {
            "status": "Terminated",
            "count": 1,
            "drug_type": "Small molecule",
            "drug_label": "ERLOTINIB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 1,
            "disease_id": "EFO_0000313",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase I",
            "disease_name": "carcinoma",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00791544%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL553"
        },
        {
            "status": "Terminated",
            "count": 1,
            "drug_type": "Small molecule",
            "drug_label": "ERLOTINIB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 1,
            "disease_id": "EFO_0000326",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase I",
            "disease_name": "central nervous system cancer",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00227032%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL553"
        },
        {
            "status": "Terminated",
            "count": 1,
            "drug_type": "Small molecule",
            "drug_label": "ERLOTINIB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 1,
            "disease_id": "EFO_0000519",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase I",
            "disease_name": "glioblastoma multiforme",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT01110876%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL553"
        },
        {
            "status": "Terminated",
            "count": 1,
            "drug_type": "Small molecule",
            "drug_label": "ERLOTINIB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 1,
            "disease_id": "EFO_0000571",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase I",
            "disease_name": "lung adenocarcinoma",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00042835%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL553"
        },
        {
            "status": "Terminated",
            "count": 3,
            "drug_type": "Small molecule",
            "drug_label": "ERLOTINIB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 1,
            "disease_id": "EFO_0000616",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase I",
            "disease_name": "neoplasm",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00811993%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00954512%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT01284335%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL553"
        },
        {
            "status": "Terminated",
            "count": 1,
            "drug_type": "Small molecule",
            "drug_label": "ERLOTINIB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 1,
            "disease_id": "EFO_0000630",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase I",
            "disease_name": "oligoastrocytoma",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT01103375%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL553"
        },
        {
            "status": "Terminated",
            "count": 2,
            "drug_type": "Small molecule",
            "drug_label": "ERLOTINIB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 1,
            "disease_id": "EFO_0000681",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase I",
            "disease_name": "renal cell carcinoma",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00522249%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT01115803%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL553"
        },
        {
            "status": "Terminated",
            "count": 1,
            "drug_type": "Small molecule",
            "drug_label": "ERLOTINIB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 1,
            "disease_id": "EFO_0000708",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase I",
            "disease_name": "squamous cell lung carcinoma",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00042835%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL553"
        },
        {
            "status": "Terminated",
            "count": 1,
            "drug_type": "Small molecule",
            "drug_label": "ERLOTINIB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 1,
            "disease_id": "EFO_0001663",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase I",
            "disease_name": "prostate carcinoma",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00996502%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL553"
        },
        {
            "status": "Terminated",
            "count": 1,
            "drug_type": "Small molecule",
            "drug_label": "ERLOTINIB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 1,
            "disease_id": "EFO_0002499",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase I",
            "disease_name": "anaplastic astrocytoma",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT01103375%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL553"
        },
        {
            "status": "Terminated",
            "count": 1,
            "drug_type": "Small molecule",
            "drug_label": "ERLOTINIB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 1,
            "disease_id": "EFO_0002501",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase I",
            "disease_name": "anaplastic oligodendroglioma",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT01103375%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL553"
        },
        {
            "status": "Terminated",
            "count": 16,
            "drug_type": "Small molecule",
            "drug_label": "ERLOTINIB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 1,
            "disease_id": "EFO_0003060",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase I",
            "disease_name": "non-small cell lung carcinoma",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00042835%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00251589%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00351039%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00503971%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00522938%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00707252%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00975767%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT01026844%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT01115803%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT01188707%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT01193881%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT01471964%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT01515969%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT02206763%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT02342353%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT02495233%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL553"
        },
        {
            "status": "Terminated",
            "count": 1,
            "drug_type": "Small molecule",
            "drug_label": "ERLOTINIB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 1,
            "disease_id": "EFO_0006859",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase I",
            "disease_name": "head and neck malignant neoplasia",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00573989%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL553"
        },
        {
            "status": "Terminated",
            "count": 1,
            "drug_type": "Small molecule",
            "drug_label": "ERLOTINIB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 1,
            "disease_id": "EFO_1001465",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase I",
            "disease_name": "gliosarcoma",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT01103375%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL553"
        },
        {
            "status": "Terminated",
            "count": 1,
            "drug_type": "Antibody",
            "drug_label": "FUTUXIMAB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 1,
            "disease_id": "EFO_1001480",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 antagonist"
            ],
            "clinical_trial_phase_label": "Phase I",
            "disease_name": "metastatic colorectal cancer",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT02568046%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL2109388"
        },
        {
            "status": "Terminated",
            "count": 1,
            "drug_type": "Small molecule",
            "drug_label": "GEFITINIB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 1,
            "disease_id": "EFO_0000178",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase I",
            "disease_name": "gastric carcinoma",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00237900%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL939"
        },
        {
            "status": "Terminated",
            "count": 2,
            "drug_type": "Small molecule",
            "drug_label": "GEFITINIB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 1,
            "disease_id": "EFO_0002916",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase I",
            "disease_name": "esophageal carcinoma",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00093652%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00290719%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL939"
        },
        {
            "status": "Terminated",
            "count": 1,
            "drug_type": "Small molecule",
            "drug_label": "GEFITINIB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 1,
            "disease_id": "EFO_0006859",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase I",
            "disease_name": "head and neck malignant neoplasia",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00195078%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL939"
        },
        {
            "status": "Terminated",
            "count": 1,
            "drug_type": "Small molecule",
            "drug_label": "GEFITINIB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 1,
            "disease_id": "EFO_1001951",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase I",
            "disease_name": "colorectal carcinoma",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00087334%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL939"
        },
        {
            "status": "Terminated",
            "count": 8,
            "drug_type": "Small molecule",
            "drug_label": "LAPATINIB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 1,
            "disease_id": "EFO_0000305",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase I",
            "disease_name": "breast carcinoma",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00634088%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00963547%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT01199367%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT01238029%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT01281163%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT01495884%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT01658358%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT02131506%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL554"
        },
        {
            "status": "Terminated",
            "count": 2,
            "drug_type": "Small molecule",
            "drug_label": "LAPATINIB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 1,
            "disease_id": "EFO_0000616",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase I",
            "disease_name": "neoplasm",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00804310%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT01497626%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL554"
        },
        {
            "status": "Terminated",
            "count": 1,
            "drug_type": "Small molecule",
            "drug_label": "LAPATINIB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 1,
            "disease_id": "EFO_0001075",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase I",
            "disease_name": "ovarian carcinoma",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00317434%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL554"
        },
        {
            "status": "Terminated",
            "count": 1,
            "drug_type": "Small molecule",
            "drug_label": "LAPATINIB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 1,
            "disease_id": "EFO_0001663",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase I",
            "disease_name": "prostate carcinoma",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00953576%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL554"
        },
        {
            "status": "Terminated",
            "count": 1,
            "drug_type": "Small molecule",
            "drug_label": "LAPATINIB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 1,
            "disease_id": "EFO_0003869",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase I",
            "disease_name": "breast neoplasm",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT02131506%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL554"
        },
        {
            "status": "Terminated",
            "count": 1,
            "drug_type": "Small molecule",
            "drug_label": "MP-412",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 1,
            "disease_id": "EFO_0000616",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase I",
            "disease_name": "neoplasm",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00381654%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL3545002"
        },
        {
            "status": "Terminated",
            "count": 2,
            "drug_type": "Small molecule",
            "drug_label": "NERATINIB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 1,
            "disease_id": "EFO_0000616",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor",
                "Epidermal growth factor receptor inhibitor"
            ],
            "clinical_trial_phase_label": "Phase I",
            "disease_name": "neoplasm",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT02593708%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT02593708%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL180022"
        },
        {
            "status": "Terminated",
            "count": 1,
            "drug_type": "Antibody",
            "drug_label": "NIMOTUZUMAB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 1,
            "disease_id": "EFO_0003060",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase I",
            "disease_name": "non-small cell lung carcinoma",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00369447%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL2108359"
        },
        {
            "status": "Terminated",
            "count": 1,
            "drug_type": "Antibody",
            "drug_label": "PANITUMUMAB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 1,
            "disease_id": "EFO_0000311",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase I",
            "disease_name": "cancer",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT01128387%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL1201827"
        },
        {
            "status": "Terminated",
            "count": 1,
            "drug_type": "Antibody",
            "drug_label": "PANITUMUMAB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 1,
            "disease_id": "EFO_0001071",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase I",
            "disease_name": "lung carcinoma",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00101907%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL1201827"
        },
        {
            "status": "Terminated",
            "count": 1,
            "drug_type": "Antibody",
            "drug_label": "PANITUMUMAB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 1,
            "disease_id": "EFO_0002618",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase I",
            "disease_name": "pancreatic carcinoma",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00101907%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL1201827"
        },
        {
            "status": "Terminated",
            "count": 1,
            "drug_type": "Antibody",
            "drug_label": "PANITUMUMAB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 1,
            "disease_id": "EFO_0002916",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase I",
            "disease_name": "esophageal carcinoma",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00101907%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL1201827"
        },
        {
            "status": "Terminated",
            "count": 2,
            "drug_type": "Antibody",
            "drug_label": "PANITUMUMAB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 1,
            "disease_id": "EFO_1001951",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase I",
            "disease_name": "colorectal carcinoma",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT01504477%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT02199223%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL1201827"
        },
        {
            "status": "Terminated",
            "count": 1,
            "drug_type": "Small molecule",
            "drug_label": "ROCILETINIB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 1,
            "disease_id": "EFO_0003060",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase I",
            "disease_name": "non-small cell lung carcinoma",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT02580708%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL3545308"
        },
        {
            "status": "Terminated",
            "count": 1,
            "drug_type": "Small molecule",
            "drug_label": "TESEVATINIB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 1,
            "disease_id": "EFO_0000305",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase I",
            "disease_name": "breast carcinoma",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT02154529%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL3544983"
        },
        {
            "status": "Terminated",
            "count": 1,
            "drug_type": "Small molecule",
            "drug_label": "THELIATINIB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 1,
            "disease_id": "EFO_0000311",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase I",
            "disease_name": "cancer",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT02601274%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL3545180"
        },
        {
            "status": "Terminated",
            "count": 1,
            "drug_type": "Small molecule",
            "drug_label": "VANDETANIB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 1,
            "disease_id": "EFO_0000621",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor inhibitor"
            ],
            "clinical_trial_phase_label": "Phase I",
            "disease_name": "neuroblastoma",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00533169%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL24828"
        },
        {
            "status": "Terminated",
            "count": 1,
            "drug_type": "Small molecule",
            "drug_label": "VANDETANIB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 1,
            "disease_id": "EFO_0001075",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor inhibitor"
            ],
            "clinical_trial_phase_label": "Phase I",
            "disease_name": "ovarian carcinoma",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00862836%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL24828"
        },
        {
            "status": "Terminated",
            "count": 1,
            "drug_type": "Small molecule",
            "drug_label": "VANDETANIB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 1,
            "disease_id": "EFO_0002892",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor inhibitor"
            ],
            "clinical_trial_phase_label": "Phase I",
            "disease_name": "thyroid carcinoma",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00923247%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL24828"
        },
        {
            "status": "Terminated",
            "count": 2,
            "drug_type": "Small molecule",
            "drug_label": "VANDETANIB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 1,
            "disease_id": "EFO_0003060",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor inhibitor"
            ],
            "clinical_trial_phase_label": "Phase I",
            "disease_name": "non-small cell lung carcinoma",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00745732%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00807170%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL24828"
        },
        {
            "status": "Terminated",
            "count": 1,
            "drug_type": "Antibody",
            "drug_label": "ZALUTUMUMAB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 1,
            "disease_id": "EFO_1001951",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 antagonist"
            ],
            "clinical_trial_phase_label": "Phase I",
            "disease_name": "colorectal carcinoma",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00677924%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL2107861"
        },
        {
            "status": "Unknown status",
            "count": 2,
            "drug_type": "Small molecule",
            "drug_label": "AFATINIB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 1,
            "disease_id": "EFO_0003060",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase I",
            "disease_name": "non-small cell lung carcinoma",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT01861223%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT02145637%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL1173655"
        },
        {
            "status": "Unknown status",
            "count": 1,
            "drug_type": "Antibody",
            "drug_label": "CETUXIMAB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 1,
            "disease_id": "EFO_0000181",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase I",
            "disease_name": "head and neck squamous cell carcinoma",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT02124850%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL1201577"
        },
        {
            "status": "Unknown status",
            "count": 1,
            "drug_type": "Antibody",
            "drug_label": "CETUXIMAB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 1,
            "disease_id": "EFO_0000231",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase I",
            "disease_name": "adenoid cystic carcinoma",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT01192087%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL1201577"
        },
        {
            "status": "Unknown status",
            "count": 1,
            "drug_type": "Antibody",
            "drug_label": "CETUXIMAB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 1,
            "disease_id": "EFO_0000305",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase I",
            "disease_name": "breast carcinoma",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00367250%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL1201577"
        },
        {
            "status": "Unknown status",
            "count": 1,
            "drug_type": "Antibody",
            "drug_label": "CETUXIMAB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 1,
            "disease_id": "EFO_0000519",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase I",
            "disease_name": "glioblastoma multiforme",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00311857%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL1201577"
        },
        {
            "status": "Unknown status",
            "count": 2,
            "drug_type": "Antibody",
            "drug_label": "CETUXIMAB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 1,
            "disease_id": "EFO_0000616",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase I",
            "disease_name": "neoplasm",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT01166035%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT02215720%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL1201577"
        },
        {
            "status": "Unknown status",
            "count": 3,
            "drug_type": "Antibody",
            "drug_label": "CETUXIMAB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 1,
            "disease_id": "EFO_0000707",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase I",
            "disease_name": "squamous cell carcinoma",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00660218%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT01760811%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT02938273%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL1201577"
        },
        {
            "status": "Unknown status",
            "count": 1,
            "drug_type": "Antibody",
            "drug_label": "CETUXIMAB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 1,
            "disease_id": "EFO_0002618",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase I",
            "disease_name": "pancreatic carcinoma",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00923299%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL1201577"
        },
        {
            "status": "Unknown status",
            "count": 1,
            "drug_type": "Antibody",
            "drug_label": "CETUXIMAB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 1,
            "disease_id": "EFO_0002916",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase I",
            "disease_name": "esophageal carcinoma",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00425425%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL1201577"
        },
        {
            "status": "Unknown status",
            "count": 1,
            "drug_type": "Antibody",
            "drug_label": "CETUXIMAB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 1,
            "disease_id": "EFO_0003869",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase I",
            "disease_name": "breast neoplasm",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00353717%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL1201577"
        },
        {
            "status": "Unknown status",
            "count": 1,
            "drug_type": "Antibody",
            "drug_label": "CETUXIMAB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 1,
            "disease_id": "EFO_0004284",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase I",
            "disease_name": "upper aerodigestive tract neoplasm",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT02817113%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL1201577"
        },
        {
            "status": "Unknown status",
            "count": 1,
            "drug_type": "Antibody",
            "drug_label": "CETUXIMAB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 1,
            "disease_id": "EFO_1001951",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase I",
            "disease_name": "colorectal carcinoma",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00392470%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL1201577"
        },
        {
            "status": "Unknown status",
            "count": 1,
            "drug_type": "Small molecule",
            "drug_label": "ERLOTINIB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 1,
            "disease_id": "EFO_0000326",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase I",
            "disease_name": "central nervous system cancer",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00360854%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL553"
        },
        {
            "status": "Unknown status",
            "count": 1,
            "drug_type": "Small molecule",
            "drug_label": "ERLOTINIB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 1,
            "disease_id": "EFO_0000616",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase I",
            "disease_name": "neoplasm",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00591383%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL553"
        },
        {
            "status": "Unknown status",
            "count": 2,
            "drug_type": "Small molecule",
            "drug_label": "ERLOTINIB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 1,
            "disease_id": "EFO_0001071",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase I",
            "disease_name": "lung carcinoma",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00278148%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT02321293%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL553"
        },
        {
            "status": "Unknown status",
            "count": 1,
            "drug_type": "Small molecule",
            "drug_label": "ERLOTINIB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 1,
            "disease_id": "EFO_0002618",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase I",
            "disease_name": "pancreatic carcinoma",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT02154737%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL553"
        },
        {
            "status": "Unknown status",
            "count": 1,
            "drug_type": "Small molecule",
            "drug_label": "ERLOTINIB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 1,
            "disease_id": "EFO_0002916",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase I",
            "disease_name": "esophageal carcinoma",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00566800%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL553"
        },
        {
            "status": "Unknown status",
            "count": 2,
            "drug_type": "Small molecule",
            "drug_label": "ERLOTINIB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 1,
            "disease_id": "EFO_0003060",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase I",
            "disease_name": "non-small cell lung carcinoma",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT02080078%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT02424617%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL553"
        },
        {
            "status": "Unknown status",
            "count": 1,
            "drug_type": "Small molecule",
            "drug_label": "ERLOTINIB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 1,
            "disease_id": "EFO_0004220",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase I",
            "disease_name": "Chronic Hepatitis C infection",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT01835938%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL553"
        },
        {
            "status": "Unknown status",
            "count": 1,
            "drug_type": "Small molecule",
            "drug_label": "ERLOTINIB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 1,
            "disease_id": "EFO_0007243",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase I",
            "disease_name": "Ebola hemorrhagic fever",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT02380625%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL553"
        },
        {
            "status": "Unknown status",
            "count": 1,
            "drug_type": "Small molecule",
            "drug_label": "GEFITINIB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 1,
            "disease_id": "EFO_0001071",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase I",
            "disease_name": "lung carcinoma",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT02321293%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL939"
        },
        {
            "status": "Unknown status",
            "count": 2,
            "drug_type": "Small molecule",
            "drug_label": "GEFITINIB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 1,
            "disease_id": "EFO_0003060",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase I",
            "disease_name": "non-small cell lung carcinoma",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00497250%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00809237%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL939"
        },
        {
            "status": "Unknown status",
            "count": 1,
            "drug_type": "Small molecule",
            "drug_label": "GEFITINIB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 1,
            "disease_id": "EFO_0009260",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase I",
            "disease_name": "non-melanoma skin carcinoma",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00423397%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL939"
        },
        {
            "status": "Unknown status",
            "count": 2,
            "drug_type": "Small molecule",
            "drug_label": "LAPATINIB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 1,
            "disease_id": "EFO_0000305",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase I",
            "disease_name": "breast carcinoma",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00424164%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00912275%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL554"
        },
        {
            "status": "Unknown status",
            "count": 1,
            "drug_type": "Small molecule",
            "drug_label": "LAPATINIB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 1,
            "disease_id": "EFO_0004230",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase I",
            "disease_name": "endometrial neoplasm",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT01454479%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL554"
        },
        {
            "status": "Unknown status",
            "count": 1,
            "drug_type": "Antibody",
            "drug_label": "NIMOTUZUMAB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 1,
            "disease_id": "EFO_0000616",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase I",
            "disease_name": "neoplasm",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT02395068%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL2108359"
        },
        {
            "status": "Unknown status",
            "count": 1,
            "drug_type": "Antibody",
            "drug_label": "NIMOTUZUMAB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 1,
            "disease_id": "EFO_0000707",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase I",
            "disease_name": "squamous cell carcinoma",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT01993784%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL2108359"
        },
        {
            "status": "Unknown status",
            "count": 1,
            "drug_type": "Antibody",
            "drug_label": "NIMOTUZUMAB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 1,
            "disease_id": "EFO_0003060",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase I",
            "disease_name": "non-small cell lung carcinoma",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT01861223%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL2108359"
        },
        {
            "status": "Unknown status",
            "count": 1,
            "drug_type": "Small molecule",
            "drug_label": "PYROTINIB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 1,
            "disease_id": "EFO_0000178",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase I",
            "disease_name": "gastric carcinoma",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT02378389%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL3544956"
        },
        {
            "status": "Unknown status",
            "count": 1,
            "drug_type": "Small molecule",
            "drug_label": "SIMOTINIB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 1,
            "disease_id": "EFO_0003060",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase I",
            "disease_name": "non-small cell lung carcinoma",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT01772732%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL3545235"
        },
        {
            "status": "Unknown status",
            "count": 1,
            "drug_type": "Small molecule",
            "drug_label": "VANDETANIB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 1,
            "disease_id": "EFO_0002916",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor inhibitor"
            ],
            "clinical_trial_phase_label": "Phase I",
            "disease_name": "esophageal carcinoma",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT01183559%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL24828"
        },
        {
            "status": "Withdrawn",
            "count": 1,
            "drug_type": "Small molecule",
            "drug_label": "AC-480",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 1,
            "disease_id": "EFO_0000616",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase I",
            "disease_name": "neoplasm",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT01245543%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL1645462"
        },
        {
            "status": "Withdrawn",
            "count": 1,
            "drug_type": "Small molecule",
            "drug_label": "AFATINIB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 1,
            "disease_id": "EFO_0003060",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase I",
            "disease_name": "non-small cell lung carcinoma",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT01836341%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL1173655"
        },
        {
            "status": "Withdrawn",
            "count": 1,
            "drug_type": "Antibody",
            "drug_label": "CETUXIMAB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 1,
            "disease_id": "EFO_0000181",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase I",
            "disease_name": "head and neck squamous cell carcinoma",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT02143622%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL1201577"
        },
        {
            "status": "Withdrawn",
            "count": 1,
            "drug_type": "Antibody",
            "drug_label": "CETUXIMAB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 1,
            "disease_id": "EFO_0000311",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase I",
            "disease_name": "cancer",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT01432119%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL1201577"
        },
        {
            "status": "Withdrawn",
            "count": 1,
            "drug_type": "Antibody",
            "drug_label": "CETUXIMAB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 1,
            "disease_id": "EFO_0000616",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase I",
            "disease_name": "neoplasm",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT01031212%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL1201577"
        },
        {
            "status": "Withdrawn",
            "count": 1,
            "drug_type": "Antibody",
            "drug_label": "CETUXIMAB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 1,
            "disease_id": "EFO_0000707",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase I",
            "disease_name": "squamous cell carcinoma",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT02298595%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL1201577"
        },
        {
            "status": "Withdrawn",
            "count": 1,
            "drug_type": "Antibody",
            "drug_label": "CETUXIMAB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 1,
            "disease_id": "EFO_1001931",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase I",
            "disease_name": "oropharynx cancer",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT02298595%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL1201577"
        },
        {
            "status": "Withdrawn",
            "count": 2,
            "drug_type": "Antibody",
            "drug_label": "CETUXIMAB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 1,
            "disease_id": "EFO_1001951",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase I",
            "disease_name": "colorectal carcinoma",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT01960023%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT02573220%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL1201577"
        },
        {
            "status": "Withdrawn",
            "count": 1,
            "drug_type": "Small molecule",
            "drug_label": "ERLOTINIB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 1,
            "disease_id": "EFO_0000181",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase I",
            "disease_name": "head and neck squamous cell carcinoma",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT01465815%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL553"
        },
        {
            "status": "Withdrawn",
            "count": 1,
            "drug_type": "Small molecule",
            "drug_label": "ERLOTINIB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 1,
            "disease_id": "EFO_0000182",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase I",
            "disease_name": "hepatocellular carcinoma",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00293436%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL553"
        },
        {
            "status": "Withdrawn",
            "count": 1,
            "drug_type": "Small molecule",
            "drug_label": "ERLOTINIB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 1,
            "disease_id": "EFO_0000311",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase I",
            "disease_name": "cancer",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT01432119%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL553"
        },
        {
            "status": "Withdrawn",
            "count": 1,
            "drug_type": "Small molecule",
            "drug_label": "ERLOTINIB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 1,
            "disease_id": "EFO_0000616",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase I",
            "disease_name": "neoplasm",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00754104%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL553"
        },
        {
            "status": "Withdrawn",
            "count": 1,
            "drug_type": "Small molecule",
            "drug_label": "ERLOTINIB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 1,
            "disease_id": "EFO_0001061",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase I",
            "disease_name": "cervical carcinoma",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00428194%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL553"
        },
        {
            "status": "Withdrawn",
            "count": 2,
            "drug_type": "Small molecule",
            "drug_label": "ERLOTINIB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 1,
            "disease_id": "EFO_0001071",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase I",
            "disease_name": "lung carcinoma",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00738335%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT02044601%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL553"
        },
        {
            "status": "Withdrawn",
            "count": 1,
            "drug_type": "Small molecule",
            "drug_label": "ERLOTINIB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 1,
            "disease_id": "EFO_0002618",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase I",
            "disease_name": "pancreatic carcinoma",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT01600807%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL553"
        },
        {
            "status": "Withdrawn",
            "count": 2,
            "drug_type": "Small molecule",
            "drug_label": "ERLOTINIB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 1,
            "disease_id": "EFO_0003060",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase I",
            "disease_name": "non-small cell lung carcinoma",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00934076%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT01728181%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL553"
        },
        {
            "status": "Withdrawn",
            "count": 1,
            "drug_type": "Antibody",
            "drug_label": "FUTUXIMAB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 1,
            "disease_id": "EFO_0003060",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 antagonist"
            ],
            "clinical_trial_phase_label": "Phase I",
            "disease_name": "non-small cell lung carcinoma",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT02924233%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL2109388"
        },
        {
            "status": "Withdrawn",
            "count": 1,
            "drug_type": "Small molecule",
            "drug_label": "GEFITINIB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 1,
            "disease_id": "EFO_0001071",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase I",
            "disease_name": "lung carcinoma",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00098462%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL939"
        },
        {
            "status": "Withdrawn",
            "count": 1,
            "drug_type": "Small molecule",
            "drug_label": "GEFITINIB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 1,
            "disease_id": "EFO_0003060",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase I",
            "disease_name": "non-small cell lung carcinoma",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00268255%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL939"
        },
        {
            "status": "Withdrawn",
            "count": 1,
            "drug_type": "Antibody",
            "drug_label": "IMGATUZUMAB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 1,
            "disease_id": "EFO_0003060",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase I",
            "disease_name": "non-small cell lung carcinoma",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT01702714%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL2109389"
        },
        {
            "status": "Withdrawn",
            "count": 1,
            "drug_type": "Small molecule",
            "drug_label": "LAPATINIB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 1,
            "disease_id": "EFO_0000616",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase I",
            "disease_name": "neoplasm",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00682279%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL554"
        },
        {
            "status": "Withdrawn",
            "count": 2,
            "drug_type": "Small molecule",
            "drug_label": "NERATINIB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 1,
            "disease_id": "EFO_1001951",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor",
                "Epidermal growth factor receptor inhibitor"
            ],
            "clinical_trial_phase_label": "Phase I",
            "disease_name": "colorectal carcinoma",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT01960023%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT01960023%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL180022"
        },
        {
            "status": "Withdrawn",
            "count": 1,
            "drug_type": "Antibody",
            "drug_label": "NIMOTUZUMAB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 1,
            "disease_id": "EFO_0003060",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase I",
            "disease_name": "non-small cell lung carcinoma",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00985998%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL2108359"
        },
        {
            "status": "Withdrawn",
            "count": 1,
            "drug_type": "Antibody",
            "drug_label": "PANITUMUMAB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 1,
            "disease_id": "EFO_0003060",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase I",
            "disease_name": "non-small cell lung carcinoma",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00352950%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL1201827"
        },
        {
            "status": "Withdrawn",
            "count": 1,
            "drug_type": "Small molecule",
            "drug_label": "VANDETANIB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 1,
            "disease_id": "EFO_0000616",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor inhibitor"
            ],
            "clinical_trial_phase_label": "Phase I",
            "disease_name": "neoplasm",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00601614%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL24828"
        },
        {
            "status": "Withdrawn",
            "count": 1,
            "drug_type": "Small molecule",
            "drug_label": "VANDETANIB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 1,
            "disease_id": "EFO_0003060",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor inhibitor"
            ],
            "clinical_trial_phase_label": "Phase I",
            "disease_name": "non-small cell lung carcinoma",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT01004419%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL24828"
        },
        {
            "status": "Active, not recruiting",
            "count": 1,
            "drug_type": "Small molecule",
            "drug_label": "AFATINIB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 2,
            "disease_id": "EFO_0000181",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase II",
            "disease_name": "head and neck squamous cell carcinoma",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT01824823%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL1173655"
        },
        {
            "status": "Active, not recruiting",
            "count": 2,
            "drug_type": "Small molecule",
            "drug_label": "AFATINIB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 2,
            "disease_id": "EFO_0001071",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase II",
            "disease_name": "lung carcinoma",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT01466660%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT02629523%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL1173655"
        },
        {
            "status": "Active, not recruiting",
            "count": 6,
            "drug_type": "Small molecule",
            "drug_label": "AFATINIB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 2,
            "disease_id": "EFO_0003060",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase II",
            "disease_name": "non-small cell lung carcinoma",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT01156545%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT01746251%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT02438722%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT02716311%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT03157089%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT03727724%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL1173655"
        },
        {
            "status": "Active, not recruiting",
            "count": 1,
            "drug_type": "Small molecule",
            "drug_label": "AFATINIB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 2,
            "disease_id": "EFO_0005922",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase II",
            "disease_name": "esophageal squamous cell carcinoma",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT02353936%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL1173655"
        },
        {
            "status": "Active, not recruiting",
            "count": 1,
            "drug_type": "Small molecule",
            "drug_label": "BRIGATINIB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 2,
            "disease_id": "EFO_0003060",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase II",
            "disease_name": "non-small cell lung carcinoma",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT02094573%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL3545311"
        },
        {
            "status": "Active, not recruiting",
            "count": 6,
            "drug_type": "Antibody",
            "drug_label": "CETUXIMAB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 2,
            "disease_id": "EFO_0000181",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase II",
            "disease_name": "head and neck squamous cell carcinoma",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00736944%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT01104922%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT01154920%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT02268695%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT02499120%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT02707588%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL1201577"
        },
        {
            "status": "Active, not recruiting",
            "count": 1,
            "drug_type": "Antibody",
            "drug_label": "CETUXIMAB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 2,
            "disease_id": "EFO_0000305",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase II",
            "disease_name": "breast carcinoma",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT01097642%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL1201577"
        },
        {
            "status": "Active, not recruiting",
            "count": 3,
            "drug_type": "Antibody",
            "drug_label": "CETUXIMAB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 2,
            "disease_id": "EFO_0000707",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase II",
            "disease_name": "squamous cell carcinoma",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT01588431%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT01864772%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT02052960%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL1201577"
        },
        {
            "status": "Active, not recruiting",
            "count": 1,
            "drug_type": "Antibody",
            "drug_label": "CETUXIMAB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 2,
            "disease_id": "EFO_0001061",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase II",
            "disease_name": "cervical carcinoma",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00997009%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL1201577"
        },
        {
            "status": "Active, not recruiting",
            "count": 1,
            "drug_type": "Antibody",
            "drug_label": "CETUXIMAB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 2,
            "disease_id": "EFO_0001071",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase II",
            "disease_name": "lung carcinoma",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT01059188%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL1201577"
        },
        {
            "status": "Active, not recruiting",
            "count": 1,
            "drug_type": "Antibody",
            "drug_label": "CETUXIMAB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 2,
            "disease_id": "EFO_0001663",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase II",
            "disease_name": "prostate carcinoma",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00661492%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL1201577"
        },
        {
            "status": "Active, not recruiting",
            "count": 1,
            "drug_type": "Antibody",
            "drug_label": "CETUXIMAB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 2,
            "disease_id": "EFO_0002916",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase II",
            "disease_name": "esophageal carcinoma",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT02636088%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL1201577"
        },
        {
            "status": "Active, not recruiting",
            "count": 3,
            "drug_type": "Antibody",
            "drug_label": "CETUXIMAB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 2,
            "disease_id": "EFO_0003060",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase II",
            "disease_name": "non-small cell lung carcinoma",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT02438722%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT02716311%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT03727724%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL1201577"
        },
        {
            "status": "Active, not recruiting",
            "count": 1,
            "drug_type": "Antibody",
            "drug_label": "CETUXIMAB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 2,
            "disease_id": "EFO_0003833",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase II",
            "disease_name": "brain neoplasm",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT01012609%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL1201577"
        },
        {
            "status": "Active, not recruiting",
            "count": 1,
            "drug_type": "Antibody",
            "drug_label": "CETUXIMAB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 2,
            "disease_id": "EFO_0003835",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase II",
            "disease_name": "anal neoplasm",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00316888%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL1201577"
        },
        {
            "status": "Active, not recruiting",
            "count": 1,
            "drug_type": "Antibody",
            "drug_label": "CETUXIMAB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 2,
            "disease_id": "EFO_0004284",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase II",
            "disease_name": "upper aerodigestive tract neoplasm",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT01566435%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL1201577"
        },
        {
            "status": "Active, not recruiting",
            "count": 4,
            "drug_type": "Antibody",
            "drug_label": "CETUXIMAB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 2,
            "disease_id": "EFO_0006859",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase II",
            "disease_name": "head and neck malignant neoplasia",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00904345%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT01412229%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT01437449%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT01979211%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL1201577"
        },
        {
            "status": "Active, not recruiting",
            "count": 1,
            "drug_type": "Antibody",
            "drug_label": "CETUXIMAB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 2,
            "disease_id": "EFO_1000657",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase II",
            "disease_name": "rectum cancer",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT03391843%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL1201577"
        },
        {
            "status": "Active, not recruiting",
            "count": 4,
            "drug_type": "Antibody",
            "drug_label": "CETUXIMAB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 2,
            "disease_id": "EFO_1001480",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase II",
            "disease_name": "metastatic colorectal cancer",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT01640444%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT01832467%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT01867697%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT02296203%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL1201577"
        },
        {
            "status": "Active, not recruiting",
            "count": 6,
            "drug_type": "Antibody",
            "drug_label": "CETUXIMAB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 2,
            "disease_id": "EFO_1001951",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase II",
            "disease_name": "colorectal carcinoma",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT01079780%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT01251536%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT01442649%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT01442935%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT01776307%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT02164916%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL1201577"
        },
        {
            "status": "Active, not recruiting",
            "count": 2,
            "drug_type": "Small molecule",
            "drug_label": "DACOMITINIB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 2,
            "disease_id": "EFO_0003060",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor",
                "Epidermal growth factor receptor inhibitor"
            ],
            "clinical_trial_phase_label": "Phase II",
            "disease_name": "non-small cell lung carcinoma",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT02382796%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT02382796%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL2110732"
        },
        {
            "status": "Active, not recruiting",
            "count": 1,
            "drug_type": "Small molecule",
            "drug_label": "ERLOTINIB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 2,
            "disease_id": "EFO_0000182",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase II",
            "disease_name": "hepatocellular carcinoma",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT01180959%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL553"
        },
        {
            "status": "Active, not recruiting",
            "count": 1,
            "drug_type": "Small molecule",
            "drug_label": "ERLOTINIB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 2,
            "disease_id": "EFO_0000708",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase II",
            "disease_name": "squamous cell lung carcinoma",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT02926638%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL553"
        },
        {
            "status": "Active, not recruiting",
            "count": 3,
            "drug_type": "Small molecule",
            "drug_label": "ERLOTINIB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 2,
            "disease_id": "EFO_0001071",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase II",
            "disease_name": "lung carcinoma",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00436332%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT01248247%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT01556191%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL553"
        },
        {
            "status": "Active, not recruiting",
            "count": 2,
            "drug_type": "Small molecule",
            "drug_label": "ERLOTINIB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 2,
            "disease_id": "EFO_0002618",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase II",
            "disease_name": "pancreatic carcinoma",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00733746%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00962520%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL553"
        },
        {
            "status": "Active, not recruiting",
            "count": 10,
            "drug_type": "Small molecule",
            "drug_label": "ERLOTINIB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 2,
            "disease_id": "EFO_0003060",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase II",
            "disease_name": "non-small cell lung carcinoma",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00563784%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00977470%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT01407822%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT01532089%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT01573702%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT01683175%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT01708954%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT01897480%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT02770014%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT03074864%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL553"
        },
        {
            "status": "Active, not recruiting",
            "count": 1,
            "drug_type": "Small molecule",
            "drug_label": "ERLOTINIB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 2,
            "disease_id": "EFO_0006544",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase II",
            "disease_name": "bladder transitional cell carcinoma",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00749892%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL553"
        },
        {
            "status": "Active, not recruiting",
            "count": 2,
            "drug_type": "Small molecule",
            "drug_label": "ERLOTINIB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 2,
            "disease_id": "EFO_0006859",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase II",
            "disease_name": "head and neck malignant neoplasia",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00076310%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT01927744%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL553"
        },
        {
            "status": "Active, not recruiting",
            "count": 1,
            "drug_type": "Small molecule",
            "drug_label": "ERLOTINIB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 2,
            "disease_id": "EFO_1000044",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase II",
            "disease_name": "pancreatic adenocarcinoma",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT01729481%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL553"
        },
        {
            "status": "Active, not recruiting",
            "count": 1,
            "drug_type": "Small molecule",
            "drug_label": "ERLOTINIB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 2,
            "disease_id": "EFO_1001480",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase II",
            "disease_name": "metastatic colorectal cancer",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT02723578%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL553"
        },
        {
            "status": "Active, not recruiting",
            "count": 1,
            "drug_type": "Small molecule",
            "drug_label": "ERLOTINIB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 2,
            "disease_id": "EFO_1001927",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase II",
            "disease_name": "cutaneous squamous cell carcinoma",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT01198028%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL553"
        },
        {
            "status": "Active, not recruiting",
            "count": 1,
            "drug_type": "Small molecule",
            "drug_label": "ERLOTINIB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 2,
            "disease_id": "EFO_1001951",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase II",
            "disease_name": "colorectal carcinoma",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00940316%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL553"
        },
        {
            "status": "Active, not recruiting",
            "count": 2,
            "drug_type": "Small molecule",
            "drug_label": "GEFITINIB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 2,
            "disease_id": "EFO_0001071",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase II",
            "disease_name": "lung carcinoma",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT01466660%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT01556191%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL939"
        },
        {
            "status": "Active, not recruiting",
            "count": 2,
            "drug_type": "Small molecule",
            "drug_label": "GEFITINIB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 2,
            "disease_id": "EFO_0003060",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase II",
            "disease_name": "non-small cell lung carcinoma",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT02976116%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT03399669%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL939"
        },
        {
            "status": "Active, not recruiting",
            "count": 8,
            "drug_type": "Small molecule",
            "drug_label": "LAPATINIB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 2,
            "disease_id": "EFO_0000305",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase II",
            "disease_name": "breast carcinoma",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00436566%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00470704%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00684983%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00759642%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00820872%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00999804%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT01873833%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT02073487%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL554"
        },
        {
            "status": "Active, not recruiting",
            "count": 1,
            "drug_type": "Small molecule",
            "drug_label": "LAPATINIB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 2,
            "disease_id": "EFO_0000311",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase II",
            "disease_name": "cancer",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT01711658%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL554"
        },
        {
            "status": "Active, not recruiting",
            "count": 1,
            "drug_type": "Small molecule",
            "drug_label": "LAPATINIB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 2,
            "disease_id": "EFO_0000519",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase II",
            "disease_name": "glioblastoma multiforme",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT01591577%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL554"
        },
        {
            "status": "Active, not recruiting",
            "count": 3,
            "drug_type": "Small molecule",
            "drug_label": "LAPATINIB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 2,
            "disease_id": "EFO_0003869",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase II",
            "disease_name": "breast neoplasm",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00444535%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT01273610%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT02213042%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL554"
        },
        {
            "status": "Active, not recruiting",
            "count": 1,
            "drug_type": "Small molecule",
            "drug_label": "LAPATINIB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 2,
            "disease_id": "EFO_1001480",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase II",
            "disease_name": "metastatic colorectal cancer",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT03225937%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL554"
        },
        {
            "status": "Active, not recruiting",
            "count": 1,
            "drug_type": "Antibody",
            "drug_label": "NECITUMUMAB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 2,
            "disease_id": "EFO_0003060",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase II",
            "disease_name": "non-small cell lung carcinoma",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT02392507%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL1743047"
        },
        {
            "status": "Active, not recruiting",
            "count": 1,
            "drug_type": "Antibody",
            "drug_label": "NIMOTUZUMAB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 2,
            "disease_id": "EFO_0006859",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase II",
            "disease_name": "head and neck malignant neoplasia",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00702481%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL2108359"
        },
        {
            "status": "Active, not recruiting",
            "count": 2,
            "drug_type": "Small molecule",
            "drug_label": "OLMUTINIB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 2,
            "disease_id": "EFO_0003060",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase II",
            "disease_name": "non-small cell lung carcinoma",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT02485652%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT03228277%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL3786343"
        },
        {
            "status": "Active, not recruiting",
            "count": 4,
            "drug_type": "Small molecule",
            "drug_label": "OSIMERTINIB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 2,
            "disease_id": "EFO_0001071",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor",
                "Epidermal growth factor receptor inhibitor"
            ],
            "clinical_trial_phase_label": "Phase II",
            "disease_name": "lung carcinoma",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT02504346%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT02504346%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT02769286%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT02769286%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL3353410"
        },
        {
            "status": "Active, not recruiting",
            "count": 8,
            "drug_type": "Small molecule",
            "drug_label": "OSIMERTINIB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 2,
            "disease_id": "EFO_0003060",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor",
                "Epidermal growth factor receptor inhibitor"
            ],
            "clinical_trial_phase_label": "Phase II",
            "disease_name": "non-small cell lung carcinoma",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT02094261%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT02094261%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT02442349%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT02442349%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT02771314%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT02771314%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT03424759%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT03424759%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL3353410"
        },
        {
            "status": "Active, not recruiting",
            "count": 1,
            "drug_type": "Antibody",
            "drug_label": "PANITUMUMAB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 2,
            "disease_id": "EFO_0000305",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase II",
            "disease_name": "breast carcinoma",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT01036087%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL1201827"
        },
        {
            "status": "Active, not recruiting",
            "count": 1,
            "drug_type": "Antibody",
            "drug_label": "PANITUMUMAB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 2,
            "disease_id": "EFO_0000311",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase II",
            "disease_name": "cancer",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT01750918%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL1201827"
        },
        {
            "status": "Active, not recruiting",
            "count": 1,
            "drug_type": "Antibody",
            "drug_label": "PANITUMUMAB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 2,
            "disease_id": "EFO_0001071",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase II",
            "disease_name": "lung carcinoma",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00979212%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL1201827"
        },
        {
            "status": "Active, not recruiting",
            "count": 1,
            "drug_type": "Antibody",
            "drug_label": "PANITUMUMAB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 2,
            "disease_id": "EFO_1001480",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase II",
            "disease_name": "metastatic colorectal cancer",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT01328171%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL1201827"
        },
        {
            "status": "Active, not recruiting",
            "count": 3,
            "drug_type": "Antibody",
            "drug_label": "PANITUMUMAB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 2,
            "disease_id": "EFO_1001951",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase II",
            "disease_name": "colorectal carcinoma",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00647530%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00940316%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT01776307%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL1201827"
        },
        {
            "status": "Active, not recruiting",
            "count": 1,
            "drug_type": "Small molecule",
            "drug_label": "POZIOTINIB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 2,
            "disease_id": "EFO_0000305",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor inhibitor"
            ],
            "clinical_trial_phase_label": "Phase II",
            "disease_name": "breast carcinoma",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT02659514%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL3545154"
        },
        {
            "status": "Active, not recruiting",
            "count": 1,
            "drug_type": "Small molecule",
            "drug_label": "ROCILETINIB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 2,
            "disease_id": "EFO_0003060",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase II",
            "disease_name": "non-small cell lung carcinoma",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT02147990%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL3545308"
        },
        {
            "status": "Active, not recruiting",
            "count": 1,
            "drug_type": "Small molecule",
            "drug_label": "TESEVATINIB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 2,
            "disease_id": "EFO_0000519",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase II",
            "disease_name": "glioblastoma multiforme",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT02844439%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL3544983"
        },
        {
            "status": "Active, not recruiting",
            "count": 1,
            "drug_type": "Small molecule",
            "drug_label": "VANDETANIB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 2,
            "disease_id": "EFO_0000199",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor inhibitor"
            ],
            "clinical_trial_phase_label": "Phase II",
            "disease_name": "oral squamous cell carcinoma",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT01414426%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL24828"
        },
        {
            "status": "Active, not recruiting",
            "count": 1,
            "drug_type": "Small molecule",
            "drug_label": "VANDETANIB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 2,
            "disease_id": "EFO_0003060",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor inhibitor"
            ],
            "clinical_trial_phase_label": "Phase II",
            "disease_name": "non-small cell lung carcinoma",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT02117167%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL24828"
        },
        {
            "status": "Active, not recruiting",
            "count": 1,
            "drug_type": "Small molecule",
            "drug_label": "VANDETANIB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 2,
            "disease_id": "EFO_0003841",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor inhibitor"
            ],
            "clinical_trial_phase_label": "Phase II",
            "disease_name": "thyroid neoplasm",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00537095%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL24828"
        },
        {
            "status": "Active, not recruiting",
            "count": 1,
            "drug_type": "Small molecule",
            "drug_label": "VANDETANIB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 2,
            "disease_id": "EFO_0007535",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor inhibitor"
            ],
            "clinical_trial_phase_label": "Phase II",
            "disease_name": "verrucous carcinoma",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT01414426%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL24828"
        },
        {
            "status": "Active, not recruiting",
            "count": 1,
            "drug_type": "Small molecule",
            "drug_label": "VANDETANIB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 2,
            "disease_id": "Orphanet_44890",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor inhibitor"
            ],
            "clinical_trial_phase_label": "Phase II",
            "disease_name": "Gastrointestinal stromal tumor",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT02015065%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL24828"
        },
        {
            "status": "Active, not recruiting",
            "count": 1,
            "drug_type": "Small molecule",
            "drug_label": "VARLITINIB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 2,
            "disease_id": "EFO_0000178",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase II",
            "disease_name": "gastric carcinoma",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT03130790%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL2103842"
        },
        {
            "status": "Active, not recruiting",
            "count": 2,
            "drug_type": "Small molecule",
            "drug_label": "VARLITINIB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 2,
            "disease_id": "EFO_0003891",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase II",
            "disease_name": "biliary tract neoplasm",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT03093870%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT03231176%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL2103842"
        },
        {
            "status": "Completed",
            "count": 1,
            "drug_type": "Small molecule",
            "drug_label": "AFATINIB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 2,
            "disease_id": "EFO_0000305",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase II",
            "disease_name": "breast carcinoma",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT01594177%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL1173655"
        },
        {
            "status": "Completed",
            "count": 1,
            "drug_type": "Small molecule",
            "drug_label": "AFATINIB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 2,
            "disease_id": "EFO_0000326",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase II",
            "disease_name": "central nervous system cancer",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00727506%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL1173655"
        },
        {
            "status": "Completed",
            "count": 1,
            "drug_type": "Small molecule",
            "drug_label": "AFATINIB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 2,
            "disease_id": "EFO_0000616",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase II",
            "disease_name": "neoplasm",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00875433%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL1173655"
        },
        {
            "status": "Completed",
            "count": 2,
            "drug_type": "Small molecule",
            "drug_label": "AFATINIB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 2,
            "disease_id": "EFO_0000673",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase II",
            "disease_name": "prostate adenocarcinoma",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00706628%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT01320280%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL1173655"
        },
        {
            "status": "Completed",
            "count": 2,
            "drug_type": "Small molecule",
            "drug_label": "AFATINIB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 2,
            "disease_id": "EFO_0000707",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase II",
            "disease_name": "squamous cell carcinoma",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT01415674%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT01538381%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL1173655"
        },
        {
            "status": "Completed",
            "count": 1,
            "drug_type": "Small molecule",
            "drug_label": "AFATINIB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 2,
            "disease_id": "EFO_0001071",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase II",
            "disease_name": "lung carcinoma",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT02625168%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL1173655"
        },
        {
            "status": "Completed",
            "count": 9,
            "drug_type": "Small molecule",
            "drug_label": "AFATINIB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 2,
            "disease_id": "EFO_0003060",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase II",
            "disease_name": "non-small cell lung carcinoma",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00525148%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00711594%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00730925%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00796549%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT01003899%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT01415011%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT02369484%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT02597946%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT02747953%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL1173655"
        },
        {
            "status": "Completed",
            "count": 6,
            "drug_type": "Small molecule",
            "drug_label": "AFATINIB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 2,
            "disease_id": "EFO_0003869",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase II",
            "disease_name": "breast neoplasm",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00431067%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00708214%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00826267%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT01271725%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT01325428%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT02115048%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL1173655"
        },
        {
            "status": "Completed",
            "count": 2,
            "drug_type": "Small molecule",
            "drug_label": "AFATINIB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 2,
            "disease_id": "EFO_0004142",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase II",
            "disease_name": "colorectal neoplasm",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00801294%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT01152437%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL1173655"
        },
        {
            "status": "Completed",
            "count": 1,
            "drug_type": "Small molecule",
            "drug_label": "AFATINIB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 2,
            "disease_id": "EFO_1001480",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase II",
            "disease_name": "metastatic colorectal cancer",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT01919879%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL1173655"
        },
        {
            "status": "Completed",
            "count": 1,
            "drug_type": "Small molecule",
            "drug_label": "BMS-690514",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 2,
            "disease_id": "EFO_0000305",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase II",
            "disease_name": "breast carcinoma",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT01068704%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL3545396"
        },
        {
            "status": "Completed",
            "count": 2,
            "drug_type": "Small molecule",
            "drug_label": "BMS-690514",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 2,
            "disease_id": "EFO_0003060",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase II",
            "disease_name": "non-small cell lung carcinoma",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00743938%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT01167244%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL3545396"
        },
        {
            "status": "Completed",
            "count": 1,
            "drug_type": "Small molecule",
            "drug_label": "CANERTINIB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 2,
            "disease_id": "EFO_0001071",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase II",
            "disease_name": "lung carcinoma",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00050830%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL31965"
        },
        {
            "status": "Completed",
            "count": 1,
            "drug_type": "Small molecule",
            "drug_label": "CANERTINIB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 2,
            "disease_id": "EFO_0003869",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase II",
            "disease_name": "breast neoplasm",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00051051%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL31965"
        },
        {
            "status": "Completed",
            "count": 6,
            "drug_type": "Antibody",
            "drug_label": "CETUXIMAB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 2,
            "disease_id": "EFO_0000178",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase II",
            "disease_name": "gastric carcinoma",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00275951%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00398398%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00477711%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00699881%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00857246%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT01388790%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL1201577"
        },
        {
            "status": "Completed",
            "count": 5,
            "drug_type": "Antibody",
            "drug_label": "CETUXIMAB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 2,
            "disease_id": "EFO_0000181",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase II",
            "disease_name": "head and neck squamous cell carcinoma",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00865098%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00957853%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00971932%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT01040832%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT01218048%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL1201577"
        },
        {
            "status": "Completed",
            "count": 2,
            "drug_type": "Antibody",
            "drug_label": "CETUXIMAB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 2,
            "disease_id": "EFO_0000182",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase II",
            "disease_name": "hepatocellular carcinoma",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00142428%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00483405%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL1201577"
        },
        {
            "status": "Completed",
            "count": 2,
            "drug_type": "Antibody",
            "drug_label": "CETUXIMAB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 2,
            "disease_id": "EFO_0000228",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase II",
            "disease_name": "adenocarcinoma",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00162110%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00395252%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL1201577"
        },
        {
            "status": "Completed",
            "count": 1,
            "drug_type": "Antibody",
            "drug_label": "CETUXIMAB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 2,
            "disease_id": "EFO_0000292",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase II",
            "disease_name": "bladder carcinoma",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00645593%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL1201577"
        },
        {
            "status": "Completed",
            "count": 4,
            "drug_type": "Antibody",
            "drug_label": "CETUXIMAB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 2,
            "disease_id": "EFO_0000305",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase II",
            "disease_name": "breast carcinoma",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00232505%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00275041%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00600249%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00633464%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL1201577"
        },
        {
            "status": "Completed",
            "count": 4,
            "drug_type": "Antibody",
            "drug_label": "CETUXIMAB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 2,
            "disease_id": "EFO_0000311",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase II",
            "disease_name": "cancer",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00226239%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00552149%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00698841%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00996567%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL1201577"
        },
        {
            "status": "Completed",
            "count": 1,
            "drug_type": "Antibody",
            "drug_label": "CETUXIMAB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 2,
            "disease_id": "EFO_0000326",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase II",
            "disease_name": "central nervous system cancer",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00463073%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL1201577"
        },
        {
            "status": "Completed",
            "count": 1,
            "drug_type": "Antibody",
            "drug_label": "CETUXIMAB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 2,
            "disease_id": "EFO_0000365",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase II",
            "disease_name": "colorectal adenocarcinoma",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00437268%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL1201577"
        },
        {
            "status": "Completed",
            "count": 1,
            "drug_type": "Antibody",
            "drug_label": "CETUXIMAB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 2,
            "disease_id": "EFO_0000478",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase II",
            "disease_name": "esophageal adenocarcinoma",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00165490%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL1201577"
        },
        {
            "status": "Completed",
            "count": 2,
            "drug_type": "Antibody",
            "drug_label": "CETUXIMAB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 2,
            "disease_id": "EFO_0000503",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase II",
            "disease_name": "gastric adenocarcinoma",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00517829%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT01123811%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL1201577"
        },
        {
            "status": "Completed",
            "count": 3,
            "drug_type": "Antibody",
            "drug_label": "CETUXIMAB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 2,
            "disease_id": "EFO_0000616",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase II",
            "disease_name": "neoplasm",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00350025%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT01063075%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT01099358%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL1201577"
        },
        {
            "status": "Completed",
            "count": 1,
            "drug_type": "Antibody",
            "drug_label": "CETUXIMAB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 2,
            "disease_id": "EFO_0000691",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase II",
            "disease_name": "sarcoma",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00148109%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL1201577"
        },
        {
            "status": "Completed",
            "count": 5,
            "drug_type": "Antibody",
            "drug_label": "CETUXIMAB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 2,
            "disease_id": "EFO_0000707",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase II",
            "disease_name": "squamous cell carcinoma",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00240682%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00661427%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00671437%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT01133665%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT01181401%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL1201577"
        },
        {
            "status": "Completed",
            "count": 2,
            "drug_type": "Antibody",
            "drug_label": "CETUXIMAB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 2,
            "disease_id": "EFO_0001061",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase II",
            "disease_name": "cervical carcinoma",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00101192%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00957411%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL1201577"
        },
        {
            "status": "Completed",
            "count": 8,
            "drug_type": "Antibody",
            "drug_label": "CETUXIMAB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 2,
            "disease_id": "EFO_0001071",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase II",
            "disease_name": "lung carcinoma",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00081302%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00085501%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00103207%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00117962%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00118118%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00124618%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00193453%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00673738%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL1201577"
        },
        {
            "status": "Completed",
            "count": 2,
            "drug_type": "Antibody",
            "drug_label": "CETUXIMAB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 2,
            "disease_id": "EFO_0001075",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase II",
            "disease_name": "ovarian carcinoma",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00063401%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00086892%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL1201577"
        },
        {
            "status": "Completed",
            "count": 1,
            "drug_type": "Antibody",
            "drug_label": "CETUXIMAB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 2,
            "disease_id": "EFO_0001378",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase II",
            "disease_name": "multiple myeloma",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT01524978%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL1201577"
        },
        {
            "status": "Completed",
            "count": 1,
            "drug_type": "Antibody",
            "drug_label": "CETUXIMAB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 2,
            "disease_id": "EFO_0001663",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase II",
            "disease_name": "prostate carcinoma",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00728663%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL1201577"
        },
        {
            "status": "Completed",
            "count": 10,
            "drug_type": "Antibody",
            "drug_label": "CETUXIMAB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 2,
            "disease_id": "EFO_0002618",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase II",
            "disease_name": "pancreatic carcinoma",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00042939%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00225784%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00305760%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00305877%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00338039%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00383149%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00408564%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00536614%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00599833%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00871169%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL1201577"
        },
        {
            "status": "Completed",
            "count": 5,
            "drug_type": "Antibody",
            "drug_label": "CETUXIMAB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 2,
            "disease_id": "EFO_0002916",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase II",
            "disease_name": "esophageal carcinoma",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00096031%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00381706%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00578201%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00733889%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00815308%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL1201577"
        },
        {
            "status": "Completed",
            "count": 2,
            "drug_type": "Antibody",
            "drug_label": "CETUXIMAB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 2,
            "disease_id": "EFO_0002938",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase II",
            "disease_name": "hypopharyngeal carcinoma",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00508664%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00939627%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL1201577"
        },
        {
            "status": "Completed",
            "count": 21,
            "drug_type": "Antibody",
            "drug_label": "CETUXIMAB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 2,
            "disease_id": "EFO_0003060",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase II",
            "disease_name": "non-small cell lung carcinoma",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00063388%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00097214%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00097227%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00112346%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00115518%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00165334%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00251498%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00315185%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00330746%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00343291%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00406302%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00492206%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00828841%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00842712%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00867009%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00870870%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00874848%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00985855%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00986674%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT01102231%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT01109524%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL1201577"
        },
        {
            "status": "Completed",
            "count": 1,
            "drug_type": "Antibody",
            "drug_label": "CETUXIMAB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 2,
            "disease_id": "EFO_0003835",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase II",
            "disease_name": "anal neoplasm",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00324415%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL1201577"
        },
        {
            "status": "Completed",
            "count": 1,
            "drug_type": "Antibody",
            "drug_label": "CETUXIMAB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 2,
            "disease_id": "EFO_0003868",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase II",
            "disease_name": "mouth neoplasm",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00933387%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL1201577"
        },
        {
            "status": "Completed",
            "count": 1,
            "drug_type": "Antibody",
            "drug_label": "CETUXIMAB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 2,
            "disease_id": "EFO_0003869",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase II",
            "disease_name": "breast neoplasm",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00463788%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL1201577"
        },
        {
            "status": "Completed",
            "count": 1,
            "drug_type": "Antibody",
            "drug_label": "CETUXIMAB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 2,
            "disease_id": "EFO_0003871",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase II",
            "disease_name": "tongue neoplasm",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00939627%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL1201577"
        },
        {
            "status": "Completed",
            "count": 1,
            "drug_type": "Antibody",
            "drug_label": "CETUXIMAB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 2,
            "disease_id": "EFO_0003891",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase II",
            "disease_name": "biliary tract neoplasm",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT01216345%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL1201577"
        },
        {
            "status": "Completed",
            "count": 5,
            "drug_type": "Antibody",
            "drug_label": "CETUXIMAB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 2,
            "disease_id": "EFO_0004142",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase II",
            "disease_name": "colorectal neoplasm",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00044863%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00055419%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00083720%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT01152437%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT01450319%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL1201577"
        },
        {
            "status": "Completed",
            "count": 1,
            "drug_type": "Antibody",
            "drug_label": "CETUXIMAB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 2,
            "disease_id": "EFO_0004230",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase II",
            "disease_name": "endometrial neoplasm",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00392769%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL1201577"
        },
        {
            "status": "Completed",
            "count": 3,
            "drug_type": "Antibody",
            "drug_label": "CETUXIMAB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 2,
            "disease_id": "EFO_0004252",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase II",
            "disease_name": "nasopharyngeal neoplasm",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00700440%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT01271439%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT01326559%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL1201577"
        },
        {
            "status": "Completed",
            "count": 2,
            "drug_type": "Antibody",
            "drug_label": "CETUXIMAB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 2,
            "disease_id": "EFO_0004284",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase II",
            "disease_name": "upper aerodigestive tract neoplasm",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT01057589%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT01087970%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL1201577"
        },
        {
            "status": "Completed",
            "count": 2,
            "drug_type": "Antibody",
            "drug_label": "CETUXIMAB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 2,
            "disease_id": "EFO_0005842",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase II",
            "disease_name": "colorectal cancer",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00309179%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00637091%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL1201577"
        },
        {
            "status": "Completed",
            "count": 1,
            "drug_type": "Antibody",
            "drug_label": "CETUXIMAB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 2,
            "disease_id": "EFO_0005922",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase II",
            "disease_name": "esophageal squamous cell carcinoma",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00165490%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL1201577"
        },
        {
            "status": "Completed",
            "count": 1,
            "drug_type": "Antibody",
            "drug_label": "CETUXIMAB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 2,
            "disease_id": "EFO_0006352",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase II",
            "disease_name": "laryngeal squamous cell carcinoma",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00939627%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL1201577"
        },
        {
            "status": "Completed",
            "count": 20,
            "drug_type": "Antibody",
            "drug_label": "CETUXIMAB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 2,
            "disease_id": "EFO_0006859",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase II",
            "disease_name": "head and neck malignant neoplasia",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00004865%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00005814%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00084318%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00089297%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00096174%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00301028%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00524017%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00617734%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00623558%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00665392%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00738868%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00791141%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00833261%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00868491%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00875849%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00968435%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT01081041%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT01084083%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT01467115%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT01577173%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL1201577"
        },
        {
            "status": "Completed",
            "count": 1,
            "drug_type": "Antibody",
            "drug_label": "CETUXIMAB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 2,
            "disease_id": "EFO_0007535",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase II",
            "disease_name": "verrucous carcinoma",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00939627%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL1201577"
        },
        {
            "status": "Completed",
            "count": 1,
            "drug_type": "Antibody",
            "drug_label": "CETUXIMAB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 2,
            "disease_id": "EFO_1000044",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase II",
            "disease_name": "pancreatic adenocarcinoma",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00091026%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL1201577"
        },
        {
            "status": "Completed",
            "count": 1,
            "drug_type": "Antibody",
            "drug_label": "CETUXIMAB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 2,
            "disease_id": "EFO_1000172",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase II",
            "disease_name": "cervical squamous cell carcinoma",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00499031%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL1201577"
        },
        {
            "status": "Completed",
            "count": 1,
            "drug_type": "Antibody",
            "drug_label": "CETUXIMAB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 2,
            "disease_id": "EFO_1000251",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase II",
            "disease_name": "Fallopian Tube Carcinoma",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00063401%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL1201577"
        },
        {
            "status": "Completed",
            "count": 4,
            "drug_type": "Antibody",
            "drug_label": "CETUXIMAB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 2,
            "disease_id": "EFO_1000657",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase II",
            "disease_name": "rectum cancer",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00297128%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00353457%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00527111%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT01609231%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL1201577"
        },
        {
            "status": "Completed",
            "count": 2,
            "drug_type": "Antibody",
            "drug_label": "CETUXIMAB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 2,
            "disease_id": "EFO_1001100",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase II",
            "disease_name": "peritoneal neoplasm",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00063401%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00086892%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL1201577"
        },
        {
            "status": "Completed",
            "count": 16,
            "drug_type": "Antibody",
            "drug_label": "CETUXIMAB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 2,
            "disease_id": "EFO_1001480",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase II",
            "disease_name": "metastatic colorectal cancer",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00254137%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00286130%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00326495%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00439517%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00614393%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00660582%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00689624%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00803647%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT01051167%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT01161316%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT01225744%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT01281761%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT01292356%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT01550055%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT01919879%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT02295930%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL1201577"
        },
        {
            "status": "Completed",
            "count": 1,
            "drug_type": "Antibody",
            "drug_label": "CETUXIMAB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 2,
            "disease_id": "EFO_1001950",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase II",
            "disease_name": "colon carcinoma",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00193219%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL1201577"
        },
        {
            "status": "Completed",
            "count": 23,
            "drug_type": "Antibody",
            "drug_label": "CETUXIMAB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 2,
            "disease_id": "EFO_1001951",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase II",
            "disease_name": "colorectal carcinoma",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00005076%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00020917%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00020930%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00202787%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00227734%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00251485%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00290615%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00362102%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00437268%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00466505%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00479752%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00503685%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00551213%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00556413%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00559741%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00598975%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00640081%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00686166%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT01068132%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT01276379%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT01326000%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT01652482%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT01836653%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL1201577"
        },
        {
            "status": "Completed",
            "count": 1,
            "drug_type": "Antibody",
            "drug_label": "CETUXIMAB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 2,
            "disease_id": "EFO_1001967",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase II",
            "disease_name": "salivary gland squamous cell carcinoma",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00939627%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL1201577"
        },
        {
            "status": "Completed",
            "count": 2,
            "drug_type": "Small molecule",
            "drug_label": "DACOMITINIB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 2,
            "disease_id": "EFO_0000181",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor",
                "Epidermal growth factor receptor inhibitor"
            ],
            "clinical_trial_phase_label": "Phase II",
            "disease_name": "head and neck squamous cell carcinoma",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT01449201%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT01449201%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL2110732"
        },
        {
            "status": "Completed",
            "count": 2,
            "drug_type": "Small molecule",
            "drug_label": "DACOMITINIB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 2,
            "disease_id": "EFO_0000313",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor",
                "Epidermal growth factor receptor inhibitor"
            ],
            "clinical_trial_phase_label": "Phase II",
            "disease_name": "carcinoma",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00818441%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00818441%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL2110732"
        },
        {
            "status": "Completed",
            "count": 4,
            "drug_type": "Small molecule",
            "drug_label": "DACOMITINIB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 2,
            "disease_id": "EFO_0000519",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor",
                "Epidermal growth factor receptor inhibitor"
            ],
            "clinical_trial_phase_label": "Phase II",
            "disease_name": "glioblastoma multiforme",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT01112527%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT01112527%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT01520870%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT01520870%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL2110732"
        },
        {
            "status": "Completed",
            "count": 8,
            "drug_type": "Small molecule",
            "drug_label": "DACOMITINIB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 2,
            "disease_id": "EFO_0003060",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor",
                "Epidermal growth factor receptor inhibitor"
            ],
            "clinical_trial_phase_label": "Phase II",
            "disease_name": "non-small cell lung carcinoma",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00548093%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00548093%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00769067%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00769067%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT01465802%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT01465802%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT01858389%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT01858389%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL2110732"
        },
        {
            "status": "Completed",
            "count": 2,
            "drug_type": "Small molecule",
            "drug_label": "DACOMITINIB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 2,
            "disease_id": "EFO_0004284",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor",
                "Epidermal growth factor receptor inhibitor"
            ],
            "clinical_trial_phase_label": "Phase II",
            "disease_name": "upper aerodigestive tract neoplasm",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00768664%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00768664%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL2110732"
        },
        {
            "status": "Completed",
            "count": 1,
            "drug_type": "Antibody",
            "drug_label": "DULIGOTUZUMAB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 2,
            "disease_id": "EFO_0006859",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase II",
            "disease_name": "head and neck malignant neoplasia",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT01577173%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL3137345"
        },
        {
            "status": "Completed",
            "count": 1,
            "drug_type": "Antibody",
            "drug_label": "DULIGOTUZUMAB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 2,
            "disease_id": "EFO_1001951",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase II",
            "disease_name": "colorectal carcinoma",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT01652482%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL3137345"
        },
        {
            "status": "Completed",
            "count": 5,
            "drug_type": "Small molecule",
            "drug_label": "ERLOTINIB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 2,
            "disease_id": "EFO_0000182",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase II",
            "disease_name": "hepatocellular carcinoma",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00242502%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00287222%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00365391%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00605722%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00881751%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL553"
        },
        {
            "status": "Completed",
            "count": 1,
            "drug_type": "Small molecule",
            "drug_label": "ERLOTINIB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 2,
            "disease_id": "EFO_0000198",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase II",
            "disease_name": "myelodysplastic syndrome",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00977548%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL553"
        },
        {
            "status": "Completed",
            "count": 1,
            "drug_type": "Small molecule",
            "drug_label": "ERLOTINIB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 2,
            "disease_id": "EFO_0000233",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase II",
            "disease_name": "adenosquamous lung carcinoma",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT01294306%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL553"
        },
        {
            "status": "Completed",
            "count": 2,
            "drug_type": "Small molecule",
            "drug_label": "ERLOTINIB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 2,
            "disease_id": "EFO_0000292",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase II",
            "disease_name": "bladder carcinoma",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00088946%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00380029%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL553"
        },
        {
            "status": "Completed",
            "count": 6,
            "drug_type": "Small molecule",
            "drug_label": "ERLOTINIB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 2,
            "disease_id": "EFO_0000305",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase II",
            "disease_name": "breast carcinoma",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00030537%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00054132%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00054275%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00059852%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00109265%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00633750%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL553"
        },
        {
            "status": "Completed",
            "count": 2,
            "drug_type": "Small molecule",
            "drug_label": "ERLOTINIB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 2,
            "disease_id": "EFO_0000308",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase II",
            "disease_name": "bronchoalveolar adenocarcinoma",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00384826%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT01294306%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL553"
        },
        {
            "status": "Completed",
            "count": 3,
            "drug_type": "Small molecule",
            "drug_label": "ERLOTINIB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 2,
            "disease_id": "EFO_0000311",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase II",
            "disease_name": "cancer",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00369512%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00497224%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00585377%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL553"
        },
        {
            "status": "Completed",
            "count": 1,
            "drug_type": "Small molecule",
            "drug_label": "ERLOTINIB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 2,
            "disease_id": "EFO_0000313",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase II",
            "disease_name": "carcinoma",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00737243%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL553"
        },
        {
            "status": "Completed",
            "count": 2,
            "drug_type": "Small molecule",
            "drug_label": "ERLOTINIB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 2,
            "disease_id": "EFO_0000326",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase II",
            "disease_name": "central nervous system cancer",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00086879%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00720356%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL553"
        },
        {
            "status": "Completed",
            "count": 1,
            "drug_type": "Small molecule",
            "drug_label": "ERLOTINIB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 2,
            "disease_id": "EFO_0000519",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase II",
            "disease_name": "glioblastoma multiforme",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00337883%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL553"
        },
        {
            "status": "Completed",
            "count": 1,
            "drug_type": "Small molecule",
            "drug_label": "ERLOTINIB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 2,
            "disease_id": "EFO_0000565",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase II",
            "disease_name": "leukemia",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT01174043%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL553"
        },
        {
            "status": "Completed",
            "count": 2,
            "drug_type": "Small molecule",
            "drug_label": "ERLOTINIB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 2,
            "disease_id": "EFO_0000571",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase II",
            "disease_name": "lung adenocarcinoma",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00087412%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT01294306%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL553"
        },
        {
            "status": "Completed",
            "count": 2,
            "drug_type": "Small molecule",
            "drug_label": "ERLOTINIB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 2,
            "disease_id": "EFO_0000588",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase II",
            "disease_name": "mesothelioma",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00039182%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00137826%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL553"
        },
        {
            "status": "Completed",
            "count": 4,
            "drug_type": "Small molecule",
            "drug_label": "ERLOTINIB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 2,
            "disease_id": "EFO_0000616",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase II",
            "disease_name": "neoplasm",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00193622%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00274833%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00360360%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT02057380%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL553"
        },
        {
            "status": "Completed",
            "count": 1,
            "drug_type": "Small molecule",
            "drug_label": "ERLOTINIB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 2,
            "disease_id": "EFO_0000640",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase II",
            "disease_name": "papillary renal cell carcinoma",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT01688973%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL553"
        },
        {
            "status": "Completed",
            "count": 3,
            "drug_type": "Small molecule",
            "drug_label": "ERLOTINIB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 2,
            "disease_id": "EFO_0000681",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase II",
            "disease_name": "renal cell carcinoma",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00060307%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00081614%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00353301%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL553"
        },
        {
            "status": "Completed",
            "count": 1,
            "drug_type": "Small molecule",
            "drug_label": "ERLOTINIB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 2,
            "disease_id": "EFO_0000691",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase II",
            "disease_name": "sarcoma",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00068367%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL553"
        },
        {
            "status": "Completed",
            "count": 1,
            "drug_type": "Small molecule",
            "drug_label": "ERLOTINIB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 2,
            "disease_id": "EFO_0000707",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase II",
            "disease_name": "squamous cell carcinoma",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00476476%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL553"
        },
        {
            "status": "Completed",
            "count": 2,
            "drug_type": "Small molecule",
            "drug_label": "ERLOTINIB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 2,
            "disease_id": "EFO_0000708",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase II",
            "disease_name": "squamous cell lung carcinoma",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00087412%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT01294306%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL553"
        },
        {
            "status": "Completed",
            "count": 1,
            "drug_type": "Small molecule",
            "drug_label": "ERLOTINIB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 2,
            "disease_id": "EFO_0000756",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase II",
            "disease_name": "melanoma",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00466687%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL553"
        },
        {
            "status": "Completed",
            "count": 23,
            "drug_type": "Small molecule",
            "drug_label": "ERLOTINIB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 2,
            "disease_id": "EFO_0001071",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase II",
            "disease_name": "lung carcinoma",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00100854%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00283244%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00287989%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00354549%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00367601%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00370383%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00410059%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00411632%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00416650%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00445848%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00547105%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00550537%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00553462%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00585533%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00660816%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00661193%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00673569%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT01116219%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT01130753%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT01344824%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT01562028%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT01565538%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT02625168%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL553"
        },
        {
            "status": "Completed",
            "count": 2,
            "drug_type": "Small molecule",
            "drug_label": "ERLOTINIB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 2,
            "disease_id": "EFO_0001075",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase II",
            "disease_name": "ovarian carcinoma",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00030446%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00520013%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL553"
        },
        {
            "status": "Completed",
            "count": 4,
            "drug_type": "Small molecule",
            "drug_label": "ERLOTINIB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 2,
            "disease_id": "EFO_0001663",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase II",
            "disease_name": "prostate carcinoma",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00087035%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00148772%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00203424%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00272038%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL553"
        },
        {
            "status": "Completed",
            "count": 15,
            "drug_type": "Small molecule",
            "drug_label": "ERLOTINIB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 2,
            "disease_id": "EFO_0002618",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase II",
            "disease_name": "pancreatic carcinoma",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00313560%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00365144%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00376948%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00461708%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00550836%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00652366%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00674973%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00696696%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00709826%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00810719%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00922896%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT01210911%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT01303029%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT01454180%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT01505413%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL553"
        },
        {
            "status": "Completed",
            "count": 3,
            "drug_type": "Small molecule",
            "drug_label": "ERLOTINIB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 2,
            "disease_id": "EFO_0002890",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase II",
            "disease_name": "renal carcinoma",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00045487%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00193154%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00425386%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL553"
        },
        {
            "status": "Completed",
            "count": 2,
            "drug_type": "Small molecule",
            "drug_label": "ERLOTINIB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 2,
            "disease_id": "EFO_0002916",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase II",
            "disease_name": "esophageal carcinoma",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00393068%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00524121%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL553"
        },
        {
            "status": "Completed",
            "count": 1,
            "drug_type": "Small molecule",
            "drug_label": "ERLOTINIB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 2,
            "disease_id": "EFO_0003050",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase II",
            "disease_name": "large cell lung carcinoma",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT01294306%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL553"
        },
        {
            "status": "Completed",
            "count": 75,
            "drug_type": "Small molecule",
            "drug_label": "ERLOTINIB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 2,
            "disease_id": "EFO_0003060",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase II",
            "disease_name": "non-small cell lung carcinoma",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00062101%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00072631%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00085839%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00087412%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00095225%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00125359%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00230126%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00265317%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00294762%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00321815%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00385996%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00391248%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00447057%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00462995%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00499655%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00518011%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00531934%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00531960%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00536640%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00550173%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00567359%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00577707%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00590902%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00600015%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00600587%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00606502%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00609804%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00615758%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00621049%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00642473%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00652340%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00654420%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00701558%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00702975%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00743938%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00750698%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00760929%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00769067%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00777309%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00800202%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00816868%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00840125%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00854308%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00855894%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00888511%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00983307%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00997334%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT01027598%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT01047059%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT01101334%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT01104155%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT01153984%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT01174563%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT01186861%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT01204697%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT01217619%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT01221077%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT01229150%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT01250119%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT01260181%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT01294306%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT01310036%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT01350817%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT01372384%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT01378962%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT01395758%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT01487265%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT01866410%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT01900652%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT01996332%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT01998919%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT02013206%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT02064491%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT02117024%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT02774278%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL553"
        },
        {
            "status": "Completed",
            "count": 1,
            "drug_type": "Small molecule",
            "drug_label": "ERLOTINIB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 2,
            "disease_id": "EFO_0003860",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase II",
            "disease_name": "pancreatic neoplasm",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT01693419%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL553"
        },
        {
            "status": "Completed",
            "count": 1,
            "drug_type": "Small molecule",
            "drug_label": "ERLOTINIB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 2,
            "disease_id": "EFO_0003893",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase II",
            "disease_name": "ovarian neoplasm",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00130520%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL553"
        },
        {
            "status": "Completed",
            "count": 1,
            "drug_type": "Small molecule",
            "drug_label": "ERLOTINIB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 2,
            "disease_id": "EFO_0004230",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase II",
            "disease_name": "endometrial neoplasm",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00030485%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL553"
        },
        {
            "status": "Completed",
            "count": 1,
            "drug_type": "Small molecule",
            "drug_label": "ERLOTINIB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 2,
            "disease_id": "EFO_0004252",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase II",
            "disease_name": "nasopharyngeal neoplasm",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00603915%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL553"
        },
        {
            "status": "Completed",
            "count": 1,
            "drug_type": "Small molecule",
            "drug_label": "ERLOTINIB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 2,
            "disease_id": "EFO_0005537",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase II",
            "disease_name": "triple-negative breast cancer",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00733408%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL553"
        },
        {
            "status": "Completed",
            "count": 1,
            "drug_type": "Small molecule",
            "drug_label": "ERLOTINIB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 2,
            "disease_id": "EFO_0005567",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase II",
            "disease_name": "malignant peritoneal mesothelioma",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT01592383%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL553"
        },
        {
            "status": "Completed",
            "count": 6,
            "drug_type": "Small molecule",
            "drug_label": "ERLOTINIB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 2,
            "disease_id": "EFO_0006859",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase II",
            "disease_name": "head and neck malignant neoplasia",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00281866%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00304278%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00392704%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00570232%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00720304%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00942734%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL553"
        },
        {
            "status": "Completed",
            "count": 1,
            "drug_type": "Small molecule",
            "drug_label": "ERLOTINIB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 2,
            "disease_id": "EFO_1000026",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase II",
            "disease_name": "diffuse intrinsic pontine glioma",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT01182350%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL553"
        },
        {
            "status": "Completed",
            "count": 6,
            "drug_type": "Small molecule",
            "drug_label": "ERLOTINIB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 2,
            "disease_id": "EFO_1000044",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase II",
            "disease_name": "pancreatic adenocarcinoma",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00091026%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00366457%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00873353%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT01204372%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT01222689%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT01389440%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL553"
        },
        {
            "status": "Completed",
            "count": 1,
            "drug_type": "Small molecule",
            "drug_label": "ERLOTINIB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 2,
            "disease_id": "EFO_1000172",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase II",
            "disease_name": "cervical squamous cell carcinoma",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00031993%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL553"
        },
        {
            "status": "Completed",
            "count": 2,
            "drug_type": "Small molecule",
            "drug_label": "ERLOTINIB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 2,
            "disease_id": "EFO_1000251",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase II",
            "disease_name": "Fallopian Tube Carcinoma",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00030446%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00520013%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL553"
        },
        {
            "status": "Completed",
            "count": 1,
            "drug_type": "Small molecule",
            "drug_label": "ERLOTINIB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 2,
            "disease_id": "EFO_1000581",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase II",
            "disease_name": "Thymoma",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00369889%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL553"
        },
        {
            "status": "Completed",
            "count": 2,
            "drug_type": "Small molecule",
            "drug_label": "ERLOTINIB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 2,
            "disease_id": "EFO_1001100",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase II",
            "disease_name": "peritoneal neoplasm",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00030446%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00520013%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL553"
        },
        {
            "status": "Completed",
            "count": 6,
            "drug_type": "Small molecule",
            "drug_label": "ERLOTINIB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 2,
            "disease_id": "EFO_1001465",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase II",
            "disease_name": "gliosarcoma",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00039494%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00187486%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00445588%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00525525%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00671970%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00672243%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL553"
        },
        {
            "status": "Completed",
            "count": 1,
            "drug_type": "Small molecule",
            "drug_label": "ERLOTINIB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 2,
            "disease_id": "EFO_1001951",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase II",
            "disease_name": "colorectal carcinoma",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT01135498%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL553"
        },
        {
            "status": "Completed",
            "count": 1,
            "drug_type": "Small molecule",
            "drug_label": "ERLOTINIB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 2,
            "disease_id": "Orphanet_733",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase II",
            "disease_name": "Familial adenomatous polyposis",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT01187901%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL553"
        },
        {
            "status": "Completed",
            "count": 1,
            "drug_type": "Antibody",
            "drug_label": "FUTUXIMAB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 2,
            "disease_id": "EFO_0000707",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 antagonist"
            ],
            "clinical_trial_phase_label": "Phase II",
            "disease_name": "squamous cell carcinoma",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT01417936%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL2109388"
        },
        {
            "status": "Completed",
            "count": 1,
            "drug_type": "Antibody",
            "drug_label": "FUTUXIMAB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 2,
            "disease_id": "EFO_1001480",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 antagonist"
            ],
            "clinical_trial_phase_label": "Phase II",
            "disease_name": "metastatic colorectal cancer",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT02083653%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL2109388"
        },
        {
            "status": "Completed",
            "count": 1,
            "drug_type": "Small molecule",
            "drug_label": "GEFITINIB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 2,
            "disease_id": "EFO_0000182",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase II",
            "disease_name": "hepatocellular carcinoma",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00071994%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL939"
        },
        {
            "status": "Completed",
            "count": 1,
            "drug_type": "Small molecule",
            "drug_label": "GEFITINIB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 2,
            "disease_id": "EFO_0000222",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase II",
            "disease_name": "acute myeloid leukemia",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00130702%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL939"
        },
        {
            "status": "Completed",
            "count": 2,
            "drug_type": "Small molecule",
            "drug_label": "GEFITINIB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 2,
            "disease_id": "EFO_0000292",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase II",
            "disease_name": "bladder carcinoma",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00014144%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00246974%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL939"
        },
        {
            "status": "Completed",
            "count": 14,
            "drug_type": "Small molecule",
            "drug_label": "GEFITINIB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 2,
            "disease_id": "EFO_0000305",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase II",
            "disease_name": "breast carcinoma",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00049062%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00057941%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00066339%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00066378%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00077025%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00080743%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00234403%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00239343%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00247481%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00255463%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00319618%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00428896%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00632723%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00637026%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL939"
        },
        {
            "status": "Completed",
            "count": 1,
            "drug_type": "Small molecule",
            "drug_label": "GEFITINIB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 2,
            "disease_id": "EFO_0000311",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase II",
            "disease_name": "cancer",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00177242%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL939"
        },
        {
            "status": "Completed",
            "count": 2,
            "drug_type": "Small molecule",
            "drug_label": "GEFITINIB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 2,
            "disease_id": "EFO_0000326",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase II",
            "disease_name": "central nervous system cancer",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00016991%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00025675%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL939"
        },
        {
            "status": "Completed",
            "count": 2,
            "drug_type": "Small molecule",
            "drug_label": "GEFITINIB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 2,
            "disease_id": "EFO_0000519",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase II",
            "disease_name": "glioblastoma multiforme",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00238797%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00250887%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL939"
        },
        {
            "status": "Completed",
            "count": 2,
            "drug_type": "Small molecule",
            "drug_label": "GEFITINIB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 2,
            "disease_id": "EFO_0000588",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase II",
            "disease_name": "mesothelioma",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00025207%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00787410%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL939"
        },
        {
            "status": "Completed",
            "count": 1,
            "drug_type": "Small molecule",
            "drug_label": "GEFITINIB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 2,
            "disease_id": "EFO_0000616",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase II",
            "disease_name": "neoplasm",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00229723%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL939"
        },
        {
            "status": "Completed",
            "count": 1,
            "drug_type": "Small molecule",
            "drug_label": "GEFITINIB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 2,
            "disease_id": "EFO_0000621",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase II",
            "disease_name": "neuroblastoma",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00135135%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL939"
        },
        {
            "status": "Completed",
            "count": 1,
            "drug_type": "Small molecule",
            "drug_label": "GEFITINIB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 2,
            "disease_id": "EFO_0000691",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase II",
            "disease_name": "sarcoma",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00052754%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL939"
        },
        {
            "status": "Completed",
            "count": 1,
            "drug_type": "Small molecule",
            "drug_label": "GEFITINIB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 2,
            "disease_id": "EFO_0000702",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase II",
            "disease_name": "small cell lung carcinoma",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00298688%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL939"
        },
        {
            "status": "Completed",
            "count": 1,
            "drug_type": "Small molecule",
            "drug_label": "GEFITINIB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 2,
            "disease_id": "EFO_0000707",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase II",
            "disease_name": "squamous cell carcinoma",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00126555%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL939"
        },
        {
            "status": "Completed",
            "count": 1,
            "drug_type": "Small molecule",
            "drug_label": "GEFITINIB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 2,
            "disease_id": "EFO_0001061",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase II",
            "disease_name": "cervical carcinoma",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00049556%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL939"
        },
        {
            "status": "Completed",
            "count": 11,
            "drug_type": "Small molecule",
            "drug_label": "GEFITINIB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 2,
            "disease_id": "EFO_0001071",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase II",
            "disease_name": "lung carcinoma",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00062062%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00068653%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00103051%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00188617%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00193336%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00217698%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00238251%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00344773%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00411047%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00452244%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT01530334%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL939"
        },
        {
            "status": "Completed",
            "count": 4,
            "drug_type": "Small molecule",
            "drug_label": "GEFITINIB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 2,
            "disease_id": "EFO_0001075",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase II",
            "disease_name": "ovarian carcinoma",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00023699%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00049556%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00181688%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00189358%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL939"
        },
        {
            "status": "Completed",
            "count": 6,
            "drug_type": "Small molecule",
            "drug_label": "GEFITINIB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 2,
            "disease_id": "EFO_0001663",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase II",
            "disease_name": "prostate carcinoma",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00025116%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00241475%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00242918%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00265070%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00319787%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00635856%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL939"
        },
        {
            "status": "Completed",
            "count": 2,
            "drug_type": "Small molecule",
            "drug_label": "GEFITINIB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 2,
            "disease_id": "EFO_0002890",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase II",
            "disease_name": "renal carcinoma",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00012337%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00014183%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL939"
        },
        {
            "status": "Completed",
            "count": 3,
            "drug_type": "Small molecule",
            "drug_label": "GEFITINIB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 2,
            "disease_id": "EFO_0002916",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase II",
            "disease_name": "esophageal carcinoma",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00100945%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00258323%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00268346%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL939"
        },
        {
            "status": "Completed",
            "count": 1,
            "drug_type": "Small molecule",
            "drug_label": "GEFITINIB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 2,
            "disease_id": "EFO_0003017",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase II",
            "disease_name": "transitional cell carcinoma of kidney",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00014144%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL939"
        },
        {
            "status": "Completed",
            "count": 22,
            "drug_type": "Small molecule",
            "drug_label": "GEFITINIB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 2,
            "disease_id": "EFO_0003060",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase II",
            "disease_name": "non-small cell lung carcinoma",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00029003%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00059722%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00173875%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00198393%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00231465%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00256711%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00259064%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00264498%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00333294%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00409006%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00588445%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00824746%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00891579%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT01017679%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT01037998%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT01196234%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT01469000%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT01498562%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT01769066%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT01783834%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT01864681%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT02179671%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL939"
        },
        {
            "status": "Completed",
            "count": 1,
            "drug_type": "Small molecule",
            "drug_label": "GEFITINIB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 2,
            "disease_id": "EFO_0003826",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase II",
            "disease_name": "salivary gland neoplasm",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00509002%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL939"
        },
        {
            "status": "Completed",
            "count": 1,
            "drug_type": "Small molecule",
            "drug_label": "GEFITINIB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 2,
            "disease_id": "EFO_0003846",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase II",
            "disease_name": "urethral neoplasm",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00014144%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL939"
        },
        {
            "status": "Completed",
            "count": 1,
            "drug_type": "Small molecule",
            "drug_label": "GEFITINIB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 2,
            "disease_id": "EFO_0003859",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase II",
            "disease_name": "uterine neoplasm",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00027690%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL939"
        },
        {
            "status": "Completed",
            "count": 1,
            "drug_type": "Small molecule",
            "drug_label": "GEFITINIB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 2,
            "disease_id": "EFO_0003869",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase II",
            "disease_name": "breast neoplasm",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00229697%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL939"
        },
        {
            "status": "Completed",
            "count": 1,
            "drug_type": "Small molecule",
            "drug_label": "GEFITINIB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 2,
            "disease_id": "EFO_0004284",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase II",
            "disease_name": "upper aerodigestive tract neoplasm",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00519077%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL939"
        },
        {
            "status": "Completed",
            "count": 8,
            "drug_type": "Small molecule",
            "drug_label": "GEFITINIB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 2,
            "disease_id": "EFO_0006859",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase II",
            "disease_name": "head and neck malignant neoplasia",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00015964%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00024089%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00095836%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00193284%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00228488%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00242749%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00242762%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT01185158%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL939"
        },
        {
            "status": "Completed",
            "count": 1,
            "drug_type": "Small molecule",
            "drug_label": "GEFITINIB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 2,
            "disease_id": "EFO_0006861",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase II",
            "disease_name": "male breast carcinoma",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00024154%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL939"
        },
        {
            "status": "Completed",
            "count": 1,
            "drug_type": "Small molecule",
            "drug_label": "GEFITINIB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 2,
            "disease_id": "EFO_0009259",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase II",
            "disease_name": "skin carcinoma",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00054691%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL939"
        },
        {
            "status": "Completed",
            "count": 2,
            "drug_type": "Small molecule",
            "drug_label": "GEFITINIB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 2,
            "disease_id": "EFO_1000251",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase II",
            "disease_name": "Fallopian Tube Carcinoma",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00049556%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00189358%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL939"
        },
        {
            "status": "Completed",
            "count": 4,
            "drug_type": "Small molecule",
            "drug_label": "GEFITINIB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 2,
            "disease_id": "EFO_1001100",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase II",
            "disease_name": "peritoneal neoplasm",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00023699%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00049556%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00181688%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00189358%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL939"
        },
        {
            "status": "Completed",
            "count": 1,
            "drug_type": "Small molecule",
            "drug_label": "GEFITINIB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 2,
            "disease_id": "EFO_1001465",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase II",
            "disease_name": "gliosarcoma",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00014170%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL939"
        },
        {
            "status": "Completed",
            "count": 4,
            "drug_type": "Small molecule",
            "drug_label": "GEFITINIB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 2,
            "disease_id": "EFO_1001951",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase II",
            "disease_name": "colorectal carcinoma",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00025142%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00025350%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00030524%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00234429%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL939"
        },
        {
            "status": "Completed",
            "count": 1,
            "drug_type": "Antibody",
            "drug_label": "IMGATUZUMAB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 2,
            "disease_id": "EFO_0003060",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase II",
            "disease_name": "non-small cell lung carcinoma",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT01185847%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL2109389"
        },
        {
            "status": "Completed",
            "count": 1,
            "drug_type": "Antibody",
            "drug_label": "IMGATUZUMAB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 2,
            "disease_id": "EFO_1001951",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase II",
            "disease_name": "colorectal carcinoma",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT01326000%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL2109389"
        },
        {
            "status": "Completed",
            "count": 2,
            "drug_type": "Small molecule",
            "drug_label": "LAPATINIB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 2,
            "disease_id": "EFO_0000178",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase II",
            "disease_name": "gastric carcinoma",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00103324%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT02015169%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL554"
        },
        {
            "status": "Completed",
            "count": 1,
            "drug_type": "Small molecule",
            "drug_label": "LAPATINIB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 2,
            "disease_id": "EFO_0000181",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase II",
            "disease_name": "head and neck squamous cell carcinoma",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00371566%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL554"
        },
        {
            "status": "Completed",
            "count": 1,
            "drug_type": "Small molecule",
            "drug_label": "LAPATINIB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 2,
            "disease_id": "EFO_0000228",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase II",
            "disease_name": "adenocarcinoma",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00259987%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL554"
        },
        {
            "status": "Completed",
            "count": 20,
            "drug_type": "Small molecule",
            "drug_label": "LAPATINIB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 2,
            "disease_id": "EFO_0000305",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase II",
            "disease_name": "breast carcinoma",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00206427%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00299286%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00404066%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00477464%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00482391%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00548184%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00694252%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00721630%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00769470%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00777101%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00841828%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00967031%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT01068704%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT01262469%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT01275859%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT01485926%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT01688609%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT01827163%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT01973660%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT02338245%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL554"
        },
        {
            "status": "Completed",
            "count": 3,
            "drug_type": "Small molecule",
            "drug_label": "LAPATINIB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 2,
            "disease_id": "EFO_0000311",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase II",
            "disease_name": "cancer",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT01013740%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT01128543%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT02342587%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL554"
        },
        {
            "status": "Completed",
            "count": 1,
            "drug_type": "Small molecule",
            "drug_label": "LAPATINIB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 2,
            "disease_id": "EFO_0000326",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase II",
            "disease_name": "central nervous system cancer",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00350727%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL554"
        },
        {
            "status": "Completed",
            "count": 1,
            "drug_type": "Small molecule",
            "drug_label": "LAPATINIB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 2,
            "disease_id": "EFO_0000402",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase II",
            "disease_name": "diffuse gastric adenocarcinoma",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00103324%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL554"
        },
        {
            "status": "Completed",
            "count": 1,
            "drug_type": "Small molecule",
            "drug_label": "LAPATINIB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 2,
            "disease_id": "EFO_0000503",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase II",
            "disease_name": "gastric adenocarcinoma",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00103324%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL554"
        },
        {
            "status": "Completed",
            "count": 1,
            "drug_type": "Small molecule",
            "drug_label": "LAPATINIB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 2,
            "disease_id": "EFO_0000504",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase II",
            "disease_name": "gastric intestinal type adenocarcinoma",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00103324%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL554"
        },
        {
            "status": "Completed",
            "count": 1,
            "drug_type": "Small molecule",
            "drug_label": "LAPATINIB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 2,
            "disease_id": "EFO_0000616",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase II",
            "disease_name": "neoplasm",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00526669%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL554"
        },
        {
            "status": "Completed",
            "count": 1,
            "drug_type": "Small molecule",
            "drug_label": "LAPATINIB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 2,
            "disease_id": "EFO_0001061",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase II",
            "disease_name": "cervical carcinoma",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00430781%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL554"
        },
        {
            "status": "Completed",
            "count": 1,
            "drug_type": "Small molecule",
            "drug_label": "LAPATINIB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 2,
            "disease_id": "EFO_0001075",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase II",
            "disease_name": "ovarian carcinoma",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00436644%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL554"
        },
        {
            "status": "Completed",
            "count": 3,
            "drug_type": "Small molecule",
            "drug_label": "LAPATINIB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 2,
            "disease_id": "EFO_0001663",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase II",
            "disease_name": "prostate carcinoma",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00095667%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00103194%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00246753%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL554"
        },
        {
            "status": "Completed",
            "count": 1,
            "drug_type": "Small molecule",
            "drug_label": "LAPATINIB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 2,
            "disease_id": "EFO_0002618",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase II",
            "disease_name": "pancreatic carcinoma",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00962312%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL554"
        },
        {
            "status": "Completed",
            "count": 1,
            "drug_type": "Small molecule",
            "drug_label": "LAPATINIB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 2,
            "disease_id": "EFO_0002938",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase II",
            "disease_name": "hypopharyngeal carcinoma",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00098631%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL554"
        },
        {
            "status": "Completed",
            "count": 1,
            "drug_type": "Small molecule",
            "drug_label": "LAPATINIB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 2,
            "disease_id": "EFO_0003859",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase II",
            "disease_name": "uterine neoplasm",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00430781%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL554"
        },
        {
            "status": "Completed",
            "count": 15,
            "drug_type": "Small molecule",
            "drug_label": "LAPATINIB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 2,
            "disease_id": "EFO_0003869",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase II",
            "disease_name": "breast neoplasm",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00089999%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00105950%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00111787%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00263588%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00320411%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00347919%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00356811%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00422903%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00429299%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00477464%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00524303%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00558103%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00709761%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00826267%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT01138046%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL554"
        },
        {
            "status": "Completed",
            "count": 1,
            "drug_type": "Small molecule",
            "drug_label": "LAPATINIB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 2,
            "disease_id": "EFO_0005950",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase II",
            "disease_name": "head and neck neoplasia",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00387127%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL554"
        },
        {
            "status": "Completed",
            "count": 1,
            "drug_type": "Small molecule",
            "drug_label": "LAPATINIB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 2,
            "disease_id": "EFO_0006352",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase II",
            "disease_name": "laryngeal squamous cell carcinoma",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00098631%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL554"
        },
        {
            "status": "Completed",
            "count": 2,
            "drug_type": "Small molecule",
            "drug_label": "LAPATINIB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 2,
            "disease_id": "EFO_0006861",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase II",
            "disease_name": "male breast carcinoma",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00098605%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00118157%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL554"
        },
        {
            "status": "Completed",
            "count": 1,
            "drug_type": "Small molecule",
            "drug_label": "LAPATINIB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 2,
            "disease_id": "EFO_1000478",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase II",
            "disease_name": "Pituitary Gland Adenoma",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00939523%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL554"
        },
        {
            "status": "Completed",
            "count": 1,
            "drug_type": "Small molecule",
            "drug_label": "LAPATINIB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 2,
            "disease_id": "EFO_1001100",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase II",
            "disease_name": "peritoneal neoplasm",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00436644%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL554"
        },
        {
            "status": "Completed",
            "count": 1,
            "drug_type": "Small molecule",
            "drug_label": "LAPATINIB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 2,
            "disease_id": "EFO_1001465",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase II",
            "disease_name": "gliosarcoma",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00107003%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL554"
        },
        {
            "status": "Completed",
            "count": 1,
            "drug_type": "Small molecule",
            "drug_label": "LAPATINIB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 2,
            "disease_id": "EFO_1001480",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase II",
            "disease_name": "metastatic colorectal cancer",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00574171%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL554"
        },
        {
            "status": "Completed",
            "count": 1,
            "drug_type": "Small molecule",
            "drug_label": "LAPATINIB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 2,
            "disease_id": "EFO_1001512",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase II",
            "disease_name": "endometrial carcinoma",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00096447%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL554"
        },
        {
            "status": "Completed",
            "count": 1,
            "drug_type": "Small molecule",
            "drug_label": "LAPATINIB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 2,
            "disease_id": "EFO_1001951",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase II",
            "disease_name": "colorectal carcinoma",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00044343%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL554"
        },
        {
            "status": "Completed",
            "count": 1,
            "drug_type": "Small molecule",
            "drug_label": "LAPATINIB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 2,
            "disease_id": "EFO_1001967",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase II",
            "disease_name": "salivary gland squamous cell carcinoma",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00098631%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL554"
        },
        {
            "status": "Completed",
            "count": 1,
            "drug_type": "Antibody",
            "drug_label": "MAB-425",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 2,
            "disease_id": "EFO_0000326",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase II",
            "disease_name": "central nervous system cancer",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00589706%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL2109390"
        },
        {
            "status": "Completed",
            "count": 1,
            "drug_type": "Antibody",
            "drug_label": "MATUZUMAB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 2,
            "disease_id": "EFO_0001075",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase II",
            "disease_name": "ovarian carcinoma",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00073541%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL2108038"
        },
        {
            "status": "Completed",
            "count": 1,
            "drug_type": "Antibody",
            "drug_label": "MATUZUMAB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 2,
            "disease_id": "EFO_0003060",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase II",
            "disease_name": "non-small cell lung carcinoma",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00111839%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL2108038"
        },
        {
            "status": "Completed",
            "count": 2,
            "drug_type": "Antibody",
            "drug_label": "NECITUMUMAB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 2,
            "disease_id": "EFO_0000616",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase II",
            "disease_name": "neoplasm",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT01606748%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT01624467%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL1743047"
        },
        {
            "status": "Completed",
            "count": 2,
            "drug_type": "Antibody",
            "drug_label": "NECITUMUMAB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 2,
            "disease_id": "EFO_0003060",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase II",
            "disease_name": "non-small cell lung carcinoma",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT01769391%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT01788566%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL1743047"
        },
        {
            "status": "Completed",
            "count": 1,
            "drug_type": "Antibody",
            "drug_label": "NECITUMUMAB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 2,
            "disease_id": "EFO_1001480",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase II",
            "disease_name": "metastatic colorectal cancer",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00835185%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL1743047"
        },
        {
            "status": "Completed",
            "count": 6,
            "drug_type": "Small molecule",
            "drug_label": "NERATINIB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 2,
            "disease_id": "EFO_0000305",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor",
                "Epidermal growth factor receptor inhibitor"
            ],
            "clinical_trial_phase_label": "Phase II",
            "disease_name": "breast carcinoma",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00777101%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00777101%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00915018%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00915018%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT01008150%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT01008150%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL180022"
        },
        {
            "status": "Completed",
            "count": 4,
            "drug_type": "Small molecule",
            "drug_label": "NERATINIB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 2,
            "disease_id": "EFO_0003060",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor",
                "Epidermal growth factor receptor inhibitor"
            ],
            "clinical_trial_phase_label": "Phase II",
            "disease_name": "non-small cell lung carcinoma",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00266877%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00266877%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT01827267%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT01827267%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL180022"
        },
        {
            "status": "Completed",
            "count": 2,
            "drug_type": "Small molecule",
            "drug_label": "NERATINIB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 2,
            "disease_id": "EFO_0003869",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor",
                "Epidermal growth factor receptor inhibitor"
            ],
            "clinical_trial_phase_label": "Phase II",
            "disease_name": "breast neoplasm",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00300781%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00300781%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL180022"
        },
        {
            "status": "Completed",
            "count": 1,
            "drug_type": "Antibody",
            "drug_label": "NIMOTUZUMAB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 2,
            "disease_id": "EFO_0000181",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase II",
            "disease_name": "head and neck squamous cell carcinoma",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT01425736%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL2108359"
        },
        {
            "status": "Completed",
            "count": 2,
            "drug_type": "Antibody",
            "drug_label": "NIMOTUZUMAB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 2,
            "disease_id": "EFO_0000326",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase II",
            "disease_name": "central nervous system cancer",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00600054%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT01145170%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL2108359"
        },
        {
            "status": "Completed",
            "count": 1,
            "drug_type": "Antibody",
            "drug_label": "NIMOTUZUMAB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 2,
            "disease_id": "EFO_0000519",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase II",
            "disease_name": "glioblastoma multiforme",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT03388372%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL2108359"
        },
        {
            "status": "Completed",
            "count": 1,
            "drug_type": "Antibody",
            "drug_label": "NIMOTUZUMAB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 2,
            "disease_id": "EFO_0002618",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase II",
            "disease_name": "pancreatic carcinoma",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00561990%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL2108359"
        },
        {
            "status": "Completed",
            "count": 1,
            "drug_type": "Antibody",
            "drug_label": "NIMOTUZUMAB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 2,
            "disease_id": "EFO_0003060",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase II",
            "disease_name": "non-small cell lung carcinoma",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT01498562%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL2108359"
        },
        {
            "status": "Completed",
            "count": 1,
            "drug_type": "Antibody",
            "drug_label": "NIMOTUZUMAB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 2,
            "disease_id": "EFO_0003897",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase II",
            "disease_name": "stomach neoplasm",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT02370849%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL2108359"
        },
        {
            "status": "Completed",
            "count": 1,
            "drug_type": "Antibody",
            "drug_label": "NIMOTUZUMAB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 2,
            "disease_id": "EFO_0004252",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase II",
            "disease_name": "nasopharyngeal neoplasm",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT01616849%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL2108359"
        },
        {
            "status": "Completed",
            "count": 1,
            "drug_type": "Antibody",
            "drug_label": "NIMOTUZUMAB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 2,
            "disease_id": "EFO_0006859",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase II",
            "disease_name": "head and neck malignant neoplasia",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00910117%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL2108359"
        },
        {
            "status": "Completed",
            "count": 1,
            "drug_type": "Small molecule",
            "drug_label": "OLMUTINIB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 2,
            "disease_id": "EFO_0003060",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase II",
            "disease_name": "non-small cell lung carcinoma",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT02444819%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL3786343"
        },
        {
            "status": "Completed",
            "count": 2,
            "drug_type": "Small molecule",
            "drug_label": "OSIMERTINIB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 2,
            "disease_id": "EFO_0003060",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor",
                "Epidermal growth factor receptor inhibitor"
            ],
            "clinical_trial_phase_label": "Phase II",
            "disease_name": "non-small cell lung carcinoma",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT02179671%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT02179671%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL3353410"
        },
        {
            "status": "Completed",
            "count": 2,
            "drug_type": "Small molecule",
            "drug_label": "OSIMERTINIB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 2,
            "disease_id": "EFO_0005842",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor",
                "Epidermal growth factor receptor inhibitor"
            ],
            "clinical_trial_phase_label": "Phase II",
            "disease_name": "colorectal cancer",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT02959749%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT02959749%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL3353410"
        },
        {
            "status": "Completed",
            "count": 3,
            "drug_type": "Antibody",
            "drug_label": "PANITUMUMAB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 2,
            "disease_id": "EFO_0000181",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase II",
            "disease_name": "head and neck squamous cell carcinoma",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00454779%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00756444%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT02643056%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL1201827"
        },
        {
            "status": "Completed",
            "count": 1,
            "drug_type": "Antibody",
            "drug_label": "PANITUMUMAB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 2,
            "disease_id": "EFO_0000305",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase II",
            "disease_name": "breast carcinoma",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00894504%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL1201827"
        },
        {
            "status": "Completed",
            "count": 1,
            "drug_type": "Antibody",
            "drug_label": "PANITUMUMAB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 2,
            "disease_id": "EFO_0000311",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase II",
            "disease_name": "cancer",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT01358812%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL1201827"
        },
        {
            "status": "Completed",
            "count": 1,
            "drug_type": "Antibody",
            "drug_label": "PANITUMUMAB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 2,
            "disease_id": "EFO_0000313",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase II",
            "disease_name": "carcinoma",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT01389414%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL1201827"
        },
        {
            "status": "Completed",
            "count": 1,
            "drug_type": "Antibody",
            "drug_label": "PANITUMUMAB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 2,
            "disease_id": "EFO_0000365",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase II",
            "disease_name": "colorectal adenocarcinoma",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT01704703%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL1201827"
        },
        {
            "status": "Completed",
            "count": 1,
            "drug_type": "Antibody",
            "drug_label": "PANITUMUMAB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 2,
            "disease_id": "EFO_0000681",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase II",
            "disease_name": "renal cell carcinoma",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00425035%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL1201827"
        },
        {
            "status": "Completed",
            "count": 1,
            "drug_type": "Antibody",
            "drug_label": "PANITUMUMAB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 2,
            "disease_id": "EFO_0000707",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase II",
            "disease_name": "squamous cell carcinoma",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT01285778%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL1201827"
        },
        {
            "status": "Completed",
            "count": 1,
            "drug_type": "Antibody",
            "drug_label": "PANITUMUMAB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 2,
            "disease_id": "EFO_0001075",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase II",
            "disease_name": "ovarian carcinoma",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00861120%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL1201827"
        },
        {
            "status": "Completed",
            "count": 2,
            "drug_type": "Antibody",
            "drug_label": "PANITUMUMAB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 2,
            "disease_id": "EFO_0001663",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase II",
            "disease_name": "prostate carcinoma",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00054574%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00061126%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL1201827"
        },
        {
            "status": "Completed",
            "count": 2,
            "drug_type": "Antibody",
            "drug_label": "PANITUMUMAB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 2,
            "disease_id": "EFO_0002618",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase II",
            "disease_name": "pancreatic carcinoma",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00550836%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00601627%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL1201827"
        },
        {
            "status": "Completed",
            "count": 1,
            "drug_type": "Antibody",
            "drug_label": "PANITUMUMAB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 2,
            "disease_id": "EFO_0002916",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase II",
            "disease_name": "esophageal carcinoma",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00836277%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL1201827"
        },
        {
            "status": "Completed",
            "count": 1,
            "drug_type": "Antibody",
            "drug_label": "PANITUMUMAB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 2,
            "disease_id": "EFO_0003060",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase II",
            "disease_name": "non-small cell lung carcinoma",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT01042288%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL1201827"
        },
        {
            "status": "Completed",
            "count": 3,
            "drug_type": "Antibody",
            "drug_label": "PANITUMUMAB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 2,
            "disease_id": "EFO_0005221",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase II",
            "disease_name": "cholangiocarcinoma",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00779454%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT01206049%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT01320254%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL1201827"
        },
        {
            "status": "Completed",
            "count": 1,
            "drug_type": "Antibody",
            "drug_label": "PANITUMUMAB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 2,
            "disease_id": "EFO_1000218",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase II",
            "disease_name": "Digestive System Carcinoma",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT01202409%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL1201827"
        },
        {
            "status": "Completed",
            "count": 1,
            "drug_type": "Antibody",
            "drug_label": "PANITUMUMAB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 2,
            "disease_id": "EFO_1000657",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase II",
            "disease_name": "rectum cancer",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT01443377%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL1201827"
        },
        {
            "status": "Completed",
            "count": 7,
            "drug_type": "Antibody",
            "drug_label": "PANITUMUMAB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 2,
            "disease_id": "EFO_1001480",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase II",
            "disease_name": "metastatic colorectal cancer",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00327119%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00475293%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00508404%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00792363%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00891930%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00958386%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT01288339%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL1201827"
        },
        {
            "status": "Completed",
            "count": 1,
            "drug_type": "Antibody",
            "drug_label": "PANITUMUMAB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 2,
            "disease_id": "EFO_1001950",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase II",
            "disease_name": "colon carcinoma",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT01108107%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL1201827"
        },
        {
            "status": "Completed",
            "count": 12,
            "drug_type": "Antibody",
            "drug_label": "PANITUMUMAB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 2,
            "disease_id": "EFO_1001951",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase II",
            "disease_name": "colorectal carcinoma",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00039273%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00089635%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00111761%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00113776%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00655499%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00814619%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00842257%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00885885%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT01126112%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT01215539%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT01226719%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT02337946%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL1201827"
        },
        {
            "status": "Completed",
            "count": 1,
            "drug_type": "Small molecule",
            "drug_label": "PELITINIB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 2,
            "disease_id": "EFO_0003060",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase II",
            "disease_name": "non-small cell lung carcinoma",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00067548%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL607707"
        },
        {
            "status": "Completed",
            "count": 1,
            "drug_type": "Small molecule",
            "drug_label": "PELITINIB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 2,
            "disease_id": "EFO_0004142",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase II",
            "disease_name": "colorectal neoplasm",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00072748%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL607707"
        },
        {
            "status": "Completed",
            "count": 1,
            "drug_type": "Small molecule",
            "drug_label": "PELITINIB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 2,
            "disease_id": "EFO_0004288",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase II",
            "disease_name": "colonic neoplasm",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00072748%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL607707"
        },
        {
            "status": "Completed",
            "count": 1,
            "drug_type": "Small molecule",
            "drug_label": "PELITINIB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 2,
            "disease_id": "EFO_1000657",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase II",
            "disease_name": "rectum cancer",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00072748%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL607707"
        },
        {
            "status": "Completed",
            "count": 1,
            "drug_type": "Small molecule",
            "drug_label": "POZIOTINIB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 2,
            "disease_id": "EFO_0000571",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor inhibitor"
            ],
            "clinical_trial_phase_label": "Phase II",
            "disease_name": "lung adenocarcinoma",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT02979821%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL3545154"
        },
        {
            "status": "Completed",
            "count": 1,
            "drug_type": "Small molecule",
            "drug_label": "POZIOTINIB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 2,
            "disease_id": "GO_0042493",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor inhibitor"
            ],
            "clinical_trial_phase_label": "Phase II",
            "disease_name": "response to drug",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT01718847%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL3545154"
        },
        {
            "status": "Completed",
            "count": 1,
            "drug_type": "Small molecule",
            "drug_label": "VANDETANIB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 2,
            "disease_id": "EFO_0000181",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor inhibitor"
            ],
            "clinical_trial_phase_label": "Phase II",
            "disease_name": "head and neck squamous cell carcinoma",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00459043%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL24828"
        },
        {
            "status": "Completed",
            "count": 1,
            "drug_type": "Small molecule",
            "drug_label": "VANDETANIB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 2,
            "disease_id": "EFO_0000182",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor inhibitor"
            ],
            "clinical_trial_phase_label": "Phase II",
            "disease_name": "hepatocellular carcinoma",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00508001%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL24828"
        },
        {
            "status": "Completed",
            "count": 1,
            "drug_type": "Small molecule",
            "drug_label": "VANDETANIB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 2,
            "disease_id": "EFO_0000305",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor inhibitor"
            ],
            "clinical_trial_phase_label": "Phase II",
            "disease_name": "breast carcinoma",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00494481%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL24828"
        },
        {
            "status": "Completed",
            "count": 1,
            "drug_type": "Small molecule",
            "drug_label": "VANDETANIB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 2,
            "disease_id": "EFO_0000311",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor inhibitor"
            ],
            "clinical_trial_phase_label": "Phase II",
            "disease_name": "cancer",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00500292%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL24828"
        },
        {
            "status": "Completed",
            "count": 1,
            "drug_type": "Small molecule",
            "drug_label": "VANDETANIB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 2,
            "disease_id": "EFO_0000630",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor inhibitor"
            ],
            "clinical_trial_phase_label": "Phase II",
            "disease_name": "oligoastrocytoma",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00995007%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL24828"
        },
        {
            "status": "Completed",
            "count": 1,
            "drug_type": "Small molecule",
            "drug_label": "VANDETANIB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 2,
            "disease_id": "EFO_0000702",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor inhibitor"
            ],
            "clinical_trial_phase_label": "Phase II",
            "disease_name": "small cell lung carcinoma",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00613626%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL24828"
        },
        {
            "status": "Completed",
            "count": 2,
            "drug_type": "Small molecule",
            "drug_label": "VANDETANIB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 2,
            "disease_id": "EFO_0001071",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor inhibitor"
            ],
            "clinical_trial_phase_label": "Phase II",
            "disease_name": "lung carcinoma",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00066313%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00410189%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL24828"
        },
        {
            "status": "Completed",
            "count": 1,
            "drug_type": "Small molecule",
            "drug_label": "VANDETANIB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 2,
            "disease_id": "EFO_0001075",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor inhibitor"
            ],
            "clinical_trial_phase_label": "Phase II",
            "disease_name": "ovarian carcinoma",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00872989%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL24828"
        },
        {
            "status": "Completed",
            "count": 1,
            "drug_type": "Small molecule",
            "drug_label": "VANDETANIB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 2,
            "disease_id": "EFO_0001378",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor inhibitor"
            ],
            "clinical_trial_phase_label": "Phase II",
            "disease_name": "multiple myeloma",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00047788%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL24828"
        },
        {
            "status": "Completed",
            "count": 3,
            "drug_type": "Small molecule",
            "drug_label": "VANDETANIB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 2,
            "disease_id": "EFO_0001663",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor inhibitor"
            ],
            "clinical_trial_phase_label": "Phase II",
            "disease_name": "prostate carcinoma",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00498797%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00659438%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00757692%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL24828"
        },
        {
            "status": "Completed",
            "count": 1,
            "drug_type": "Small molecule",
            "drug_label": "VANDETANIB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 2,
            "disease_id": "EFO_0002499",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor inhibitor"
            ],
            "clinical_trial_phase_label": "Phase II",
            "disease_name": "anaplastic astrocytoma",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00995007%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL24828"
        },
        {
            "status": "Completed",
            "count": 1,
            "drug_type": "Small molecule",
            "drug_label": "VANDETANIB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 2,
            "disease_id": "EFO_0002501",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor inhibitor"
            ],
            "clinical_trial_phase_label": "Phase II",
            "disease_name": "anaplastic oligodendroglioma",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00995007%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL24828"
        },
        {
            "status": "Completed",
            "count": 1,
            "drug_type": "Small molecule",
            "drug_label": "VANDETANIB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 2,
            "disease_id": "EFO_0002890",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor inhibitor"
            ],
            "clinical_trial_phase_label": "Phase II",
            "disease_name": "renal carcinoma",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00566995%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL24828"
        },
        {
            "status": "Completed",
            "count": 2,
            "drug_type": "Small molecule",
            "drug_label": "VANDETANIB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 2,
            "disease_id": "EFO_0002892",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor inhibitor"
            ],
            "clinical_trial_phase_label": "Phase II",
            "disease_name": "thyroid carcinoma",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00098345%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00358956%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL24828"
        },
        {
            "status": "Completed",
            "count": 7,
            "drug_type": "Small molecule",
            "drug_label": "VANDETANIB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 2,
            "disease_id": "EFO_0003060",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor inhibitor"
            ],
            "clinical_trial_phase_label": "Phase II",
            "disease_name": "non-small cell lung carcinoma",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00047840%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00059722%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00071188%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00252746%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00687297%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00753714%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00777179%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL24828"
        },
        {
            "status": "Completed",
            "count": 1,
            "drug_type": "Small molecule",
            "drug_label": "VANDETANIB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 2,
            "disease_id": "EFO_0003869",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor inhibitor"
            ],
            "clinical_trial_phase_label": "Phase II",
            "disease_name": "breast neoplasm",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00034918%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL24828"
        },
        {
            "status": "Completed",
            "count": 1,
            "drug_type": "Small molecule",
            "drug_label": "VANDETANIB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 2,
            "disease_id": "EFO_0006544",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor inhibitor"
            ],
            "clinical_trial_phase_label": "Phase II",
            "disease_name": "bladder transitional cell carcinoma",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00880334%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL24828"
        },
        {
            "status": "Completed",
            "count": 1,
            "drug_type": "Small molecule",
            "drug_label": "VANDETANIB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 2,
            "disease_id": "EFO_1000251",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor inhibitor"
            ],
            "clinical_trial_phase_label": "Phase II",
            "disease_name": "Fallopian Tube Carcinoma",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00872989%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL24828"
        },
        {
            "status": "Completed",
            "count": 1,
            "drug_type": "Small molecule",
            "drug_label": "VANDETANIB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 2,
            "disease_id": "EFO_1001100",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor inhibitor"
            ],
            "clinical_trial_phase_label": "Phase II",
            "disease_name": "peritoneal neoplasm",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00872989%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL24828"
        },
        {
            "status": "Completed",
            "count": 1,
            "drug_type": "Small molecule",
            "drug_label": "VANDETANIB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 2,
            "disease_id": "EFO_1001465",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor inhibitor"
            ],
            "clinical_trial_phase_label": "Phase II",
            "disease_name": "gliosarcoma",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00995007%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL24828"
        },
        {
            "status": "Completed",
            "count": 1,
            "drug_type": "Small molecule",
            "drug_label": "VANDETANIB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 2,
            "disease_id": "EFO_1001951",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor inhibitor"
            ],
            "clinical_trial_phase_label": "Phase II",
            "disease_name": "colorectal carcinoma",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00454116%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL24828"
        },
        {
            "status": "Completed",
            "count": 1,
            "drug_type": "Small molecule",
            "drug_label": "VARLITINIB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 2,
            "disease_id": "EFO_0005221",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase II",
            "disease_name": "cholangiocarcinoma",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT02609958%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL2103842"
        },
        {
            "status": "Enrolling by invitation",
            "count": 1,
            "drug_type": "Small molecule",
            "drug_label": "ERLOTINIB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 2,
            "disease_id": "EFO_0003060",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase II",
            "disease_name": "non-small cell lung carcinoma",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT02556593%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL553"
        },
        {
            "status": "Not yet recruiting",
            "count": 1,
            "drug_type": "Small molecule",
            "drug_label": "AFATINIB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 2,
            "disease_id": "EFO_0000707",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase II",
            "disease_name": "squamous cell carcinoma",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT03486509%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL1173655"
        },
        {
            "status": "Not yet recruiting",
            "count": 1,
            "drug_type": "Small molecule",
            "drug_label": "AFATINIB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 2,
            "disease_id": "EFO_0003060",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase II",
            "disease_name": "non-small cell lung carcinoma",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT03574402%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL1173655"
        },
        {
            "status": "Not yet recruiting",
            "count": 1,
            "drug_type": "Small molecule",
            "drug_label": "BRIGATINIB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 2,
            "disease_id": "EFO_0003060",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase II",
            "disease_name": "non-small cell lung carcinoma",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT03737994%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL3545311"
        },
        {
            "status": "Not yet recruiting",
            "count": 1,
            "drug_type": "Antibody",
            "drug_label": "CETUXIMAB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 2,
            "disease_id": "EFO_0004142",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase II",
            "disease_name": "colorectal neoplasm",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT03608046%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL1201577"
        },
        {
            "status": "Not yet recruiting",
            "count": 1,
            "drug_type": "Antibody",
            "drug_label": "CETUXIMAB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 2,
            "disease_id": "EFO_0004198",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase II",
            "disease_name": "skin neoplasm",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT03666325%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL1201577"
        },
        {
            "status": "Not yet recruiting",
            "count": 3,
            "drug_type": "Antibody",
            "drug_label": "CETUXIMAB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 2,
            "disease_id": "EFO_1001951",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase II",
            "disease_name": "colorectal carcinoma",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT02515734%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT02942706%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT02978313%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL1201577"
        },
        {
            "status": "Not yet recruiting",
            "count": 1,
            "drug_type": "Small molecule",
            "drug_label": "ERLOTINIB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 2,
            "disease_id": "EFO_0001071",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase II",
            "disease_name": "lung carcinoma",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT02704767%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL553"
        },
        {
            "status": "Not yet recruiting",
            "count": 1,
            "drug_type": "Small molecule",
            "drug_label": "ERLOTINIB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 2,
            "disease_id": "EFO_0003060",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase II",
            "disease_name": "non-small cell lung carcinoma",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT03123484%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL553"
        },
        {
            "status": "Not yet recruiting",
            "count": 1,
            "drug_type": "Small molecule",
            "drug_label": "ERLOTINIB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 2,
            "disease_id": "EFO_0003891",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase II",
            "disease_name": "biliary tract neoplasm",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT03110484%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL553"
        },
        {
            "status": "Not yet recruiting",
            "count": 2,
            "drug_type": "Small molecule",
            "drug_label": "GEFITINIB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 2,
            "disease_id": "EFO_0000571",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase II",
            "disease_name": "lung adenocarcinoma",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT02951637%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT03486496%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL939"
        },
        {
            "status": "Not yet recruiting",
            "count": 2,
            "drug_type": "Small molecule",
            "drug_label": "GEFITINIB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 2,
            "disease_id": "EFO_0003060",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase II",
            "disease_name": "non-small cell lung carcinoma",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT03123484%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT03457337%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL939"
        },
        {
            "status": "Not yet recruiting",
            "count": 2,
            "drug_type": "Small molecule",
            "drug_label": "NERATINIB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 2,
            "disease_id": "EFO_0000305",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor",
                "Epidermal growth factor receptor inhibitor"
            ],
            "clinical_trial_phase_label": "Phase II",
            "disease_name": "breast carcinoma",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT03812393%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT03812393%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL180022"
        },
        {
            "status": "Not yet recruiting",
            "count": 1,
            "drug_type": "Antibody",
            "drug_label": "NIMOTUZUMAB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 2,
            "disease_id": "EFO_0005922",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase II",
            "disease_name": "esophageal squamous cell carcinoma",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT03766178%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL2108359"
        },
        {
            "status": "Not yet recruiting",
            "count": 2,
            "drug_type": "Small molecule",
            "drug_label": "OSIMERTINIB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 2,
            "disease_id": "EFO_0001071",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor",
                "Epidermal growth factor receptor inhibitor"
            ],
            "clinical_trial_phase_label": "Phase II",
            "disease_name": "lung carcinoma",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT02824952%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT02824952%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL3353410"
        },
        {
            "status": "Not yet recruiting",
            "count": 8,
            "drug_type": "Small molecule",
            "drug_label": "OSIMERTINIB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 2,
            "disease_id": "EFO_0003060",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor",
                "Epidermal growth factor receptor inhibitor"
            ],
            "clinical_trial_phase_label": "Phase II",
            "disease_name": "non-small cell lung carcinoma",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT03497767%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT03497767%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT03532698%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT03532698%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT03543683%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT03543683%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT03810066%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT03810066%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL3353410"
        },
        {
            "status": "Not yet recruiting",
            "count": 1,
            "drug_type": "Small molecule",
            "drug_label": "POZIOTINIB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 2,
            "disease_id": "EFO_0005922",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor inhibitor"
            ],
            "clinical_trial_phase_label": "Phase II",
            "disease_name": "esophageal squamous cell carcinoma",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT03770988%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL3545154"
        },
        {
            "status": "Not yet recruiting",
            "count": 1,
            "drug_type": "Small molecule",
            "drug_label": "PYROTINIB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 2,
            "disease_id": "EFO_0000305",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase II",
            "disease_name": "breast carcinoma",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT03691051%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL3544956"
        },
        {
            "status": "Recruiting",
            "count": 1,
            "drug_type": "Small molecule",
            "drug_label": "AFATINIB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 2,
            "disease_id": "EFO_0000181",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase II",
            "disease_name": "head and neck squamous cell carcinoma",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT02979977%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL1173655"
        },
        {
            "status": "Recruiting",
            "count": 2,
            "drug_type": "Small molecule",
            "drug_label": "AFATINIB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 2,
            "disease_id": "EFO_0000616",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase II",
            "disease_name": "neoplasm",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT02506517%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT03239015%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL1173655"
        },
        {
            "status": "Recruiting",
            "count": 1,
            "drug_type": "Small molecule",
            "drug_label": "AFATINIB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 2,
            "disease_id": "EFO_0000702",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase II",
            "disease_name": "small cell lung carcinoma",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT03810872%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL1173655"
        },
        {
            "status": "Recruiting",
            "count": 1,
            "drug_type": "Small molecule",
            "drug_label": "AFATINIB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 2,
            "disease_id": "EFO_0000707",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase II",
            "disease_name": "squamous cell carcinoma",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT03088059%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL1173655"
        },
        {
            "status": "Recruiting",
            "count": 1,
            "drug_type": "Small molecule",
            "drug_label": "AFATINIB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 2,
            "disease_id": "EFO_0001071",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase II",
            "disease_name": "lung carcinoma",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT01553942%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL1173655"
        },
        {
            "status": "Recruiting",
            "count": 1,
            "drug_type": "Small molecule",
            "drug_label": "AFATINIB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 2,
            "disease_id": "EFO_0003060",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase II",
            "disease_name": "non-small cell lung carcinoma",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT02183883%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL1173655"
        },
        {
            "status": "Recruiting",
            "count": 1,
            "drug_type": "Small molecule",
            "drug_label": "AFATINIB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 2,
            "disease_id": "EFO_0003859",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase II",
            "disease_name": "uterine neoplasm",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT02491099%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL1173655"
        },
        {
            "status": "Recruiting",
            "count": 1,
            "drug_type": "Small molecule",
            "drug_label": "AFATINIB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 2,
            "disease_id": "EFO_0003863",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase II",
            "disease_name": "urogenital neoplasm",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT02780687%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL1173655"
        },
        {
            "status": "Recruiting",
            "count": 1,
            "drug_type": "Small molecule",
            "drug_label": "AFATINIB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 2,
            "disease_id": "EFO_1000465",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase II",
            "disease_name": "Penile Carcinoma",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT02541903%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL1173655"
        },
        {
            "status": "Recruiting",
            "count": 1,
            "drug_type": "Small molecule",
            "drug_label": "AFATINIB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 2,
            "disease_id": "Orphanet_178",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase II",
            "disease_name": "Chordoma",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT03083678%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL1173655"
        },
        {
            "status": "Recruiting",
            "count": 1,
            "drug_type": "Small molecule",
            "drug_label": "BRIGATINIB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 2,
            "disease_id": "EFO_0003032",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase II",
            "disease_name": "anaplastic large cell lymphoma",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT03719898%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL3545311"
        },
        {
            "status": "Recruiting",
            "count": 3,
            "drug_type": "Small molecule",
            "drug_label": "BRIGATINIB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 2,
            "disease_id": "EFO_0003060",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase II",
            "disease_name": "non-small cell lung carcinoma",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT02706626%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT03410108%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT03535740%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL3545311"
        },
        {
            "status": "Recruiting",
            "count": 4,
            "drug_type": "Antibody",
            "drug_label": "CETUXIMAB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 2,
            "disease_id": "EFO_0000181",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase II",
            "disease_name": "head and neck squamous cell carcinoma",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT02624128%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT02979977%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT03001570%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT03389477%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL1201577"
        },
        {
            "status": "Recruiting",
            "count": 1,
            "drug_type": "Antibody",
            "drug_label": "CETUXIMAB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 2,
            "disease_id": "EFO_0000311",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase II",
            "disease_name": "cancer",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT03524820%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL1201577"
        },
        {
            "status": "Recruiting",
            "count": 1,
            "drug_type": "Antibody",
            "drug_label": "CETUXIMAB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 2,
            "disease_id": "EFO_0000707",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase II",
            "disease_name": "squamous cell carcinoma",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT02128906%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL1201577"
        },
        {
            "status": "Recruiting",
            "count": 1,
            "drug_type": "Antibody",
            "drug_label": "CETUXIMAB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 2,
            "disease_id": "EFO_0002916",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase II",
            "disease_name": "esophageal carcinoma",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT03126708%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL1201577"
        },
        {
            "status": "Recruiting",
            "count": 1,
            "drug_type": "Antibody",
            "drug_label": "CETUXIMAB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 2,
            "disease_id": "EFO_0003060",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase II",
            "disease_name": "non-small cell lung carcinoma",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT03717155%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL1201577"
        },
        {
            "status": "Recruiting",
            "count": 1,
            "drug_type": "Antibody",
            "drug_label": "CETUXIMAB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 2,
            "disease_id": "EFO_0004142",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase II",
            "disease_name": "colorectal neoplasm",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT02717923%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL1201577"
        },
        {
            "status": "Recruiting",
            "count": 2,
            "drug_type": "Antibody",
            "drug_label": "CETUXIMAB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 2,
            "disease_id": "EFO_0006859",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase II",
            "disease_name": "head and neck malignant neoplasia",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT02057107%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT03727061%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL1201577"
        },
        {
            "status": "Recruiting",
            "count": 7,
            "drug_type": "Antibody",
            "drug_label": "CETUXIMAB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 2,
            "disease_id": "EFO_1001480",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase II",
            "disease_name": "metastatic colorectal cancer",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT01703390%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT02063529%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT02404935%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT03164655%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT03186326%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT03457896%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT03693170%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL1201577"
        },
        {
            "status": "Recruiting",
            "count": 1,
            "drug_type": "Antibody",
            "drug_label": "CETUXIMAB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 2,
            "disease_id": "EFO_1001931",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase II",
            "disease_name": "oropharynx cancer",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT03416153%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL1201577"
        },
        {
            "status": "Recruiting",
            "count": 2,
            "drug_type": "Antibody",
            "drug_label": "CETUXIMAB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 2,
            "disease_id": "EFO_1001950",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase II",
            "disease_name": "colon carcinoma",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT01675999%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT03446157%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL1201577"
        },
        {
            "status": "Recruiting",
            "count": 2,
            "drug_type": "Antibody",
            "drug_label": "CETUXIMAB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 2,
            "disease_id": "EFO_1001951",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase II",
            "disease_name": "colorectal carcinoma",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT01802645%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT03727763%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL1201577"
        },
        {
            "status": "Recruiting",
            "count": 1,
            "drug_type": "Antibody",
            "drug_label": "DEPATUXIZUMAB MAFODOTIN",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 2,
            "disease_id": "EFO_0000519",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 binding agent"
            ],
            "clinical_trial_phase_label": "Phase II",
            "disease_name": "glioblastoma multiforme",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT02343406%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "up_or_down",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL3707277"
        },
        {
            "status": "Recruiting",
            "count": 1,
            "drug_type": "Antibody",
            "drug_label": "DEPATUXIZUMAB MAFODOTIN",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 2,
            "disease_id": "EFO_1001465",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 binding agent"
            ],
            "clinical_trial_phase_label": "Phase II",
            "disease_name": "gliosarcoma",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT02573324%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "up_or_down",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL3707277"
        },
        {
            "status": "Recruiting",
            "count": 1,
            "drug_type": "Small molecule",
            "drug_label": "EGF816",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 2,
            "disease_id": "EFO_0001071",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase II",
            "disease_name": "lung carcinoma",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT03292133%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL3545234"
        },
        {
            "status": "Recruiting",
            "count": 1,
            "drug_type": "Small molecule",
            "drug_label": "EGF816",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 2,
            "disease_id": "EFO_0003060",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase II",
            "disease_name": "non-small cell lung carcinoma",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT02323126%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL3545234"
        },
        {
            "status": "Recruiting",
            "count": 1,
            "drug_type": "Small molecule",
            "drug_label": "ERLOTINIB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 2,
            "disease_id": "EFO_0000222",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase II",
            "disease_name": "acute myeloid leukemia",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT02638428%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL553"
        },
        {
            "status": "Recruiting",
            "count": 3,
            "drug_type": "Small molecule",
            "drug_label": "ERLOTINIB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 2,
            "disease_id": "EFO_0000311",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase II",
            "disease_name": "cancer",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT02714530%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT02925234%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT03498521%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL553"
        },
        {
            "status": "Recruiting",
            "count": 1,
            "drug_type": "Small molecule",
            "drug_label": "ERLOTINIB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 2,
            "disease_id": "EFO_0000616",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase II",
            "disease_name": "neoplasm",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT03239015%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL553"
        },
        {
            "status": "Recruiting",
            "count": 1,
            "drug_type": "Small molecule",
            "drug_label": "ERLOTINIB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 2,
            "disease_id": "EFO_0000708",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase II",
            "disease_name": "squamous cell lung carcinoma",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT02154490%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL553"
        },
        {
            "status": "Recruiting",
            "count": 3,
            "drug_type": "Small molecule",
            "drug_label": "ERLOTINIB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 2,
            "disease_id": "EFO_0003060",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase II",
            "disease_name": "non-small cell lung carcinoma",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT01470716%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT03126799%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT03137771%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL553"
        },
        {
            "status": "Recruiting",
            "count": 1,
            "drug_type": "Small molecule",
            "drug_label": "ERLOTINIB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 2,
            "disease_id": "EFO_1000026",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase II",
            "disease_name": "diffuse intrinsic pontine glioma",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT02233049%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL553"
        },
        {
            "status": "Recruiting",
            "count": 1,
            "drug_type": "Small molecule",
            "drug_label": "ERLOTINIB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 2,
            "disease_id": "EFO_1000044",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase II",
            "disease_name": "pancreatic adenocarcinoma",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT03213626%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL553"
        },
        {
            "status": "Recruiting",
            "count": 1,
            "drug_type": "Small molecule",
            "drug_label": "ERLOTINIB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 2,
            "disease_id": "EFO_1000657",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase II",
            "disease_name": "rectum cancer",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT03086538%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL553"
        },
        {
            "status": "Recruiting",
            "count": 1,
            "drug_type": "Small molecule",
            "drug_label": "ERLOTINIB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 2,
            "disease_id": "Orphanet_733",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase II",
            "disease_name": "Familial adenomatous polyposis",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT02961374%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL553"
        },
        {
            "status": "Recruiting",
            "count": 1,
            "drug_type": "Antibody",
            "drug_label": "FUTUXIMAB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 2,
            "disease_id": "EFO_0000326",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 antagonist"
            ],
            "clinical_trial_phase_label": "Phase II",
            "disease_name": "central nervous system cancer",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT02540161%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL2109388"
        },
        {
            "status": "Recruiting",
            "count": 2,
            "drug_type": "Small molecule",
            "drug_label": "GEFITINIB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 2,
            "disease_id": "EFO_0000616",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase II",
            "disease_name": "neoplasm",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT02447419%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT03239015%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL939"
        },
        {
            "status": "Recruiting",
            "count": 2,
            "drug_type": "Small molecule",
            "drug_label": "GEFITINIB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 2,
            "disease_id": "EFO_0001071",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase II",
            "disease_name": "lung carcinoma",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT02347839%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT03292133%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL939"
        },
        {
            "status": "Recruiting",
            "count": 4,
            "drug_type": "Small molecule",
            "drug_label": "GEFITINIB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 2,
            "disease_id": "EFO_0003060",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase II",
            "disease_name": "non-small cell lung carcinoma",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT02804776%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT02856893%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT03267654%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT03374280%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL939"
        },
        {
            "status": "Recruiting",
            "count": 1,
            "drug_type": "Small molecule",
            "drug_label": "GEFITINIB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 2,
            "disease_id": "EFO_0003897",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase II",
            "disease_name": "stomach neoplasm",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT03170180%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL939"
        },
        {
            "status": "Recruiting",
            "count": 4,
            "drug_type": "Small molecule",
            "drug_label": "LAPATINIB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 2,
            "disease_id": "EFO_0000305",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase II",
            "disease_name": "breast carcinoma",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT01622868%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT02362958%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT03085368%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT03500380%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL554"
        },
        {
            "status": "Recruiting",
            "count": 1,
            "drug_type": "Small molecule",
            "drug_label": "LAPATINIB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 2,
            "disease_id": "EFO_0000616",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase II",
            "disease_name": "neoplasm",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT02029001%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL554"
        },
        {
            "status": "Recruiting",
            "count": 1,
            "drug_type": "Small molecule",
            "drug_label": "LAPATINIB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 2,
            "disease_id": "EFO_0000621",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase II",
            "disease_name": "neuroblastoma",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT02559778%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL554"
        },
        {
            "status": "Recruiting",
            "count": 2,
            "drug_type": "Small molecule",
            "drug_label": "LAPATINIB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 2,
            "disease_id": "EFO_0003869",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase II",
            "disease_name": "breast neoplasm",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT03273595%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT03500380%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL554"
        },
        {
            "status": "Recruiting",
            "count": 1,
            "drug_type": "Antibody",
            "drug_label": "NECITUMUMAB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 2,
            "disease_id": "EFO_0000708",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase II",
            "disease_name": "squamous cell lung carcinoma",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT03574818%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL1743047"
        },
        {
            "status": "Recruiting",
            "count": 14,
            "drug_type": "Small molecule",
            "drug_label": "NERATINIB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 2,
            "disease_id": "EFO_0000305",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor",
                "Epidermal growth factor receptor inhibitor"
            ],
            "clinical_trial_phase_label": "Phase II",
            "disease_name": "breast carcinoma",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT01042379%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT01042379%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT01494662%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT01494662%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT02400476%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT02400476%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT02673398%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT02673398%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT03094052%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT03094052%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT03182634%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT03182634%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT03289039%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT03289039%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL180022"
        },
        {
            "status": "Recruiting",
            "count": 2,
            "drug_type": "Small molecule",
            "drug_label": "NERATINIB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 2,
            "disease_id": "EFO_0000519",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor",
                "Epidermal growth factor receptor inhibitor"
            ],
            "clinical_trial_phase_label": "Phase II",
            "disease_name": "glioblastoma multiforme",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT02977780%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT02977780%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL180022"
        },
        {
            "status": "Recruiting",
            "count": 4,
            "drug_type": "Small molecule",
            "drug_label": "NERATINIB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 2,
            "disease_id": "EFO_0003869",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor",
                "Epidermal growth factor receptor inhibitor"
            ],
            "clinical_trial_phase_label": "Phase II",
            "disease_name": "breast neoplasm",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT01042379%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT01042379%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT01670877%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT01670877%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL180022"
        },
        {
            "status": "Recruiting",
            "count": 2,
            "drug_type": "Small molecule",
            "drug_label": "NERATINIB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 2,
            "disease_id": "EFO_1000256",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor",
                "Epidermal growth factor receptor inhibitor"
            ],
            "clinical_trial_phase_label": "Phase II",
            "disease_name": "Fibrolamellar Carcinoma",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT01953926%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT01953926%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL180022"
        },
        {
            "status": "Recruiting",
            "count": 2,
            "drug_type": "Small molecule",
            "drug_label": "NERATINIB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 2,
            "disease_id": "EFO_1001480",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor",
                "Epidermal growth factor receptor inhibitor"
            ],
            "clinical_trial_phase_label": "Phase II",
            "disease_name": "metastatic colorectal cancer",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT03457896%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT03457896%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL180022"
        },
        {
            "status": "Recruiting",
            "count": 1,
            "drug_type": "Antibody",
            "drug_label": "NIMOTUZUMAB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 2,
            "disease_id": "EFO_0001071",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase II",
            "disease_name": "lung carcinoma",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT02428764%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL2108359"
        },
        {
            "status": "Recruiting",
            "count": 1,
            "drug_type": "Antibody",
            "drug_label": "NIMOTUZUMAB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 2,
            "disease_id": "EFO_0002916",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase II",
            "disease_name": "esophageal carcinoma",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT02858206%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL2108359"
        },
        {
            "status": "Recruiting",
            "count": 1,
            "drug_type": "Antibody",
            "drug_label": "NIMOTUZUMAB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 2,
            "disease_id": "EFO_0003060",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase II",
            "disease_name": "non-small cell lung carcinoma",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT02577341%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL2108359"
        },
        {
            "status": "Recruiting",
            "count": 1,
            "drug_type": "Antibody",
            "drug_label": "NIMOTUZUMAB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 2,
            "disease_id": "EFO_0003897",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase II",
            "disease_name": "stomach neoplasm",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT03400592%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL2108359"
        },
        {
            "status": "Recruiting",
            "count": 3,
            "drug_type": "Antibody",
            "drug_label": "NIMOTUZUMAB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 2,
            "disease_id": "EFO_0004252",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase II",
            "disease_name": "nasopharyngeal neoplasm",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT03025958%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT03557112%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT03666221%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL2108359"
        },
        {
            "status": "Recruiting",
            "count": 1,
            "drug_type": "Antibody",
            "drug_label": "NIMOTUZUMAB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 2,
            "disease_id": "EFO_1000026",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase II",
            "disease_name": "diffuse intrinsic pontine glioma",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT03620032%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL2108359"
        },
        {
            "status": "Recruiting",
            "count": 1,
            "drug_type": "Antibody",
            "drug_label": "NIMOTUZUMAB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 2,
            "disease_id": "EFO_1000172",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase II",
            "disease_name": "cervical squamous cell carcinoma",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT03469531%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL2108359"
        },
        {
            "status": "Recruiting",
            "count": 1,
            "drug_type": "Antibody",
            "drug_label": "NIMOTUZUMAB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 2,
            "disease_id": "EFO_1001767",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase II",
            "disease_name": "brain stem neoplasm",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT02672241%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL2108359"
        },
        {
            "status": "Recruiting",
            "count": 2,
            "drug_type": "Small molecule",
            "drug_label": "OSIMERTINIB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 2,
            "disease_id": "EFO_0000228",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor",
                "Epidermal growth factor receptor inhibitor"
            ],
            "clinical_trial_phase_label": "Phase II",
            "disease_name": "adenocarcinoma",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT02664935%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT02664935%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL3353410"
        },
        {
            "status": "Recruiting",
            "count": 2,
            "drug_type": "Small molecule",
            "drug_label": "OSIMERTINIB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 2,
            "disease_id": "EFO_0000313",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor",
                "Epidermal growth factor receptor inhibitor"
            ],
            "clinical_trial_phase_label": "Phase II",
            "disease_name": "carcinoma",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT03778229%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT03778229%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL3353410"
        },
        {
            "status": "Recruiting",
            "count": 2,
            "drug_type": "Small molecule",
            "drug_label": "OSIMERTINIB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 2,
            "disease_id": "EFO_0000519",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor",
                "Epidermal growth factor receptor inhibitor"
            ],
            "clinical_trial_phase_label": "Phase II",
            "disease_name": "glioblastoma multiforme",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT03732352%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT03732352%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL3353410"
        },
        {
            "status": "Recruiting",
            "count": 2,
            "drug_type": "Small molecule",
            "drug_label": "OSIMERTINIB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 2,
            "disease_id": "EFO_0000571",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor",
                "Epidermal growth factor receptor inhibitor"
            ],
            "clinical_trial_phase_label": "Phase II",
            "disease_name": "lung adenocarcinoma",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT02759835%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT02759835%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL3353410"
        },
        {
            "status": "Recruiting",
            "count": 2,
            "drug_type": "Small molecule",
            "drug_label": "OSIMERTINIB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 2,
            "disease_id": "EFO_0000707",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor",
                "Epidermal growth factor receptor inhibitor"
            ],
            "clinical_trial_phase_label": "Phase II",
            "disease_name": "squamous cell carcinoma",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT02664935%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT02664935%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL3353410"
        },
        {
            "status": "Recruiting",
            "count": 4,
            "drug_type": "Small molecule",
            "drug_label": "OSIMERTINIB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 2,
            "disease_id": "EFO_0001071",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor",
                "Epidermal growth factor receptor inhibitor"
            ],
            "clinical_trial_phase_label": "Phase II",
            "disease_name": "lung carcinoma",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT02736513%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT02736513%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT03804580%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT03804580%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL3353410"
        },
        {
            "status": "Recruiting",
            "count": 38,
            "drug_type": "Small molecule",
            "drug_label": "OSIMERTINIB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 2,
            "disease_id": "EFO_0003060",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor",
                "Epidermal growth factor receptor inhibitor"
            ],
            "clinical_trial_phase_label": "Phase II",
            "disease_name": "non-small cell lung carcinoma",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT02664935%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT02664935%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT02811354%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT02811354%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT02841579%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT02841579%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT02856893%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT02856893%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT02971501%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT02971501%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT03133546%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT03133546%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT03191149%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT03191149%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT03239340%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT03239340%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT03257124%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT03257124%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT03392246%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT03392246%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT03394118%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT03394118%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT03410043%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT03410043%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT03414814%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT03414814%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT03433469%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT03433469%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT03434418%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT03434418%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT03460275%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT03460275%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT03586453%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT03586453%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT03667820%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT03667820%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT03784599%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT03784599%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL3353410"
        },
        {
            "status": "Recruiting",
            "count": 1,
            "drug_type": "Antibody",
            "drug_label": "PANITUMUMAB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 2,
            "disease_id": "EFO_0000305",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase II",
            "disease_name": "breast carcinoma",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT02593175%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL1201827"
        },
        {
            "status": "Recruiting",
            "count": 1,
            "drug_type": "Antibody",
            "drug_label": "PANITUMUMAB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 2,
            "disease_id": "EFO_0000311",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase II",
            "disease_name": "cancer",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT02925234%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL1201827"
        },
        {
            "status": "Recruiting",
            "count": 1,
            "drug_type": "Antibody",
            "drug_label": "PANITUMUMAB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 2,
            "disease_id": "EFO_0000365",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase II",
            "disease_name": "colorectal adenocarcinoma",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT03069950%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL1201827"
        },
        {
            "status": "Recruiting",
            "count": 1,
            "drug_type": "Antibody",
            "drug_label": "PANITUMUMAB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 2,
            "disease_id": "EFO_0003869",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase II",
            "disease_name": "breast neoplasm",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT02876107%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL1201827"
        },
        {
            "status": "Recruiting",
            "count": 1,
            "drug_type": "Antibody",
            "drug_label": "PANITUMUMAB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 2,
            "disease_id": "EFO_0005842",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase II",
            "disease_name": "colorectal cancer",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT03311750%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL1201827"
        },
        {
            "status": "Recruiting",
            "count": 1,
            "drug_type": "Antibody",
            "drug_label": "PANITUMUMAB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 2,
            "disease_id": "EFO_1000657",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase II",
            "disease_name": "rectum cancer",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT03000374%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL1201827"
        },
        {
            "status": "Recruiting",
            "count": 8,
            "drug_type": "Antibody",
            "drug_label": "PANITUMUMAB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 2,
            "disease_id": "EFO_1001480",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase II",
            "disease_name": "metastatic colorectal cancer",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT01312857%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT01991873%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT02904031%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT02980510%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT03164655%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT03186326%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT03584711%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT03751176%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL1201827"
        },
        {
            "status": "Recruiting",
            "count": 1,
            "drug_type": "Antibody",
            "drug_label": "PANITUMUMAB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 2,
            "disease_id": "EFO_1001950",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase II",
            "disease_name": "colon carcinoma",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT03442569%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL1201827"
        },
        {
            "status": "Recruiting",
            "count": 3,
            "drug_type": "Antibody",
            "drug_label": "PANITUMUMAB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 2,
            "disease_id": "EFO_1001951",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase II",
            "disease_name": "colorectal carcinoma",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT02399943%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT03087071%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT03227926%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL1201827"
        },
        {
            "status": "Recruiting",
            "count": 1,
            "drug_type": "Small molecule",
            "drug_label": "POZIOTINIB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 2,
            "disease_id": "EFO_0000305",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor inhibitor"
            ],
            "clinical_trial_phase_label": "Phase II",
            "disease_name": "breast carcinoma",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT02544997%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL3545154"
        },
        {
            "status": "Recruiting",
            "count": 2,
            "drug_type": "Small molecule",
            "drug_label": "POZIOTINIB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 2,
            "disease_id": "EFO_0003060",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor inhibitor"
            ],
            "clinical_trial_phase_label": "Phase II",
            "disease_name": "non-small cell lung carcinoma",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT03066206%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT03318939%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL3545154"
        },
        {
            "status": "Recruiting",
            "count": 1,
            "drug_type": "Small molecule",
            "drug_label": "POZIOTINIB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 2,
            "disease_id": "EFO_0004284",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor inhibitor"
            ],
            "clinical_trial_phase_label": "Phase II",
            "disease_name": "upper aerodigestive tract neoplasm",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT03292250%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL3545154"
        },
        {
            "status": "Recruiting",
            "count": 1,
            "drug_type": "Small molecule",
            "drug_label": "PYROTINIB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 2,
            "disease_id": "EFO_0000305",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase II",
            "disease_name": "breast carcinoma",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT03412383%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL3544956"
        },
        {
            "status": "Recruiting",
            "count": 1,
            "drug_type": "Small molecule",
            "drug_label": "VANDETANIB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 2,
            "disease_id": "EFO_0000222",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor inhibitor"
            ],
            "clinical_trial_phase_label": "Phase II",
            "disease_name": "acute myeloid leukemia",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT02638428%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL24828"
        },
        {
            "status": "Recruiting",
            "count": 1,
            "drug_type": "Small molecule",
            "drug_label": "VANDETANIB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 2,
            "disease_id": "EFO_0000305",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor inhibitor"
            ],
            "clinical_trial_phase_label": "Phase II",
            "disease_name": "breast carcinoma",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT02299999%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL24828"
        },
        {
            "status": "Recruiting",
            "count": 1,
            "drug_type": "Small molecule",
            "drug_label": "VANDETANIB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 2,
            "disease_id": "EFO_0000501",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor inhibitor"
            ],
            "clinical_trial_phase_label": "Phase II",
            "disease_name": "follicular thyroid carcinoma",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT03630120%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL24828"
        },
        {
            "status": "Recruiting",
            "count": 1,
            "drug_type": "Small molecule",
            "drug_label": "VANDETANIB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 2,
            "disease_id": "EFO_0000616",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor inhibitor"
            ],
            "clinical_trial_phase_label": "Phase II",
            "disease_name": "neoplasm",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT02530411%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL24828"
        },
        {
            "status": "Recruiting",
            "count": 1,
            "drug_type": "Small molecule",
            "drug_label": "VANDETANIB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 2,
            "disease_id": "EFO_0000641",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor inhibitor"
            ],
            "clinical_trial_phase_label": "Phase II",
            "disease_name": "papillary thyroid carcinoma",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT03630120%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL24828"
        },
        {
            "status": "Recruiting",
            "count": 1,
            "drug_type": "Small molecule",
            "drug_label": "VANDETANIB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 2,
            "disease_id": "EFO_1000489",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor inhibitor"
            ],
            "clinical_trial_phase_label": "Phase II",
            "disease_name": "Poorly Differentiated Thyroid Gland Carcinoma",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT03630120%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL24828"
        },
        {
            "status": "Suspended",
            "count": 1,
            "drug_type": "Small molecule",
            "drug_label": "AFATINIB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 2,
            "disease_id": "EFO_0003060",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase II",
            "disease_name": "non-small cell lung carcinoma",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT02470065%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL1173655"
        },
        {
            "status": "Suspended",
            "count": 1,
            "drug_type": "Antibody",
            "drug_label": "CETUXIMAB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 2,
            "disease_id": "EFO_1001951",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase II",
            "disease_name": "colorectal carcinoma",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT02291289%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL1201577"
        },
        {
            "status": "Suspended",
            "count": 1,
            "drug_type": "Small molecule",
            "drug_label": "ERLOTINIB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 2,
            "disease_id": "EFO_0002618",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase II",
            "disease_name": "pancreatic carcinoma",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00536770%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL553"
        },
        {
            "status": "Suspended",
            "count": 1,
            "drug_type": "Small molecule",
            "drug_label": "ERLOTINIB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 2,
            "disease_id": "EFO_0003060",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase II",
            "disease_name": "non-small cell lung carcinoma",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00200395%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL553"
        },
        {
            "status": "Suspended",
            "count": 1,
            "drug_type": "Small molecule",
            "drug_label": "GEFITINIB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 2,
            "disease_id": "EFO_0003060",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase II",
            "disease_name": "non-small cell lung carcinoma",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00986284%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL939"
        },
        {
            "status": "Suspended",
            "count": 1,
            "drug_type": "Antibody",
            "drug_label": "NIMOTUZUMAB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 2,
            "disease_id": "EFO_0005922",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase II",
            "disease_name": "esophageal squamous cell carcinoma",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT02272699%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL2108359"
        },
        {
            "status": "Suspended",
            "count": 1,
            "drug_type": "Antibody",
            "drug_label": "PANITUMUMAB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 2,
            "disease_id": "EFO_0003060",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase II",
            "disease_name": "non-small cell lung carcinoma",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT01088620%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL1201827"
        },
        {
            "status": "Terminated",
            "count": 1,
            "drug_type": "Small molecule",
            "drug_label": "AFATINIB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 2,
            "disease_id": "EFO_0000616",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase II",
            "disease_name": "neoplasm",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00748709%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL1173655"
        },
        {
            "status": "Terminated",
            "count": 1,
            "drug_type": "Small molecule",
            "drug_label": "AFATINIB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 2,
            "disease_id": "EFO_0001071",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase II",
            "disease_name": "lung carcinoma",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT02271906%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL1173655"
        },
        {
            "status": "Terminated",
            "count": 1,
            "drug_type": "Small molecule",
            "drug_label": "AFATINIB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 2,
            "disease_id": "EFO_0003060",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase II",
            "disease_name": "non-small cell lung carcinoma",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT02488694%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL1173655"
        },
        {
            "status": "Terminated",
            "count": 1,
            "drug_type": "Antibody",
            "drug_label": "CETUXIMAB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 2,
            "disease_id": "EFO_0000181",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase II",
            "disease_name": "head and neck squamous cell carcinoma",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT01488318%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL1201577"
        },
        {
            "status": "Terminated",
            "count": 1,
            "drug_type": "Antibody",
            "drug_label": "CETUXIMAB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 2,
            "disease_id": "EFO_0000519",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase II",
            "disease_name": "glioblastoma multiforme",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT01044225%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL1201577"
        },
        {
            "status": "Terminated",
            "count": 1,
            "drug_type": "Antibody",
            "drug_label": "CETUXIMAB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 2,
            "disease_id": "EFO_0000673",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase II",
            "disease_name": "prostate adenocarcinoma",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00448097%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL1201577"
        },
        {
            "status": "Terminated",
            "count": 1,
            "drug_type": "Antibody",
            "drug_label": "CETUXIMAB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 2,
            "disease_id": "EFO_0000707",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase II",
            "disease_name": "squamous cell carcinoma",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT01326923%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL1201577"
        },
        {
            "status": "Terminated",
            "count": 1,
            "drug_type": "Antibody",
            "drug_label": "CETUXIMAB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 2,
            "disease_id": "EFO_0001061",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase II",
            "disease_name": "cervical carcinoma",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00518193%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL1201577"
        },
        {
            "status": "Terminated",
            "count": 1,
            "drug_type": "Antibody",
            "drug_label": "CETUXIMAB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 2,
            "disease_id": "EFO_0001071",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase II",
            "disease_name": "lung carcinoma",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00519831%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL1201577"
        },
        {
            "status": "Terminated",
            "count": 1,
            "drug_type": "Antibody",
            "drug_label": "CETUXIMAB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 2,
            "disease_id": "EFO_0001075",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase II",
            "disease_name": "ovarian carcinoma",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00082212%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL1201577"
        },
        {
            "status": "Terminated",
            "count": 1,
            "drug_type": "Antibody",
            "drug_label": "CETUXIMAB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 2,
            "disease_id": "EFO_0001378",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase II",
            "disease_name": "multiple myeloma",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00368121%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL1201577"
        },
        {
            "status": "Terminated",
            "count": 3,
            "drug_type": "Antibody",
            "drug_label": "CETUXIMAB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 2,
            "disease_id": "EFO_0002618",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase II",
            "disease_name": "pancreatic carcinoma",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00276744%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00326911%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT01050426%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL1201577"
        },
        {
            "status": "Terminated",
            "count": 4,
            "drug_type": "Antibody",
            "drug_label": "CETUXIMAB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 2,
            "disease_id": "EFO_0002916",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase II",
            "disease_name": "esophageal carcinoma",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00109850%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00551759%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00735345%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00827671%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL1201577"
        },
        {
            "status": "Terminated",
            "count": 2,
            "drug_type": "Antibody",
            "drug_label": "CETUXIMAB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 2,
            "disease_id": "EFO_0003060",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase II",
            "disease_name": "non-small cell lung carcinoma",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00203931%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00694603%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL1201577"
        },
        {
            "status": "Terminated",
            "count": 2,
            "drug_type": "Antibody",
            "drug_label": "CETUXIMAB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 2,
            "disease_id": "EFO_0003817",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase II",
            "disease_name": "laryngeal neoplasm",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00599131%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00941135%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL1201577"
        },
        {
            "status": "Terminated",
            "count": 1,
            "drug_type": "Antibody",
            "drug_label": "CETUXIMAB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 2,
            "disease_id": "EFO_0004142",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase II",
            "disease_name": "colorectal neoplasm",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00321100%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL1201577"
        },
        {
            "status": "Terminated",
            "count": 1,
            "drug_type": "Antibody",
            "drug_label": "CETUXIMAB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 2,
            "disease_id": "EFO_0004252",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase II",
            "disease_name": "nasopharyngeal neoplasm",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT01230476%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL1201577"
        },
        {
            "status": "Terminated",
            "count": 1,
            "drug_type": "Antibody",
            "drug_label": "CETUXIMAB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 2,
            "disease_id": "EFO_0004284",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase II",
            "disease_name": "upper aerodigestive tract neoplasm",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT02633800%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL1201577"
        },
        {
            "status": "Terminated",
            "count": 2,
            "drug_type": "Antibody",
            "drug_label": "CETUXIMAB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 2,
            "disease_id": "EFO_0006859",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase II",
            "disease_name": "head and neck malignant neoplasia",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00319839%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00646659%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL1201577"
        },
        {
            "status": "Terminated",
            "count": 2,
            "drug_type": "Antibody",
            "drug_label": "CETUXIMAB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 2,
            "disease_id": "EFO_1000657",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase II",
            "disease_name": "rectum cancer",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00580073%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00611858%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL1201577"
        },
        {
            "status": "Terminated",
            "count": 6,
            "drug_type": "Antibody",
            "drug_label": "CETUXIMAB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 2,
            "disease_id": "EFO_1001480",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase II",
            "disease_name": "metastatic colorectal cancer",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00531115%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT01522612%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT01718808%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT01858662%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT01925274%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT02316496%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL1201577"
        },
        {
            "status": "Terminated",
            "count": 10,
            "drug_type": "Antibody",
            "drug_label": "CETUXIMAB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 2,
            "disease_id": "EFO_1001951",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase II",
            "disease_name": "colorectal carcinoma",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00251186%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00271011%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00537823%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00538291%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00681876%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00755118%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00755534%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT01004159%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT01032291%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT01060423%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL1201577"
        },
        {
            "status": "Terminated",
            "count": 2,
            "drug_type": "Small molecule",
            "drug_label": "DACOMITINIB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 2,
            "disease_id": "EFO_0003833",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor",
                "Epidermal growth factor receptor inhibitor"
            ],
            "clinical_trial_phase_label": "Phase II",
            "disease_name": "brain neoplasm",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT02047747%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT02047747%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL2110732"
        },
        {
            "status": "Terminated",
            "count": 1,
            "drug_type": "Small molecule",
            "drug_label": "ERLOTINIB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 2,
            "disease_id": "EFO_0000181",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase II",
            "disease_name": "head and neck squamous cell carcinoma",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00392665%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL553"
        },
        {
            "status": "Terminated",
            "count": 2,
            "drug_type": "Small molecule",
            "drug_label": "ERLOTINIB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 2,
            "disease_id": "EFO_0000182",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase II",
            "disease_name": "hepatocellular carcinoma",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00047333%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00532441%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL553"
        },
        {
            "status": "Terminated",
            "count": 1,
            "drug_type": "Small molecule",
            "drug_label": "ERLOTINIB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 2,
            "disease_id": "EFO_0000292",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase II",
            "disease_name": "bladder carcinoma",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT02169284%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL553"
        },
        {
            "status": "Terminated",
            "count": 5,
            "drug_type": "Small molecule",
            "drug_label": "ERLOTINIB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 2,
            "disease_id": "EFO_0000305",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase II",
            "disease_name": "breast carcinoma",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00570258%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00597597%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00611715%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00739063%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT01205685%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL553"
        },
        {
            "status": "Terminated",
            "count": 2,
            "drug_type": "Small molecule",
            "drug_label": "ERLOTINIB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 2,
            "disease_id": "EFO_0000311",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase II",
            "disease_name": "cancer",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT01376310%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT01518621%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL553"
        },
        {
            "status": "Terminated",
            "count": 1,
            "drug_type": "Small molecule",
            "drug_label": "ERLOTINIB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 2,
            "disease_id": "EFO_0000514",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase II",
            "disease_name": "germ cell tumor",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT01962896%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL553"
        },
        {
            "status": "Terminated",
            "count": 1,
            "drug_type": "Small molecule",
            "drug_label": "ERLOTINIB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 2,
            "disease_id": "EFO_0000707",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase II",
            "disease_name": "squamous cell carcinoma",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT01009203%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL553"
        },
        {
            "status": "Terminated",
            "count": 4,
            "drug_type": "Small molecule",
            "drug_label": "ERLOTINIB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 2,
            "disease_id": "EFO_0001071",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase II",
            "disease_name": "lung carcinoma",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00063258%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00554775%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00988169%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT01189435%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL553"
        },
        {
            "status": "Terminated",
            "count": 1,
            "drug_type": "Small molecule",
            "drug_label": "ERLOTINIB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 2,
            "disease_id": "EFO_0001075",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase II",
            "disease_name": "ovarian carcinoma",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT01003938%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL553"
        },
        {
            "status": "Terminated",
            "count": 1,
            "drug_type": "Small molecule",
            "drug_label": "ERLOTINIB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 2,
            "disease_id": "EFO_0002429",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase II",
            "disease_name": "polycythemia vera",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT01038856%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL553"
        },
        {
            "status": "Terminated",
            "count": 9,
            "drug_type": "Small molecule",
            "drug_label": "ERLOTINIB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 2,
            "disease_id": "EFO_0002618",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase II",
            "disease_name": "pancreatic carcinoma",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00276744%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00336700%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00470535%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00564720%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00640978%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00766636%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00841035%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT01108458%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT01531712%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL553"
        },
        {
            "status": "Terminated",
            "count": 2,
            "drug_type": "Small molecule",
            "drug_label": "ERLOTINIB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 2,
            "disease_id": "EFO_0002916",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase II",
            "disease_name": "esophageal carcinoma",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00442507%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00539617%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL553"
        },
        {
            "status": "Terminated",
            "count": 18,
            "drug_type": "Small molecule",
            "drug_label": "ERLOTINIB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 2,
            "disease_id": "EFO_0003060",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase II",
            "disease_name": "non-small cell lung carcinoma",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00087269%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00281021%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00283634%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00391586%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00452075%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00592007%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00749567%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00773383%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00783471%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00830245%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00940875%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00976677%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT01383148%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT01822496%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT01857271%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT02095782%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT02186301%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT02318368%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL553"
        },
        {
            "status": "Terminated",
            "count": 1,
            "drug_type": "Small molecule",
            "drug_label": "ERLOTINIB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 2,
            "disease_id": "EFO_0003833",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase II",
            "disease_name": "brain neoplasm",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00387894%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL553"
        },
        {
            "status": "Terminated",
            "count": 1,
            "drug_type": "Small molecule",
            "drug_label": "ERLOTINIB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 2,
            "disease_id": "EFO_0006859",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase II",
            "disease_name": "head and neck malignant neoplasia",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00750555%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL553"
        },
        {
            "status": "Terminated",
            "count": 1,
            "drug_type": "Small molecule",
            "drug_label": "ERLOTINIB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 2,
            "disease_id": "EFO_0009259",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase II",
            "disease_name": "skin carcinoma",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT01059305%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL553"
        },
        {
            "status": "Terminated",
            "count": 2,
            "drug_type": "Small molecule",
            "drug_label": "ERLOTINIB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 2,
            "disease_id": "EFO_1000028",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase II",
            "disease_name": "ependymoma",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT01032070%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT01247922%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL553"
        },
        {
            "status": "Terminated",
            "count": 2,
            "drug_type": "Small molecule",
            "drug_label": "ERLOTINIB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 2,
            "disease_id": "EFO_1001480",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase II",
            "disease_name": "metastatic colorectal cancer",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00459901%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00642746%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL553"
        },
        {
            "status": "Terminated",
            "count": 1,
            "drug_type": "Small molecule",
            "drug_label": "GEFITINIB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 2,
            "disease_id": "EFO_0000292",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase II",
            "disease_name": "bladder carcinoma",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00479089%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL939"
        },
        {
            "status": "Terminated",
            "count": 3,
            "drug_type": "Small molecule",
            "drug_label": "GEFITINIB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 2,
            "disease_id": "EFO_0000305",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase II",
            "disease_name": "breast carcinoma",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00082667%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00206414%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00206492%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL939"
        },
        {
            "status": "Terminated",
            "count": 1,
            "drug_type": "Small molecule",
            "drug_label": "GEFITINIB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 2,
            "disease_id": "EFO_0000514",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase II",
            "disease_name": "germ cell tumor",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00198159%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL939"
        },
        {
            "status": "Terminated",
            "count": 1,
            "drug_type": "Small molecule",
            "drug_label": "GEFITINIB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 2,
            "disease_id": "EFO_0000519",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase II",
            "disease_name": "glioblastoma multiforme",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT01310855%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL939"
        },
        {
            "status": "Terminated",
            "count": 1,
            "drug_type": "Small molecule",
            "drug_label": "GEFITINIB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 2,
            "disease_id": "EFO_0001071",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase II",
            "disease_name": "lung carcinoma",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT02025218%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL939"
        },
        {
            "status": "Terminated",
            "count": 1,
            "drug_type": "Small molecule",
            "drug_label": "GEFITINIB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 2,
            "disease_id": "EFO_0001663",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase II",
            "disease_name": "prostate carcinoma",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00483561%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL939"
        },
        {
            "status": "Terminated",
            "count": 1,
            "drug_type": "Small molecule",
            "drug_label": "GEFITINIB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 2,
            "disease_id": "EFO_0002890",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase II",
            "disease_name": "renal carcinoma",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00467077%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL939"
        },
        {
            "status": "Terminated",
            "count": 2,
            "drug_type": "Small molecule",
            "drug_label": "GEFITINIB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 2,
            "disease_id": "EFO_0002916",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase II",
            "disease_name": "esophageal carcinoma",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00258297%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00493025%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL939"
        },
        {
            "status": "Terminated",
            "count": 2,
            "drug_type": "Small molecule",
            "drug_label": "GEFITINIB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 2,
            "disease_id": "EFO_0003060",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase II",
            "disease_name": "non-small cell lung carcinoma",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT01871480%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT02326285%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL939"
        },
        {
            "status": "Terminated",
            "count": 1,
            "drug_type": "Small molecule",
            "drug_label": "GEFITINIB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 2,
            "disease_id": "EFO_0006859",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase II",
            "disease_name": "head and neck malignant neoplasia",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00169221%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL939"
        },
        {
            "status": "Terminated",
            "count": 1,
            "drug_type": "Small molecule",
            "drug_label": "LAPATINIB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 2,
            "disease_id": "EFO_0000178",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase II",
            "disease_name": "gastric carcinoma",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT01769508%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL554"
        },
        {
            "status": "Terminated",
            "count": 1,
            "drug_type": "Small molecule",
            "drug_label": "LAPATINIB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 2,
            "disease_id": "EFO_0000292",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase II",
            "disease_name": "bladder carcinoma",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT01382706%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL554"
        },
        {
            "status": "Terminated",
            "count": 13,
            "drug_type": "Small molecule",
            "drug_label": "LAPATINIB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 2,
            "disease_id": "EFO_0000305",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase II",
            "disease_name": "breast carcinoma",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00225758%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00479856%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00496366%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00499681%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00657137%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00754702%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00756470%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00903656%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT01161368%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT01272141%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT01477060%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT01534455%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT01934894%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL554"
        },
        {
            "status": "Terminated",
            "count": 3,
            "drug_type": "Small molecule",
            "drug_label": "LAPATINIB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 2,
            "disease_id": "EFO_0000311",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase II",
            "disease_name": "cancer",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00447226%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00888810%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT02294786%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL554"
        },
        {
            "status": "Terminated",
            "count": 1,
            "drug_type": "Small molecule",
            "drug_label": "LAPATINIB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 2,
            "disease_id": "EFO_0000707",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase II",
            "disease_name": "squamous cell carcinoma",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT01666431%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL554"
        },
        {
            "status": "Terminated",
            "count": 1,
            "drug_type": "Small molecule",
            "drug_label": "LAPATINIB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 2,
            "disease_id": "EFO_0000756",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase II",
            "disease_name": "melanoma",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT01264081%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL554"
        },
        {
            "status": "Terminated",
            "count": 2,
            "drug_type": "Small molecule",
            "drug_label": "LAPATINIB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 2,
            "disease_id": "EFO_0002618",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase II",
            "disease_name": "pancreatic carcinoma",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00447122%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00881621%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL554"
        },
        {
            "status": "Terminated",
            "count": 1,
            "drug_type": "Small molecule",
            "drug_label": "LAPATINIB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 2,
            "disease_id": "EFO_0002916",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase II",
            "disease_name": "esophageal carcinoma",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT01145404%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL554"
        },
        {
            "status": "Terminated",
            "count": 1,
            "drug_type": "Small molecule",
            "drug_label": "LAPATINIB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 2,
            "disease_id": "EFO_0003060",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase II",
            "disease_name": "non-small cell lung carcinoma",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00073008%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL554"
        },
        {
            "status": "Terminated",
            "count": 5,
            "drug_type": "Small molecule",
            "drug_label": "LAPATINIB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 2,
            "disease_id": "EFO_0003869",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase II",
            "disease_name": "breast neoplasm",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00437073%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00479856%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00709618%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00820924%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT01272141%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL554"
        },
        {
            "status": "Terminated",
            "count": 1,
            "drug_type": "Small molecule",
            "drug_label": "LAPATINIB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 2,
            "disease_id": "EFO_0005922",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase II",
            "disease_name": "esophageal squamous cell carcinoma",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00239200%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL554"
        },
        {
            "status": "Terminated",
            "count": 1,
            "drug_type": "Small molecule",
            "drug_label": "LAPATINIB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 2,
            "disease_id": "EFO_0006861",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase II",
            "disease_name": "male breast carcinoma",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT01868503%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL554"
        },
        {
            "status": "Terminated",
            "count": 1,
            "drug_type": "Antibody",
            "drug_label": "NECITUMUMAB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 2,
            "disease_id": "EFO_0003060",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase II",
            "disease_name": "non-small cell lung carcinoma",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT02443337%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL1743047"
        },
        {
            "status": "Terminated",
            "count": 1,
            "drug_type": "Antibody",
            "drug_label": "NIMOTUZUMAB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 2,
            "disease_id": "EFO_0000707",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase II",
            "disease_name": "squamous cell carcinoma",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT01382745%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL2108359"
        },
        {
            "status": "Terminated",
            "count": 2,
            "drug_type": "Antibody",
            "drug_label": "NIMOTUZUMAB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 2,
            "disease_id": "EFO_0003060",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase II",
            "disease_name": "non-small cell lung carcinoma",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00872482%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00983047%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL2108359"
        },
        {
            "status": "Terminated",
            "count": 1,
            "drug_type": "Antibody",
            "drug_label": "NIMOTUZUMAB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 2,
            "disease_id": "EFO_1001951",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase II",
            "disease_name": "colorectal carcinoma",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00493857%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL2108359"
        },
        {
            "status": "Terminated",
            "count": 1,
            "drug_type": "Antibody",
            "drug_label": "PANITUMUMAB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 2,
            "disease_id": "EFO_0000181",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase II",
            "disease_name": "head and neck squamous cell carcinoma",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT01305772%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL1201827"
        },
        {
            "status": "Terminated",
            "count": 2,
            "drug_type": "Antibody",
            "drug_label": "PANITUMUMAB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 2,
            "disease_id": "EFO_0000292",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase II",
            "disease_name": "bladder carcinoma",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT01374789%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT01916109%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL1201827"
        },
        {
            "status": "Terminated",
            "count": 1,
            "drug_type": "Antibody",
            "drug_label": "PANITUMUMAB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 2,
            "disease_id": "EFO_0000305",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase II",
            "disease_name": "breast carcinoma",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT01009983%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL1201827"
        },
        {
            "status": "Terminated",
            "count": 1,
            "drug_type": "Antibody",
            "drug_label": "PANITUMUMAB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 2,
            "disease_id": "EFO_0000313",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase II",
            "disease_name": "carcinoma",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT01843452%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL1201827"
        },
        {
            "status": "Terminated",
            "count": 1,
            "drug_type": "Antibody",
            "drug_label": "PANITUMUMAB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 2,
            "disease_id": "EFO_0000326",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase II",
            "disease_name": "central nervous system cancer",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT01017653%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL1201827"
        },
        {
            "status": "Terminated",
            "count": 1,
            "drug_type": "Antibody",
            "drug_label": "PANITUMUMAB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 2,
            "disease_id": "EFO_0000478",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase II",
            "disease_name": "esophageal adenocarcinoma",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT01262183%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL1201827"
        },
        {
            "status": "Terminated",
            "count": 1,
            "drug_type": "Antibody",
            "drug_label": "PANITUMUMAB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 2,
            "disease_id": "EFO_0000503",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase II",
            "disease_name": "gastric adenocarcinoma",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT01351038%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL1201827"
        },
        {
            "status": "Terminated",
            "count": 1,
            "drug_type": "Antibody",
            "drug_label": "PANITUMUMAB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 2,
            "disease_id": "EFO_0001075",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase II",
            "disease_name": "ovarian carcinoma",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT01296035%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL1201827"
        },
        {
            "status": "Terminated",
            "count": 1,
            "drug_type": "Antibody",
            "drug_label": "PANITUMUMAB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 2,
            "disease_id": "EFO_0002618",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase II",
            "disease_name": "pancreatic carcinoma",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00613730%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL1201827"
        },
        {
            "status": "Terminated",
            "count": 1,
            "drug_type": "Antibody",
            "drug_label": "PANITUMUMAB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 2,
            "disease_id": "EFO_0003060",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase II",
            "disease_name": "non-small cell lung carcinoma",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT01038037%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL1201827"
        },
        {
            "status": "Terminated",
            "count": 1,
            "drug_type": "Antibody",
            "drug_label": "PANITUMUMAB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 2,
            "disease_id": "EFO_0004142",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase II",
            "disease_name": "colorectal neoplasm",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00950820%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL1201827"
        },
        {
            "status": "Terminated",
            "count": 1,
            "drug_type": "Antibody",
            "drug_label": "PANITUMUMAB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 2,
            "disease_id": "EFO_0005922",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase II",
            "disease_name": "esophageal squamous cell carcinoma",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT01262183%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL1201827"
        },
        {
            "status": "Terminated",
            "count": 1,
            "drug_type": "Antibody",
            "drug_label": "PANITUMUMAB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 2,
            "disease_id": "EFO_1000251",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase II",
            "disease_name": "Fallopian Tube Carcinoma",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT01296035%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL1201827"
        },
        {
            "status": "Terminated",
            "count": 1,
            "drug_type": "Antibody",
            "drug_label": "PANITUMUMAB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 2,
            "disease_id": "EFO_1000657",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase II",
            "disease_name": "rectum cancer",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00973193%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL1201827"
        },
        {
            "status": "Terminated",
            "count": 1,
            "drug_type": "Antibody",
            "drug_label": "PANITUMUMAB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 2,
            "disease_id": "EFO_1001100",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase II",
            "disease_name": "peritoneal neoplasm",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT01296035%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL1201827"
        },
        {
            "status": "Terminated",
            "count": 1,
            "drug_type": "Antibody",
            "drug_label": "PANITUMUMAB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 2,
            "disease_id": "EFO_1001480",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase II",
            "disease_name": "metastatic colorectal cancer",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT02448810%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL1201827"
        },
        {
            "status": "Terminated",
            "count": 1,
            "drug_type": "Antibody",
            "drug_label": "PANITUMUMAB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 2,
            "disease_id": "EFO_1001951",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase II",
            "disease_name": "colorectal carcinoma",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT01418742%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL1201827"
        },
        {
            "status": "Terminated",
            "count": 1,
            "drug_type": "Small molecule",
            "drug_label": "POZIOTINIB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 2,
            "disease_id": "EFO_0000571",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor inhibitor"
            ],
            "clinical_trial_phase_label": "Phase II",
            "disease_name": "lung adenocarcinoma",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT01819428%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL3545154"
        },
        {
            "status": "Terminated",
            "count": 1,
            "drug_type": "Small molecule",
            "drug_label": "ROCILETINIB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 2,
            "disease_id": "EFO_0003060",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase II",
            "disease_name": "non-small cell lung carcinoma",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT02186301%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL3545308"
        },
        {
            "status": "Terminated",
            "count": 1,
            "drug_type": "Small molecule",
            "drug_label": "TESEVATINIB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 2,
            "disease_id": "EFO_1001496",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase II",
            "disease_name": "Autosomal dominant polycystic kidney disease",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT02616055%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL3544983"
        },
        {
            "status": "Terminated",
            "count": 1,
            "drug_type": "Small molecule",
            "drug_label": "VANDETANIB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 2,
            "disease_id": "EFO_0000178",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor inhibitor"
            ],
            "clinical_trial_phase_label": "Phase II",
            "disease_name": "gastric carcinoma",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00683787%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL24828"
        },
        {
            "status": "Terminated",
            "count": 3,
            "drug_type": "Small molecule",
            "drug_label": "VANDETANIB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 2,
            "disease_id": "EFO_0000305",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor inhibitor"
            ],
            "clinical_trial_phase_label": "Phase II",
            "disease_name": "breast carcinoma",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00481845%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00752986%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT01934335%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL24828"
        },
        {
            "status": "Terminated",
            "count": 1,
            "drug_type": "Small molecule",
            "drug_label": "VANDETANIB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 2,
            "disease_id": "EFO_0000349",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor inhibitor"
            ],
            "clinical_trial_phase_label": "Phase II",
            "disease_name": "clear cell renal carcinoma",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT01372813%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL24828"
        },
        {
            "status": "Terminated",
            "count": 1,
            "drug_type": "Small molecule",
            "drug_label": "VANDETANIB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 2,
            "disease_id": "EFO_0000588",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor inhibitor"
            ],
            "clinical_trial_phase_label": "Phase II",
            "disease_name": "mesothelioma",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00597116%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL24828"
        },
        {
            "status": "Terminated",
            "count": 2,
            "drug_type": "Small molecule",
            "drug_label": "VANDETANIB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 2,
            "disease_id": "EFO_0001071",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor inhibitor"
            ],
            "clinical_trial_phase_label": "Phase II",
            "disease_name": "lung carcinoma",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00290537%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00459121%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL24828"
        },
        {
            "status": "Terminated",
            "count": 1,
            "drug_type": "Small molecule",
            "drug_label": "VANDETANIB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 2,
            "disease_id": "EFO_0001663",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor inhibitor"
            ],
            "clinical_trial_phase_label": "Phase II",
            "disease_name": "prostate carcinoma",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00686036%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL24828"
        },
        {
            "status": "Terminated",
            "count": 1,
            "drug_type": "Small molecule",
            "drug_label": "VANDETANIB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 2,
            "disease_id": "EFO_0006859",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor inhibitor"
            ],
            "clinical_trial_phase_label": "Phase II",
            "disease_name": "head and neck malignant neoplasia",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00720083%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL24828"
        },
        {
            "status": "Terminated",
            "count": 1,
            "drug_type": "Antibody",
            "drug_label": "ZALUTUMUMAB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 2,
            "disease_id": "EFO_0003060",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 antagonist"
            ],
            "clinical_trial_phase_label": "Phase II",
            "disease_name": "non-small cell lung carcinoma",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00460551%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL2107861"
        },
        {
            "status": "Unknown status",
            "count": 1,
            "drug_type": "Small molecule",
            "drug_label": "AFATINIB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 2,
            "disease_id": "EFO_0000305",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase II",
            "disease_name": "breast carcinoma",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT02511847%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL1173655"
        },
        {
            "status": "Unknown status",
            "count": 2,
            "drug_type": "Small molecule",
            "drug_label": "AFATINIB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 2,
            "disease_id": "EFO_0003060",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase II",
            "disease_name": "non-small cell lung carcinoma",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT01542437%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT01932229%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL1173655"
        },
        {
            "status": "Unknown status",
            "count": 1,
            "drug_type": "Antibody",
            "drug_label": "CETUXIMAB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 2,
            "disease_id": "EFO_0000181",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase II",
            "disease_name": "head and neck squamous cell carcinoma",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT01830556%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL1201577"
        },
        {
            "status": "Unknown status",
            "count": 1,
            "drug_type": "Antibody",
            "drug_label": "CETUXIMAB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 2,
            "disease_id": "EFO_0000313",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase II",
            "disease_name": "carcinoma",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00894569%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL1201577"
        },
        {
            "status": "Unknown status",
            "count": 1,
            "drug_type": "Antibody",
            "drug_label": "CETUXIMAB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 2,
            "disease_id": "EFO_0000365",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase II",
            "disease_name": "colorectal adenocarcinoma",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT02071069%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL1201577"
        },
        {
            "status": "Unknown status",
            "count": 1,
            "drug_type": "Antibody",
            "drug_label": "CETUXIMAB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 2,
            "disease_id": "EFO_0000616",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase II",
            "disease_name": "neoplasm",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00251381%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL1201577"
        },
        {
            "status": "Unknown status",
            "count": 1,
            "drug_type": "Antibody",
            "drug_label": "CETUXIMAB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 2,
            "disease_id": "EFO_0000707",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase II",
            "disease_name": "squamous cell carcinoma",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT02753140%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL1201577"
        },
        {
            "status": "Unknown status",
            "count": 1,
            "drug_type": "Antibody",
            "drug_label": "CETUXIMAB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 2,
            "disease_id": "EFO_0001061",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase II",
            "disease_name": "cervical carcinoma",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00292955%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL1201577"
        },
        {
            "status": "Unknown status",
            "count": 3,
            "drug_type": "Antibody",
            "drug_label": "CETUXIMAB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 2,
            "disease_id": "EFO_0002916",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase II",
            "disease_name": "esophageal carcinoma",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00509561%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT01034189%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT01787006%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL1201577"
        },
        {
            "status": "Unknown status",
            "count": 1,
            "drug_type": "Antibody",
            "drug_label": "CETUXIMAB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 2,
            "disease_id": "EFO_0003060",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase II",
            "disease_name": "non-small cell lung carcinoma",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00561054%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL1201577"
        },
        {
            "status": "Unknown status",
            "count": 1,
            "drug_type": "Antibody",
            "drug_label": "CETUXIMAB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 2,
            "disease_id": "EFO_0003835",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase II",
            "disease_name": "anal neoplasm",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00955240%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL1201577"
        },
        {
            "status": "Unknown status",
            "count": 1,
            "drug_type": "Antibody",
            "drug_label": "CETUXIMAB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 2,
            "disease_id": "EFO_0003897",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase II",
            "disease_name": "stomach neoplasm",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00384878%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL1201577"
        },
        {
            "status": "Unknown status",
            "count": 1,
            "drug_type": "Antibody",
            "drug_label": "CETUXIMAB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 2,
            "disease_id": "EFO_0004252",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase II",
            "disease_name": "nasopharyngeal neoplasm",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT01614938%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL1201577"
        },
        {
            "status": "Unknown status",
            "count": 2,
            "drug_type": "Antibody",
            "drug_label": "CETUXIMAB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 2,
            "disease_id": "EFO_0004284",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase II",
            "disease_name": "upper aerodigestive tract neoplasm",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT01020864%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT01301248%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL1201577"
        },
        {
            "status": "Unknown status",
            "count": 1,
            "drug_type": "Antibody",
            "drug_label": "CETUXIMAB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 2,
            "disease_id": "EFO_0005221",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase II",
            "disease_name": "cholangiocarcinoma",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT01247337%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL1201577"
        },
        {
            "status": "Unknown status",
            "count": 1,
            "drug_type": "Antibody",
            "drug_label": "CETUXIMAB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 2,
            "disease_id": "EFO_0005922",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase II",
            "disease_name": "esophageal squamous cell carcinoma",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT02123381%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL1201577"
        },
        {
            "status": "Unknown status",
            "count": 4,
            "drug_type": "Antibody",
            "drug_label": "CETUXIMAB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 2,
            "disease_id": "EFO_0006859",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase II",
            "disease_name": "head and neck malignant neoplasia",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00468169%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00721513%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00765011%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT01472653%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL1201577"
        },
        {
            "status": "Unknown status",
            "count": 4,
            "drug_type": "Antibody",
            "drug_label": "CETUXIMAB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 2,
            "disease_id": "EFO_1000657",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase II",
            "disease_name": "rectum cancer",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00506844%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00689702%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00795301%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00964457%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL1201577"
        },
        {
            "status": "Unknown status",
            "count": 2,
            "drug_type": "Antibody",
            "drug_label": "CETUXIMAB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 2,
            "disease_id": "EFO_1001480",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase II",
            "disease_name": "metastatic colorectal cancer",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00784667%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00931840%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL1201577"
        },
        {
            "status": "Unknown status",
            "count": 4,
            "drug_type": "Antibody",
            "drug_label": "CETUXIMAB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 2,
            "disease_id": "EFO_1001951",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase II",
            "disease_name": "colorectal carcinoma",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00215722%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00383695%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00541112%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT01190462%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL1201577"
        },
        {
            "status": "Unknown status",
            "count": 4,
            "drug_type": "Small molecule",
            "drug_label": "DACOMITINIB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 2,
            "disease_id": "EFO_0000707",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor",
                "Epidermal growth factor receptor inhibitor"
            ],
            "clinical_trial_phase_label": "Phase II",
            "disease_name": "squamous cell carcinoma",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT01728233%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT01728233%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT02268747%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT02268747%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL2110732"
        },
        {
            "status": "Unknown status",
            "count": 2,
            "drug_type": "Small molecule",
            "drug_label": "DACOMITINIB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 2,
            "disease_id": "EFO_1001094",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor",
                "Epidermal growth factor receptor inhibitor"
            ],
            "clinical_trial_phase_label": "Phase II",
            "disease_name": "penile neoplasm",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT01728233%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT01728233%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL2110732"
        },
        {
            "status": "Unknown status",
            "count": 1,
            "drug_type": "Small molecule",
            "drug_label": "ERLOTINIB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 2,
            "disease_id": "EFO_0000305",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase II",
            "disease_name": "breast carcinoma",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00491816%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL553"
        },
        {
            "status": "Unknown status",
            "count": 1,
            "drug_type": "Small molecule",
            "drug_label": "ERLOTINIB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 2,
            "disease_id": "EFO_0000308",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase II",
            "disease_name": "bronchoalveolar adenocarcinoma",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00339586%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL553"
        },
        {
            "status": "Unknown status",
            "count": 1,
            "drug_type": "Small molecule",
            "drug_label": "ERLOTINIB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 2,
            "disease_id": "EFO_0000313",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase II",
            "disease_name": "carcinoma",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT02066038%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL553"
        },
        {
            "status": "Unknown status",
            "count": 1,
            "drug_type": "Small molecule",
            "drug_label": "ERLOTINIB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 2,
            "disease_id": "EFO_0000326",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase II",
            "disease_name": "central nervous system cancer",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00054496%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL553"
        },
        {
            "status": "Unknown status",
            "count": 1,
            "drug_type": "Small molecule",
            "drug_label": "ERLOTINIB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 2,
            "disease_id": "EFO_0000616",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase II",
            "disease_name": "neoplasm",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT01771458%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL553"
        },
        {
            "status": "Unknown status",
            "count": 2,
            "drug_type": "Small molecule",
            "drug_label": "ERLOTINIB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 2,
            "disease_id": "EFO_0001071",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase II",
            "disease_name": "lung carcinoma",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00278187%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00801385%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL553"
        },
        {
            "status": "Unknown status",
            "count": 1,
            "drug_type": "Small molecule",
            "drug_label": "ERLOTINIB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 2,
            "disease_id": "EFO_0002618",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase II",
            "disease_name": "pancreatic carcinoma",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT01608841%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL553"
        },
        {
            "status": "Unknown status",
            "count": 24,
            "drug_type": "Small molecule",
            "drug_label": "ERLOTINIB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 2,
            "disease_id": "EFO_0003060",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase II",
            "disease_name": "non-small cell lung carcinoma",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00137800%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00339586%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00466089%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00466284%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00553800%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00620269%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00678964%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00722969%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00835471%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00908336%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00950365%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT01091376%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT01130779%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT01131429%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT01410214%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT01714908%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT01796288%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT01955421%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT02006043%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT02036359%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT02037997%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT02098954%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT02146118%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT02738983%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL553"
        },
        {
            "status": "Unknown status",
            "count": 1,
            "drug_type": "Small molecule",
            "drug_label": "ERLOTINIB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 2,
            "disease_id": "EFO_1001480",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase II",
            "disease_name": "metastatic colorectal cancer",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00784667%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL553"
        },
        {
            "status": "Unknown status",
            "count": 1,
            "drug_type": "Small molecule",
            "drug_label": "GEFITINIB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 2,
            "disease_id": "EFO_0000182",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase II",
            "disease_name": "hepatocellular carcinoma",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00282100%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL939"
        },
        {
            "status": "Unknown status",
            "count": 1,
            "drug_type": "Small molecule",
            "drug_label": "GEFITINIB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 2,
            "disease_id": "EFO_0000305",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase II",
            "disease_name": "breast carcinoma",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT01732276%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL939"
        },
        {
            "status": "Unknown status",
            "count": 1,
            "drug_type": "Small molecule",
            "drug_label": "GEFITINIB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 2,
            "disease_id": "EFO_0000707",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase II",
            "disease_name": "squamous cell carcinoma",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT01485809%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL939"
        },
        {
            "status": "Unknown status",
            "count": 2,
            "drug_type": "Small molecule",
            "drug_label": "GEFITINIB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 2,
            "disease_id": "EFO_0001071",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase II",
            "disease_name": "lung carcinoma",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00616499%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT01024712%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL939"
        },
        {
            "status": "Unknown status",
            "count": 1,
            "drug_type": "Small molecule",
            "drug_label": "GEFITINIB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 2,
            "disease_id": "EFO_0002916",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase II",
            "disease_name": "esophageal carcinoma",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT01291823%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL939"
        },
        {
            "status": "Unknown status",
            "count": 15,
            "drug_type": "Small molecule",
            "drug_label": "GEFITINIB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 2,
            "disease_id": "EFO_0003060",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase II",
            "disease_name": "non-small cell lung carcinoma",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00319800%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT01192243%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT01312337%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT01391260%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT01510990%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT01579630%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT01749072%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT01755923%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT01784549%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT01833572%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT01933347%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT01955421%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT02319577%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT02387086%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT02930954%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL939"
        },
        {
            "status": "Unknown status",
            "count": 1,
            "drug_type": "Small molecule",
            "drug_label": "LAPATINIB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 2,
            "disease_id": "EFO_0000178",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase II",
            "disease_name": "gastric carcinoma",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00450203%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL554"
        },
        {
            "status": "Unknown status",
            "count": 1,
            "drug_type": "Small molecule",
            "drug_label": "LAPATINIB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 2,
            "disease_id": "EFO_0000292",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase II",
            "disease_name": "bladder carcinoma",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00949455%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL554"
        },
        {
            "status": "Unknown status",
            "count": 5,
            "drug_type": "Small molecule",
            "drug_label": "LAPATINIB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 2,
            "disease_id": "EFO_0000305",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase II",
            "disease_name": "breast carcinoma",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00842998%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT01283789%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT01309607%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT01730677%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT02238509%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL554"
        },
        {
            "status": "Unknown status",
            "count": 1,
            "drug_type": "Small molecule",
            "drug_label": "LAPATINIB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 2,
            "disease_id": "EFO_0000616",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase II",
            "disease_name": "neoplasm",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT01771458%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL554"
        },
        {
            "status": "Unknown status",
            "count": 1,
            "drug_type": "Small molecule",
            "drug_label": "LAPATINIB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 2,
            "disease_id": "EFO_0006318",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase II",
            "disease_name": "breast ductal adenocarcinoma",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT01891357%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL554"
        },
        {
            "status": "Unknown status",
            "count": 1,
            "drug_type": "Antibody",
            "drug_label": "NIMOTUZUMAB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 2,
            "disease_id": "EFO_0000178",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase II",
            "disease_name": "gastric carcinoma",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT01180166%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL2108359"
        },
        {
            "status": "Unknown status",
            "count": 1,
            "drug_type": "Antibody",
            "drug_label": "NIMOTUZUMAB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 2,
            "disease_id": "EFO_0000181",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase II",
            "disease_name": "head and neck squamous cell carcinoma",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT01393184%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL2108359"
        },
        {
            "status": "Unknown status",
            "count": 1,
            "drug_type": "Antibody",
            "drug_label": "NIMOTUZUMAB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 2,
            "disease_id": "EFO_0000305",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase II",
            "disease_name": "breast carcinoma",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT01939054%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL2108359"
        },
        {
            "status": "Unknown status",
            "count": 3,
            "drug_type": "Antibody",
            "drug_label": "NIMOTUZUMAB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 2,
            "disease_id": "EFO_0000707",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase II",
            "disease_name": "squamous cell carcinoma",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT01232374%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT01336049%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT01688700%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL2108359"
        },
        {
            "status": "Unknown status",
            "count": 3,
            "drug_type": "Antibody",
            "drug_label": "NIMOTUZUMAB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 2,
            "disease_id": "EFO_0001061",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase II",
            "disease_name": "cervical carcinoma",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT01938105%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT02039791%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT02705612%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL2108359"
        },
        {
            "status": "Unknown status",
            "count": 2,
            "drug_type": "Antibody",
            "drug_label": "NIMOTUZUMAB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 2,
            "disease_id": "EFO_0002916",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase II",
            "disease_name": "esophageal carcinoma",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT01463605%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT01486992%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL2108359"
        },
        {
            "status": "Unknown status",
            "count": 1,
            "drug_type": "Antibody",
            "drug_label": "NIMOTUZUMAB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 2,
            "disease_id": "EFO_0005842",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase II",
            "disease_name": "colorectal cancer",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00972465%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL2108359"
        },
        {
            "status": "Unknown status",
            "count": 1,
            "drug_type": "Antibody",
            "drug_label": "NIMOTUZUMAB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 2,
            "disease_id": "EFO_0005922",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase II",
            "disease_name": "esophageal squamous cell carcinoma",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT01402180%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL2108359"
        },
        {
            "status": "Unknown status",
            "count": 1,
            "drug_type": "Antibody",
            "drug_label": "NIMOTUZUMAB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 2,
            "disease_id": "EFO_1000657",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase II",
            "disease_name": "rectum cancer",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT01899118%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL2108359"
        },
        {
            "status": "Unknown status",
            "count": 1,
            "drug_type": "Antibody",
            "drug_label": "PANITUMUMAB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 2,
            "disease_id": "EFO_0000707",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase II",
            "disease_name": "squamous cell carcinoma",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT01129154%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL1201827"
        },
        {
            "status": "Unknown status",
            "count": 1,
            "drug_type": "Antibody",
            "drug_label": "PANITUMUMAB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 2,
            "disease_id": "EFO_0001061",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase II",
            "disease_name": "cervical carcinoma",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT01158248%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL1201827"
        },
        {
            "status": "Unknown status",
            "count": 1,
            "drug_type": "Antibody",
            "drug_label": "PANITUMUMAB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 2,
            "disease_id": "EFO_0001075",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase II",
            "disease_name": "ovarian carcinoma",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT01388621%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL1201827"
        },
        {
            "status": "Unknown status",
            "count": 1,
            "drug_type": "Antibody",
            "drug_label": "PANITUMUMAB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 2,
            "disease_id": "EFO_0006859",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase II",
            "disease_name": "head and neck malignant neoplasia",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT01264328%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL1201827"
        },
        {
            "status": "Unknown status",
            "count": 1,
            "drug_type": "Antibody",
            "drug_label": "PANITUMUMAB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 2,
            "disease_id": "EFO_1000657",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase II",
            "disease_name": "rectum cancer",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT01257360%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL1201827"
        },
        {
            "status": "Unknown status",
            "count": 3,
            "drug_type": "Antibody",
            "drug_label": "PANITUMUMAB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 2,
            "disease_id": "EFO_1001480",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase II",
            "disease_name": "metastatic colorectal cancer",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT01144195%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT01801904%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT02476045%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL1201827"
        },
        {
            "status": "Unknown status",
            "count": 2,
            "drug_type": "Antibody",
            "drug_label": "PANITUMUMAB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 2,
            "disease_id": "EFO_1001951",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase II",
            "disease_name": "colorectal carcinoma",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00967655%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT01110785%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL1201827"
        },
        {
            "status": "Unknown status",
            "count": 1,
            "drug_type": "Small molecule",
            "drug_label": "POZIOTINIB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 2,
            "disease_id": "EFO_0000305",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor inhibitor"
            ],
            "clinical_trial_phase_label": "Phase II",
            "disease_name": "breast carcinoma",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT02418689%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL3545154"
        },
        {
            "status": "Unknown status",
            "count": 2,
            "drug_type": "Small molecule",
            "drug_label": "PYROTINIB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 2,
            "disease_id": "EFO_0003060",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase II",
            "disease_name": "non-small cell lung carcinoma",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT02535507%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT02834936%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL3544956"
        },
        {
            "status": "Unknown status",
            "count": 1,
            "drug_type": "Small molecule",
            "drug_label": "VANDETANIB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 2,
            "disease_id": "EFO_0000292",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor inhibitor"
            ],
            "clinical_trial_phase_label": "Phase II",
            "disease_name": "bladder carcinoma",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT01191892%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL24828"
        },
        {
            "status": "Unknown status",
            "count": 1,
            "drug_type": "Small molecule",
            "drug_label": "VANDETANIB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 2,
            "disease_id": "EFO_0002618",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor inhibitor"
            ],
            "clinical_trial_phase_label": "Phase II",
            "disease_name": "pancreatic carcinoma",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT01601808%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL24828"
        },
        {
            "status": "Unknown status",
            "count": 1,
            "drug_type": "Small molecule",
            "drug_label": "VANDETANIB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 2,
            "disease_id": "EFO_0003017",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor inhibitor"
            ],
            "clinical_trial_phase_label": "Phase II",
            "disease_name": "transitional cell carcinoma of kidney",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT01191892%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL24828"
        },
        {
            "status": "Unknown status",
            "count": 1,
            "drug_type": "Small molecule",
            "drug_label": "VANDETANIB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 2,
            "disease_id": "EFO_0003060",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor inhibitor"
            ],
            "clinical_trial_phase_label": "Phase II",
            "disease_name": "non-small cell lung carcinoma",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT01823068%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL24828"
        },
        {
            "status": "Unknown status",
            "count": 1,
            "drug_type": "Small molecule",
            "drug_label": "VANDETANIB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 2,
            "disease_id": "EFO_0003844",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor inhibitor"
            ],
            "clinical_trial_phase_label": "Phase II",
            "disease_name": "ureteral neoplasm",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT01191892%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL24828"
        },
        {
            "status": "Unknown status",
            "count": 1,
            "drug_type": "Small molecule",
            "drug_label": "VANDETANIB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 2,
            "disease_id": "EFO_0003846",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor inhibitor"
            ],
            "clinical_trial_phase_label": "Phase II",
            "disease_name": "urethral neoplasm",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT01191892%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL24828"
        },
        {
            "status": "Withdrawn",
            "count": 1,
            "drug_type": "Small molecule",
            "drug_label": "AFATINIB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 2,
            "disease_id": "EFO_0000702",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase II",
            "disease_name": "small cell lung carcinoma",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT02876081%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL1173655"
        },
        {
            "status": "Withdrawn",
            "count": 1,
            "drug_type": "Small molecule",
            "drug_label": "AFATINIB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 2,
            "disease_id": "EFO_0001071",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase II",
            "disease_name": "lung carcinoma",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT01480141%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL1173655"
        },
        {
            "status": "Withdrawn",
            "count": 1,
            "drug_type": "Antibody",
            "drug_label": "CETUXIMAB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 2,
            "disease_id": "EFO_0000181",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase II",
            "disease_name": "head and neck squamous cell carcinoma",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00934518%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL1201577"
        },
        {
            "status": "Withdrawn",
            "count": 1,
            "drug_type": "Antibody",
            "drug_label": "CETUXIMAB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 2,
            "disease_id": "EFO_0000707",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase II",
            "disease_name": "squamous cell carcinoma",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT02014831%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL1201577"
        },
        {
            "status": "Withdrawn",
            "count": 1,
            "drug_type": "Antibody",
            "drug_label": "CETUXIMAB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 2,
            "disease_id": "EFO_0001071",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase II",
            "disease_name": "lung carcinoma",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00998101%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL1201577"
        },
        {
            "status": "Withdrawn",
            "count": 1,
            "drug_type": "Antibody",
            "drug_label": "CETUXIMAB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 2,
            "disease_id": "EFO_0002618",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase II",
            "disease_name": "pancreatic carcinoma",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00005591%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL1201577"
        },
        {
            "status": "Withdrawn",
            "count": 1,
            "drug_type": "Antibody",
            "drug_label": "CETUXIMAB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 2,
            "disease_id": "EFO_0002916",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase II",
            "disease_name": "esophageal carcinoma",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00636298%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL1201577"
        },
        {
            "status": "Withdrawn",
            "count": 1,
            "drug_type": "Antibody",
            "drug_label": "CETUXIMAB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 2,
            "disease_id": "EFO_0003060",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase II",
            "disease_name": "non-small cell lung carcinoma",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00768131%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL1201577"
        },
        {
            "status": "Withdrawn",
            "count": 2,
            "drug_type": "Antibody",
            "drug_label": "CETUXIMAB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 2,
            "disease_id": "EFO_0006859",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase II",
            "disease_name": "head and neck malignant neoplasia",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00881114%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT01427205%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL1201577"
        },
        {
            "status": "Withdrawn",
            "count": 1,
            "drug_type": "Antibody",
            "drug_label": "CETUXIMAB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 2,
            "disease_id": "EFO_1001480",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase II",
            "disease_name": "metastatic colorectal cancer",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00954876%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL1201577"
        },
        {
            "status": "Withdrawn",
            "count": 1,
            "drug_type": "Antibody",
            "drug_label": "CETUXIMAB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 2,
            "disease_id": "EFO_1001950",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase II",
            "disease_name": "colon carcinoma",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00766220%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL1201577"
        },
        {
            "status": "Withdrawn",
            "count": 2,
            "drug_type": "Antibody",
            "drug_label": "CETUXIMAB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 2,
            "disease_id": "EFO_1001951",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase II",
            "disease_name": "colorectal carcinoma",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00571740%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00577109%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL1201577"
        },
        {
            "status": "Withdrawn",
            "count": 1,
            "drug_type": "Small molecule",
            "drug_label": "ERLOTINIB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 2,
            "disease_id": "EFO_0000198",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase II",
            "disease_name": "myelodysplastic syndrome",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00570375%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL553"
        },
        {
            "status": "Withdrawn",
            "count": 1,
            "drug_type": "Small molecule",
            "drug_label": "ERLOTINIB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 2,
            "disease_id": "EFO_0000305",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase II",
            "disease_name": "breast carcinoma",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT01013506%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL553"
        },
        {
            "status": "Withdrawn",
            "count": 1,
            "drug_type": "Small molecule",
            "drug_label": "ERLOTINIB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 2,
            "disease_id": "EFO_0000311",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase II",
            "disease_name": "cancer",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT02034097%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL553"
        },
        {
            "status": "Withdrawn",
            "count": 1,
            "drug_type": "Small molecule",
            "drug_label": "ERLOTINIB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 2,
            "disease_id": "EFO_0000676",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase II",
            "disease_name": "psoriasis",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT01006096%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL553"
        },
        {
            "status": "Withdrawn",
            "count": 1,
            "drug_type": "Small molecule",
            "drug_label": "ERLOTINIB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 2,
            "disease_id": "EFO_0001071",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase II",
            "disease_name": "lung carcinoma",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00385398%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL553"
        },
        {
            "status": "Withdrawn",
            "count": 2,
            "drug_type": "Small molecule",
            "drug_label": "ERLOTINIB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 2,
            "disease_id": "EFO_0003060",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase II",
            "disease_name": "non-small cell lung carcinoma",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT01928160%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT02355431%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL553"
        },
        {
            "status": "Withdrawn",
            "count": 1,
            "drug_type": "Small molecule",
            "drug_label": "ERLOTINIB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 2,
            "disease_id": "EFO_1000044",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase II",
            "disease_name": "pancreatic adenocarcinoma",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00728000%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL553"
        },
        {
            "status": "Withdrawn",
            "count": 1,
            "drug_type": "Antibody",
            "drug_label": "FUTUXIMAB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 2,
            "disease_id": "EFO_1001480",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 antagonist"
            ],
            "clinical_trial_phase_label": "Phase II",
            "disease_name": "metastatic colorectal cancer",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT02965417%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL2109388"
        },
        {
            "status": "Withdrawn",
            "count": 1,
            "drug_type": "Small molecule",
            "drug_label": "GEFITINIB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 2,
            "disease_id": "EFO_0000305",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase II",
            "disease_name": "breast carcinoma",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00252811%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL939"
        },
        {
            "status": "Withdrawn",
            "count": 1,
            "drug_type": "Small molecule",
            "drug_label": "GEFITINIB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 2,
            "disease_id": "EFO_0003060",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase II",
            "disease_name": "non-small cell lung carcinoma",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00048087%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL939"
        },
        {
            "status": "Withdrawn",
            "count": 1,
            "drug_type": "Small molecule",
            "drug_label": "GEFITINIB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 2,
            "disease_id": "EFO_1001480",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase II",
            "disease_name": "metastatic colorectal cancer",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00233623%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL939"
        },
        {
            "status": "Withdrawn",
            "count": 3,
            "drug_type": "Small molecule",
            "drug_label": "LAPATINIB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 2,
            "disease_id": "EFO_0000305",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase II",
            "disease_name": "breast carcinoma",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00343759%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT01005641%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT01985893%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL554"
        },
        {
            "status": "Withdrawn",
            "count": 3,
            "drug_type": "Small molecule",
            "drug_label": "LAPATINIB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 2,
            "disease_id": "EFO_0003869",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase II",
            "disease_name": "breast neoplasm",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT01137994%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT01205217%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT01557764%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL554"
        },
        {
            "status": "Withdrawn",
            "count": 1,
            "drug_type": "Antibody",
            "drug_label": "NECITUMUMAB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 2,
            "disease_id": "EFO_0003060",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase II",
            "disease_name": "non-small cell lung carcinoma",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT02941601%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL1743047"
        },
        {
            "status": "Withdrawn",
            "count": 1,
            "drug_type": "Antibody",
            "drug_label": "NIMOTUZUMAB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 2,
            "disease_id": "EFO_0000228",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase II",
            "disease_name": "adenocarcinoma",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT01301612%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL2108359"
        },
        {
            "status": "Withdrawn",
            "count": 3,
            "drug_type": "Antibody",
            "drug_label": "NIMOTUZUMAB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 2,
            "disease_id": "EFO_0000707",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase II",
            "disease_name": "squamous cell carcinoma",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT01301612%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT02011594%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT02034968%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL2108359"
        },
        {
            "status": "Withdrawn",
            "count": 1,
            "drug_type": "Antibody",
            "drug_label": "NIMOTUZUMAB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 2,
            "disease_id": "EFO_0005922",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase II",
            "disease_name": "esophageal squamous cell carcinoma",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT02041819%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL2108359"
        },
        {
            "status": "Withdrawn",
            "count": 1,
            "drug_type": "Antibody",
            "drug_label": "PANITUMUMAB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 2,
            "disease_id": "EFO_0000311",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase II",
            "disease_name": "cancer",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT01634880%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL1201827"
        },
        {
            "status": "Withdrawn",
            "count": 1,
            "drug_type": "Antibody",
            "drug_label": "PANITUMUMAB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 2,
            "disease_id": "EFO_0002618",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase II",
            "disease_name": "pancreatic carcinoma",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT01130701%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL1201827"
        },
        {
            "status": "Withdrawn",
            "count": 1,
            "drug_type": "Antibody",
            "drug_label": "PANITUMUMAB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 2,
            "disease_id": "EFO_0006859",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase II",
            "disease_name": "head and neck malignant neoplasia",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT01312493%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL1201827"
        },
        {
            "status": "Withdrawn",
            "count": 1,
            "drug_type": "Antibody",
            "drug_label": "PANITUMUMAB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 2,
            "disease_id": "EFO_1000852",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase II",
            "disease_name": "carcinoid syndrome",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT01172717%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL1201827"
        },
        {
            "status": "Withdrawn",
            "count": 1,
            "drug_type": "Small molecule",
            "drug_label": "ROCILETINIB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 2,
            "disease_id": "EFO_0003060",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase II",
            "disease_name": "non-small cell lung carcinoma",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT02705339%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL3545308"
        },
        {
            "status": "Withdrawn",
            "count": 1,
            "drug_type": "Small molecule",
            "drug_label": "VANDETANIB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 2,
            "disease_id": "EFO_0003060",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor inhibitor"
            ],
            "clinical_trial_phase_label": "Phase II",
            "disease_name": "non-small cell lung carcinoma",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT02087839%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL24828"
        },
        {
            "status": "Withdrawn",
            "count": 1,
            "drug_type": "Small molecule",
            "drug_label": "VARLITINIB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 2,
            "disease_id": "EFO_0003891",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase II",
            "disease_name": "biliary tract neoplasm",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT03129074%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL2103842"
        },
        {
            "status": "Withdrawn",
            "count": 1,
            "drug_type": "Antibody",
            "drug_label": "ZALUTUMUMAB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 2,
            "disease_id": "EFO_0003060",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 antagonist"
            ],
            "clinical_trial_phase_label": "Phase II",
            "disease_name": "non-small cell lung carcinoma",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT01449357%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL2107861"
        },
        {
            "status": "Active, not recruiting",
            "count": 1,
            "drug_type": "Small molecule",
            "drug_label": "AFATINIB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 3,
            "disease_id": "EFO_0000181",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase III",
            "disease_name": "head and neck squamous cell carcinoma",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT01427478%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL1173655"
        },
        {
            "status": "Active, not recruiting",
            "count": 1,
            "drug_type": "Small molecule",
            "drug_label": "AFATINIB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 3,
            "disease_id": "EFO_0003060",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase III",
            "disease_name": "non-small cell lung carcinoma",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT01853826%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL1173655"
        },
        {
            "status": "Active, not recruiting",
            "count": 1,
            "drug_type": "Small molecule",
            "drug_label": "AFATINIB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 3,
            "disease_id": "EFO_0004284",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase III",
            "disease_name": "upper aerodigestive tract neoplasm",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT01856478%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL1173655"
        },
        {
            "status": "Active, not recruiting",
            "count": 1,
            "drug_type": "Small molecule",
            "drug_label": "BRIGATINIB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 3,
            "disease_id": "EFO_0003060",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase III",
            "disease_name": "non-small cell lung carcinoma",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT02737501%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL3545311"
        },
        {
            "status": "Active, not recruiting",
            "count": 5,
            "drug_type": "Antibody",
            "drug_label": "CETUXIMAB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 3,
            "disease_id": "EFO_0000181",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase III",
            "disease_name": "head and neck squamous cell carcinoma",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00999700%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT01884623%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT02105636%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT02551159%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT03349710%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL1201577"
        },
        {
            "status": "Active, not recruiting",
            "count": 1,
            "drug_type": "Antibody",
            "drug_label": "CETUXIMAB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 3,
            "disease_id": "EFO_0000311",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase III",
            "disease_name": "cancer",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT01969877%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL1201577"
        },
        {
            "status": "Active, not recruiting",
            "count": 2,
            "drug_type": "Antibody",
            "drug_label": "CETUXIMAB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 3,
            "disease_id": "EFO_0000707",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase III",
            "disease_name": "squamous cell carcinoma",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT02252042%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT02383966%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL1201577"
        },
        {
            "status": "Active, not recruiting",
            "count": 1,
            "drug_type": "Antibody",
            "drug_label": "CETUXIMAB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 3,
            "disease_id": "EFO_0001071",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase III",
            "disease_name": "lung carcinoma",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00533949%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL1201577"
        },
        {
            "status": "Active, not recruiting",
            "count": 1,
            "drug_type": "Antibody",
            "drug_label": "CETUXIMAB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 3,
            "disease_id": "EFO_0002916",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase III",
            "disease_name": "esophageal carcinoma",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00655876%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL1201577"
        },
        {
            "status": "Active, not recruiting",
            "count": 6,
            "drug_type": "Antibody",
            "drug_label": "CETUXIMAB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 3,
            "disease_id": "EFO_0006859",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase III",
            "disease_name": "head and neck malignant neoplasia",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00265941%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00956007%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT01302834%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT02358031%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT02741570%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT03358472%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL1201577"
        },
        {
            "status": "Active, not recruiting",
            "count": 1,
            "drug_type": "Antibody",
            "drug_label": "CETUXIMAB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 3,
            "disease_id": "EFO_1001480",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase III",
            "disease_name": "metastatic colorectal cancer",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT02928224%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL1201577"
        },
        {
            "status": "Active, not recruiting",
            "count": 1,
            "drug_type": "Antibody",
            "drug_label": "CETUXIMAB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 3,
            "disease_id": "EFO_1001951",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase III",
            "disease_name": "colorectal carcinoma",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT02563002%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL1201577"
        },
        {
            "status": "Active, not recruiting",
            "count": 2,
            "drug_type": "Antibody",
            "drug_label": "CETUXIMAB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 3,
            "disease_id": "EFO_1001965",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase III",
            "disease_name": "pharyngeal squamous cell carcinoma",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT01855451%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT01874171%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL1201577"
        },
        {
            "status": "Active, not recruiting",
            "count": 2,
            "drug_type": "Small molecule",
            "drug_label": "DACOMITINIB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 3,
            "disease_id": "EFO_0003060",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor",
                "Epidermal growth factor receptor inhibitor"
            ],
            "clinical_trial_phase_label": "Phase III",
            "disease_name": "non-small cell lung carcinoma",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT01774721%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT01774721%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL2110732"
        },
        {
            "status": "Active, not recruiting",
            "count": 6,
            "drug_type": "Small molecule",
            "drug_label": "ERLOTINIB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 3,
            "disease_id": "EFO_0003060",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase III",
            "disease_name": "non-small cell lung carcinoma",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00130728%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT02152631%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT02296125%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT02352948%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT02411448%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT02759614%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL553"
        },
        {
            "status": "Active, not recruiting",
            "count": 5,
            "drug_type": "Small molecule",
            "drug_label": "GEFITINIB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 3,
            "disease_id": "EFO_0003060",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase III",
            "disease_name": "non-small cell lung carcinoma",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT01405079%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT01544179%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT01774721%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT02296125%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT02411448%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL939"
        },
        {
            "status": "Active, not recruiting",
            "count": 6,
            "drug_type": "Small molecule",
            "drug_label": "LAPATINIB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 3,
            "disease_id": "EFO_0000305",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase III",
            "disease_name": "breast carcinoma",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00390455%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00667251%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT01104571%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT01526369%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT01808573%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT03084939%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL554"
        },
        {
            "status": "Active, not recruiting",
            "count": 1,
            "drug_type": "Small molecule",
            "drug_label": "LAPATINIB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 3,
            "disease_id": "EFO_0000616",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase III",
            "disease_name": "neoplasm",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00680901%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL554"
        },
        {
            "status": "Active, not recruiting",
            "count": 6,
            "drug_type": "Small molecule",
            "drug_label": "LAPATINIB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 3,
            "disease_id": "EFO_0003869",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase III",
            "disease_name": "breast neoplasm",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00272987%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00281658%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00490139%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00508274%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00553358%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT01160211%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL554"
        },
        {
            "status": "Active, not recruiting",
            "count": 1,
            "drug_type": "Small molecule",
            "drug_label": "LAPATINIB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 3,
            "disease_id": "EFO_0006861",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase III",
            "disease_name": "male breast carcinoma",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00770809%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL554"
        },
        {
            "status": "Active, not recruiting",
            "count": 1,
            "drug_type": "Antibody",
            "drug_label": "NECITUMUMAB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 3,
            "disease_id": "EFO_0003060",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase III",
            "disease_name": "non-small cell lung carcinoma",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00981058%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL1743047"
        },
        {
            "status": "Active, not recruiting",
            "count": 4,
            "drug_type": "Small molecule",
            "drug_label": "NERATINIB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 3,
            "disease_id": "EFO_0000305",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor",
                "Epidermal growth factor receptor inhibitor"
            ],
            "clinical_trial_phase_label": "Phase III",
            "disease_name": "breast carcinoma",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00878709%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00878709%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT01808573%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT01808573%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL180022"
        },
        {
            "status": "Active, not recruiting",
            "count": 2,
            "drug_type": "Small molecule",
            "drug_label": "OSIMERTINIB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 3,
            "disease_id": "EFO_0000311",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor",
                "Epidermal growth factor receptor inhibitor"
            ],
            "clinical_trial_phase_label": "Phase III",
            "disease_name": "cancer",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT02151981%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT02151981%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL3353410"
        },
        {
            "status": "Active, not recruiting",
            "count": 2,
            "drug_type": "Small molecule",
            "drug_label": "OSIMERTINIB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 3,
            "disease_id": "EFO_0001071",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor",
                "Epidermal growth factor receptor inhibitor"
            ],
            "clinical_trial_phase_label": "Phase III",
            "disease_name": "lung carcinoma",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT02474355%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT02474355%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL3353410"
        },
        {
            "status": "Active, not recruiting",
            "count": 8,
            "drug_type": "Small molecule",
            "drug_label": "OSIMERTINIB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 3,
            "disease_id": "EFO_0003060",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor",
                "Epidermal growth factor receptor inhibitor"
            ],
            "clinical_trial_phase_label": "Phase III",
            "disease_name": "non-small cell lung carcinoma",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT02296125%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT02296125%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT02411448%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT02411448%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT02454933%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT02454933%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT02511106%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT02511106%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL3353410"
        },
        {
            "status": "Active, not recruiting",
            "count": 2,
            "drug_type": "Antibody",
            "drug_label": "PANITUMUMAB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 3,
            "disease_id": "EFO_1001951",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase III",
            "disease_name": "colorectal carcinoma",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT02394795%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT02394834%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL1201827"
        },
        {
            "status": "Active, not recruiting",
            "count": 1,
            "drug_type": "Small molecule",
            "drug_label": "PYROTINIB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 3,
            "disease_id": "EFO_0000305",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase III",
            "disease_name": "breast carcinoma",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT02973737%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL3544956"
        },
        {
            "status": "Active, not recruiting",
            "count": 3,
            "drug_type": "Small molecule",
            "drug_label": "VANDETANIB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 3,
            "disease_id": "EFO_0002892",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor inhibitor"
            ],
            "clinical_trial_phase_label": "Phase III",
            "disease_name": "thyroid carcinoma",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00410761%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT01298323%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT01876784%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL24828"
        },
        {
            "status": "Active, not recruiting",
            "count": 1,
            "drug_type": "Small molecule",
            "drug_label": "VANDETANIB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 3,
            "disease_id": "EFO_0003060",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor inhibitor"
            ],
            "clinical_trial_phase_label": "Phase III",
            "disease_name": "non-small cell lung carcinoma",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00418886%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL24828"
        },
        {
            "status": "Completed",
            "count": 6,
            "drug_type": "Small molecule",
            "drug_label": "AFATINIB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 3,
            "disease_id": "EFO_0003060",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase III",
            "disease_name": "non-small cell lung carcinoma",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00656136%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT01085136%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT01523587%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT01814553%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT01953913%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT02044380%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL1173655"
        },
        {
            "status": "Completed",
            "count": 1,
            "drug_type": "Small molecule",
            "drug_label": "AFATINIB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 3,
            "disease_id": "EFO_0003869",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase III",
            "disease_name": "breast neoplasm",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT01125566%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL1173655"
        },
        {
            "status": "Completed",
            "count": 1,
            "drug_type": "Antibody",
            "drug_label": "CETUXIMAB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 3,
            "disease_id": "EFO_0000178",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase III",
            "disease_name": "gastric carcinoma",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00678535%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL1201577"
        },
        {
            "status": "Completed",
            "count": 3,
            "drug_type": "Antibody",
            "drug_label": "CETUXIMAB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 3,
            "disease_id": "EFO_0000181",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase III",
            "disease_name": "head and neck squamous cell carcinoma",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT01012258%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT01086826%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT01177956%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL1201577"
        },
        {
            "status": "Completed",
            "count": 1,
            "drug_type": "Antibody",
            "drug_label": "CETUXIMAB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 3,
            "disease_id": "EFO_0000365",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase III",
            "disease_name": "colorectal adenocarcinoma",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00079274%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL1201577"
        },
        {
            "status": "Completed",
            "count": 1,
            "drug_type": "Antibody",
            "drug_label": "CETUXIMAB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 3,
            "disease_id": "EFO_0002618",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase III",
            "disease_name": "pancreatic carcinoma",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00075686%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL1201577"
        },
        {
            "status": "Completed",
            "count": 4,
            "drug_type": "Antibody",
            "drug_label": "CETUXIMAB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 3,
            "disease_id": "EFO_0003060",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase III",
            "disease_name": "non-small cell lung carcinoma",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00095199%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00112294%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00148798%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00820755%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL1201577"
        },
        {
            "status": "Completed",
            "count": 3,
            "drug_type": "Antibody",
            "drug_label": "CETUXIMAB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 3,
            "disease_id": "EFO_0006859",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase III",
            "disease_name": "head and neck malignant neoplasia",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00003809%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00122460%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT01228565%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL1201577"
        },
        {
            "status": "Completed",
            "count": 7,
            "drug_type": "Antibody",
            "drug_label": "CETUXIMAB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 3,
            "disease_id": "EFO_1001480",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase III",
            "disease_name": "metastatic colorectal cancer",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00145314%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00154102%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00252564%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT01001377%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT01030042%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT01228734%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT01878422%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL1201577"
        },
        {
            "status": "Completed",
            "count": 7,
            "drug_type": "Antibody",
            "drug_label": "CETUXIMAB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 3,
            "disease_id": "EFO_1001951",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase III",
            "disease_name": "colorectal carcinoma",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00061815%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00063141%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00079066%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00208546%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00265811%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00640471%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT03362684%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL1201577"
        },
        {
            "status": "Completed",
            "count": 2,
            "drug_type": "Small molecule",
            "drug_label": "DACOMITINIB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 3,
            "disease_id": "EFO_0001071",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor",
                "Epidermal growth factor receptor inhibitor"
            ],
            "clinical_trial_phase_label": "Phase III",
            "disease_name": "lung carcinoma",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT01000025%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT01000025%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL2110732"
        },
        {
            "status": "Completed",
            "count": 2,
            "drug_type": "Small molecule",
            "drug_label": "DACOMITINIB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 3,
            "disease_id": "EFO_0003060",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor",
                "Epidermal growth factor receptor inhibitor"
            ],
            "clinical_trial_phase_label": "Phase III",
            "disease_name": "non-small cell lung carcinoma",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT01360554%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT01360554%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL2110732"
        },
        {
            "status": "Completed",
            "count": 1,
            "drug_type": "Small molecule",
            "drug_label": "ERLOTINIB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 3,
            "disease_id": "EFO_0000181",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase III",
            "disease_name": "head and neck squamous cell carcinoma",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00442455%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL553"
        },
        {
            "status": "Completed",
            "count": 1,
            "drug_type": "Small molecule",
            "drug_label": "ERLOTINIB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 3,
            "disease_id": "EFO_0000182",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase III",
            "disease_name": "hepatocellular carcinoma",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00901901%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL553"
        },
        {
            "status": "Completed",
            "count": 1,
            "drug_type": "Small molecule",
            "drug_label": "ERLOTINIB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 3,
            "disease_id": "EFO_0000313",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase III",
            "disease_name": "carcinoma",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT01149122%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL553"
        },
        {
            "status": "Completed",
            "count": 2,
            "drug_type": "Small molecule",
            "drug_label": "ERLOTINIB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 3,
            "disease_id": "EFO_0000616",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase III",
            "disease_name": "neoplasm",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT01024413%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT02488330%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL553"
        },
        {
            "status": "Completed",
            "count": 2,
            "drug_type": "Small molecule",
            "drug_label": "ERLOTINIB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 3,
            "disease_id": "EFO_0001071",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase III",
            "disease_name": "lung carcinoma",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00047736%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00275132%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL553"
        },
        {
            "status": "Completed",
            "count": 1,
            "drug_type": "Small molecule",
            "drug_label": "ERLOTINIB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 3,
            "disease_id": "EFO_0001075",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase III",
            "disease_name": "ovarian carcinoma",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00263822%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL553"
        },
        {
            "status": "Completed",
            "count": 4,
            "drug_type": "Small molecule",
            "drug_label": "ERLOTINIB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 3,
            "disease_id": "EFO_0002618",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase III",
            "disease_name": "pancreatic carcinoma",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00026338%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00040183%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00634725%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT02694536%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL553"
        },
        {
            "status": "Completed",
            "count": 28,
            "drug_type": "Small molecule",
            "drug_label": "ERLOTINIB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 3,
            "disease_id": "EFO_0003060",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase III",
            "disease_name": "non-small cell lung carcinoma",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00036647%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00091663%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00153803%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00257608%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00300586%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00349219%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00364351%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00373425%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00440414%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00446225%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00457392%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00556322%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00556712%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00718315%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00874419%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00883779%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT01183858%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT01244191%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT01328951%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT01342965%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT01351415%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT01360554%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT01456325%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT01523587%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT01652469%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT01667562%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT01887886%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT02031744%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL553"
        },
        {
            "status": "Completed",
            "count": 1,
            "drug_type": "Small molecule",
            "drug_label": "ERLOTINIB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 3,
            "disease_id": "EFO_0003868",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase III",
            "disease_name": "mouth neoplasm",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00402779%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL553"
        },
        {
            "status": "Completed",
            "count": 1,
            "drug_type": "Small molecule",
            "drug_label": "ERLOTINIB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 3,
            "disease_id": "EFO_1000251",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase III",
            "disease_name": "Fallopian Tube Carcinoma",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00263822%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL553"
        },
        {
            "status": "Completed",
            "count": 1,
            "drug_type": "Small molecule",
            "drug_label": "ERLOTINIB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 3,
            "disease_id": "EFO_1001100",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase III",
            "disease_name": "peritoneal neoplasm",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00263822%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL553"
        },
        {
            "status": "Completed",
            "count": 1,
            "drug_type": "Small molecule",
            "drug_label": "ERLOTINIB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 3,
            "disease_id": "EFO_1001480",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase III",
            "disease_name": "metastatic colorectal cancer",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00598156%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL553"
        },
        {
            "status": "Completed",
            "count": 2,
            "drug_type": "Small molecule",
            "drug_label": "ERLOTINIB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 3,
            "disease_id": "EFO_1001951",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase III",
            "disease_name": "colorectal carcinoma",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00265824%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT01229813%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL553"
        },
        {
            "status": "Completed",
            "count": 1,
            "drug_type": "Small molecule",
            "drug_label": "GEFITINIB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 3,
            "disease_id": "EFO_0000181",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase III",
            "disease_name": "head and neck squamous cell carcinoma",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00206219%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL939"
        },
        {
            "status": "Completed",
            "count": 1,
            "drug_type": "Small molecule",
            "drug_label": "GEFITINIB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 3,
            "disease_id": "EFO_0000305",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase III",
            "disease_name": "breast carcinoma",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00357734%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL939"
        },
        {
            "status": "Completed",
            "count": 1,
            "drug_type": "Small molecule",
            "drug_label": "GEFITINIB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 3,
            "disease_id": "EFO_0000311",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase III",
            "disease_name": "cancer",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00635973%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL939"
        },
        {
            "status": "Completed",
            "count": 1,
            "drug_type": "Small molecule",
            "drug_label": "GEFITINIB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 3,
            "disease_id": "EFO_0000571",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase III",
            "disease_name": "lung adenocarcinoma",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00020709%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL939"
        },
        {
            "status": "Completed",
            "count": 1,
            "drug_type": "Small molecule",
            "drug_label": "GEFITINIB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 3,
            "disease_id": "EFO_0000616",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase III",
            "disease_name": "neoplasm",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT01024413%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL939"
        },
        {
            "status": "Completed",
            "count": 1,
            "drug_type": "Small molecule",
            "drug_label": "GEFITINIB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 3,
            "disease_id": "EFO_0000708",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase III",
            "disease_name": "squamous cell lung carcinoma",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00020709%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL939"
        },
        {
            "status": "Completed",
            "count": 3,
            "drug_type": "Small molecule",
            "drug_label": "GEFITINIB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 3,
            "disease_id": "EFO_0001071",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase III",
            "disease_name": "lung carcinoma",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00144066%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00357734%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00455936%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL939"
        },
        {
            "status": "Completed",
            "count": 13,
            "drug_type": "Small molecule",
            "drug_label": "GEFITINIB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 3,
            "disease_id": "EFO_0003060",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase III",
            "disease_name": "non-small cell lung carcinoma",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00020709%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00034879%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00076388%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00080340%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00242801%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00252707%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00322452%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00478049%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00683306%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00807066%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT01017874%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT01040780%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT01404260%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL939"
        },
        {
            "status": "Completed",
            "count": 3,
            "drug_type": "Small molecule",
            "drug_label": "LAPATINIB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 3,
            "disease_id": "EFO_0000305",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase III",
            "disease_name": "breast carcinoma",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00078572%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00567554%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00829166%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL554"
        },
        {
            "status": "Completed",
            "count": 1,
            "drug_type": "Small molecule",
            "drug_label": "LAPATINIB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 3,
            "disease_id": "EFO_0000311",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase III",
            "disease_name": "cancer",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00968968%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL554"
        },
        {
            "status": "Completed",
            "count": 1,
            "drug_type": "Small molecule",
            "drug_label": "LAPATINIB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 3,
            "disease_id": "EFO_0000616",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase III",
            "disease_name": "neoplasm",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00486954%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL554"
        },
        {
            "status": "Completed",
            "count": 4,
            "drug_type": "Small molecule",
            "drug_label": "LAPATINIB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 3,
            "disease_id": "EFO_0003869",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase III",
            "disease_name": "breast neoplasm",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00073528%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00075270%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00320385%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00374322%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL554"
        },
        {
            "status": "Completed",
            "count": 1,
            "drug_type": "Small molecule",
            "drug_label": "LAPATINIB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 3,
            "disease_id": "EFO_0005774",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase III",
            "disease_name": "brain disease",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00820222%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL554"
        },
        {
            "status": "Completed",
            "count": 1,
            "drug_type": "Small molecule",
            "drug_label": "LAPATINIB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 3,
            "disease_id": "EFO_0005950",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase III",
            "disease_name": "head and neck neoplasia",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00424255%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL554"
        },
        {
            "status": "Completed",
            "count": 1,
            "drug_type": "Antibody",
            "drug_label": "NIMOTUZUMAB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 3,
            "disease_id": "EFO_0000519",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase III",
            "disease_name": "glioblastoma multiforme",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00753246%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL2108359"
        },
        {
            "status": "Completed",
            "count": 1,
            "drug_type": "Antibody",
            "drug_label": "NIMOTUZUMAB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 3,
            "disease_id": "EFO_0001061",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase III",
            "disease_name": "cervical carcinoma",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT02083211%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL2108359"
        },
        {
            "status": "Completed",
            "count": 2,
            "drug_type": "Small molecule",
            "drug_label": "OSIMERTINIB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 3,
            "disease_id": "EFO_0001071",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor",
                "Epidermal growth factor receptor inhibitor"
            ],
            "clinical_trial_phase_label": "Phase III",
            "disease_name": "lung carcinoma",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT02997501%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT02997501%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL3353410"
        },
        {
            "status": "Completed",
            "count": 1,
            "drug_type": "Antibody",
            "drug_label": "PANITUMUMAB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 3,
            "disease_id": "EFO_0006859",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase III",
            "disease_name": "head and neck malignant neoplasia",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00820248%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL1201827"
        },
        {
            "status": "Completed",
            "count": 4,
            "drug_type": "Antibody",
            "drug_label": "PANITUMUMAB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 3,
            "disease_id": "EFO_1001480",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase III",
            "disease_name": "metastatic colorectal cancer",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00339183%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00364013%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT01001377%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT01412957%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL1201827"
        },
        {
            "status": "Completed",
            "count": 2,
            "drug_type": "Antibody",
            "drug_label": "PANITUMUMAB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 3,
            "disease_id": "EFO_1001951",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase III",
            "disease_name": "colorectal carcinoma",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00113763%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00115765%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL1201827"
        },
        {
            "status": "Completed",
            "count": 3,
            "drug_type": "Small molecule",
            "drug_label": "VANDETANIB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 3,
            "disease_id": "EFO_0003060",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor inhibitor"
            ],
            "clinical_trial_phase_label": "Phase III",
            "disease_name": "non-small cell lung carcinoma",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00312377%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00364351%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00404924%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL24828"
        },
        {
            "status": "Completed",
            "count": 1,
            "drug_type": "Antibody",
            "drug_label": "ZALUTUMUMAB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 3,
            "disease_id": "EFO_0000707",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 antagonist"
            ],
            "clinical_trial_phase_label": "Phase III",
            "disease_name": "squamous cell carcinoma",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00382031%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL2107861"
        },
        {
            "status": "Completed",
            "count": 2,
            "drug_type": "Antibody",
            "drug_label": "ZALUTUMUMAB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 3,
            "disease_id": "EFO_0006859",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 antagonist"
            ],
            "clinical_trial_phase_label": "Phase III",
            "disease_name": "head and neck malignant neoplasia",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00382031%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00496652%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL2107861"
        },
        {
            "status": "Enrolling by invitation",
            "count": 1,
            "drug_type": "Small molecule",
            "drug_label": "GEFITINIB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 3,
            "disease_id": "EFO_0000311",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase III",
            "disease_name": "cancer",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT02929693%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL939"
        },
        {
            "status": "Not yet recruiting",
            "count": 1,
            "drug_type": "Small molecule",
            "drug_label": "BRIGATINIB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 3,
            "disease_id": "EFO_0003060",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase III",
            "disease_name": "non-small cell lung carcinoma",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT03596866%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL3545311"
        },
        {
            "status": "Not yet recruiting",
            "count": 2,
            "drug_type": "Small molecule",
            "drug_label": "GEFITINIB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 3,
            "disease_id": "EFO_0003060",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase III",
            "disease_name": "non-small cell lung carcinoma",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT03787992%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT03856697%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL939"
        },
        {
            "status": "Not yet recruiting",
            "count": 1,
            "drug_type": "Small molecule",
            "drug_label": "LAPATINIB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 3,
            "disease_id": "EFO_1001968",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase III",
            "disease_name": "soft tissue sarcoma",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT03784014%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL554"
        },
        {
            "status": "Not yet recruiting",
            "count": 1,
            "drug_type": "Small molecule",
            "drug_label": "PYROTINIB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 3,
            "disease_id": "EFO_0000305",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase III",
            "disease_name": "breast carcinoma",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT03863223%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL3544956"
        },
        {
            "status": "Recruiting",
            "count": 1,
            "drug_type": "Antibody",
            "drug_label": "CETUXIMAB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 3,
            "disease_id": "EFO_0004252",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase III",
            "disease_name": "nasopharyngeal neoplasm",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT02633176%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL1201577"
        },
        {
            "status": "Recruiting",
            "count": 3,
            "drug_type": "Antibody",
            "drug_label": "CETUXIMAB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 3,
            "disease_id": "EFO_1001480",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase III",
            "disease_name": "metastatic colorectal cancer",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT01910610%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT02934529%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT03391934%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL1201577"
        },
        {
            "status": "Recruiting",
            "count": 1,
            "drug_type": "Antibody",
            "drug_label": "DEPATUXIZUMAB MAFODOTIN",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 3,
            "disease_id": "EFO_0000519",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 binding agent"
            ],
            "clinical_trial_phase_label": "Phase III",
            "disease_name": "glioblastoma multiforme",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT03419403%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "up_or_down",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL3707277"
        },
        {
            "status": "Recruiting",
            "count": 4,
            "drug_type": "Small molecule",
            "drug_label": "ERLOTINIB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 3,
            "disease_id": "EFO_0003060",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase III",
            "disease_name": "non-small cell lung carcinoma",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT02193282%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT02633189%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT02882984%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT02893332%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL553"
        },
        {
            "status": "Recruiting",
            "count": 1,
            "drug_type": "Small molecule",
            "drug_label": "GEFITINIB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 3,
            "disease_id": "EFO_0001071",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase III",
            "disease_name": "lung carcinoma",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT02518802%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL939"
        },
        {
            "status": "Recruiting",
            "count": 6,
            "drug_type": "Small molecule",
            "drug_label": "GEFITINIB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 3,
            "disease_id": "EFO_0003060",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase III",
            "disease_name": "non-small cell lung carcinoma",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT02824458%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT02882984%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT02893332%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT03381066%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT03656393%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT03849768%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL939"
        },
        {
            "status": "Recruiting",
            "count": 3,
            "drug_type": "Small molecule",
            "drug_label": "LAPATINIB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 3,
            "disease_id": "EFO_0000305",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase III",
            "disease_name": "breast carcinoma",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT01619111%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT03080805%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT03523585%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL554"
        },
        {
            "status": "Recruiting",
            "count": 1,
            "drug_type": "Antibody",
            "drug_label": "NIMOTUZUMAB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 3,
            "disease_id": "EFO_0000707",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase III",
            "disease_name": "squamous cell carcinoma",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00957086%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL2108359"
        },
        {
            "status": "Recruiting",
            "count": 1,
            "drug_type": "Antibody",
            "drug_label": "NIMOTUZUMAB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 3,
            "disease_id": "EFO_0001061",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase III",
            "disease_name": "cervical carcinoma",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT03413579%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL2108359"
        },
        {
            "status": "Recruiting",
            "count": 1,
            "drug_type": "Antibody",
            "drug_label": "NIMOTUZUMAB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 3,
            "disease_id": "EFO_0005922",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase III",
            "disease_name": "esophageal squamous cell carcinoma",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT02611700%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL2108359"
        },
        {
            "status": "Recruiting",
            "count": 2,
            "drug_type": "Small molecule",
            "drug_label": "OSIMERTINIB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 3,
            "disease_id": "EFO_0003060",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor",
                "Epidermal growth factor receptor inhibitor"
            ],
            "clinical_trial_phase_label": "Phase III",
            "disease_name": "non-small cell lung carcinoma",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT03521154%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT03521154%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL3353410"
        },
        {
            "status": "Recruiting",
            "count": 1,
            "drug_type": "Antibody",
            "drug_label": "PANITUMUMAB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 3,
            "disease_id": "EFO_0004142",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase III",
            "disease_name": "colorectal neoplasm",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT02885753%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL1201827"
        },
        {
            "status": "Recruiting",
            "count": 2,
            "drug_type": "Antibody",
            "drug_label": "PANITUMUMAB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 3,
            "disease_id": "EFO_1001480",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase III",
            "disease_name": "metastatic colorectal cancer",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT01910610%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT03231722%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL1201827"
        },
        {
            "status": "Recruiting",
            "count": 1,
            "drug_type": "Antibody",
            "drug_label": "PANITUMUMAB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 3,
            "disease_id": "EFO_1001951",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase III",
            "disease_name": "colorectal carcinoma",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT03635021%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL1201827"
        },
        {
            "status": "Recruiting",
            "count": 2,
            "drug_type": "Small molecule",
            "drug_label": "PYROTINIB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 3,
            "disease_id": "EFO_0000305",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase III",
            "disease_name": "breast carcinoma",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT03080805%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT03588091%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL3544956"
        },
        {
            "status": "Suspended",
            "count": 1,
            "drug_type": "Small molecule",
            "drug_label": "ERLOTINIB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 3,
            "disease_id": "EFO_0003060",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase III",
            "disease_name": "non-small cell lung carcinoma",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT02775006%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL553"
        },
        {
            "status": "Suspended",
            "count": 1,
            "drug_type": "Antibody",
            "drug_label": "NECITUMUMAB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 3,
            "disease_id": "EFO_0003060",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase III",
            "disease_name": "non-small cell lung carcinoma",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00982111%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL1743047"
        },
        {
            "status": "Terminated",
            "count": 2,
            "drug_type": "Small molecule",
            "drug_label": "AFATINIB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 3,
            "disease_id": "EFO_0004284",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase III",
            "disease_name": "upper aerodigestive tract neoplasm",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT01345669%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT02131155%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL1173655"
        },
        {
            "status": "Terminated",
            "count": 2,
            "drug_type": "Antibody",
            "drug_label": "CETUXIMAB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 3,
            "disease_id": "EFO_0006859",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase III",
            "disease_name": "head and neck malignant neoplasia",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00004227%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT03386838%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL1201577"
        },
        {
            "status": "Terminated",
            "count": 2,
            "drug_type": "Antibody",
            "drug_label": "CETUXIMAB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 3,
            "disease_id": "EFO_1001951",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase III",
            "disease_name": "colorectal carcinoma",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00077233%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT01309126%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL1201577"
        },
        {
            "status": "Terminated",
            "count": 1,
            "drug_type": "Small molecule",
            "drug_label": "ERLOTINIB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 3,
            "disease_id": "EFO_0000707",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase III",
            "disease_name": "squamous cell carcinoma",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00673049%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL553"
        },
        {
            "status": "Terminated",
            "count": 1,
            "drug_type": "Small molecule",
            "drug_label": "ERLOTINIB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 3,
            "disease_id": "EFO_0003050",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase III",
            "disease_name": "large cell lung carcinoma",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00673049%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL553"
        },
        {
            "status": "Terminated",
            "count": 7,
            "drug_type": "Small molecule",
            "drug_label": "ERLOTINIB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 3,
            "disease_id": "EFO_0003060",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase III",
            "disease_name": "non-small cell lung carcinoma",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00673049%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00738881%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT01377376%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT01487174%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT02134015%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT02178397%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT02588261%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL553"
        },
        {
            "status": "Terminated",
            "count": 1,
            "drug_type": "Small molecule",
            "drug_label": "ERLOTINIB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 3,
            "disease_id": "EFO_0006859",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase III",
            "disease_name": "head and neck malignant neoplasia",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00412217%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL553"
        },
        {
            "status": "Terminated",
            "count": 1,
            "drug_type": "Small molecule",
            "drug_label": "GEFITINIB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 3,
            "disease_id": "EFO_0000292",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase III",
            "disease_name": "bladder carcinoma",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00352079%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL939"
        },
        {
            "status": "Terminated",
            "count": 1,
            "drug_type": "Small molecule",
            "drug_label": "GEFITINIB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 3,
            "disease_id": "EFO_0001071",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase III",
            "disease_name": "lung carcinoma",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00091156%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL939"
        },
        {
            "status": "Terminated",
            "count": 2,
            "drug_type": "Small molecule",
            "drug_label": "GEFITINIB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 3,
            "disease_id": "EFO_0003060",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase III",
            "disease_name": "non-small cell lung carcinoma",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00234468%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT02588261%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL939"
        },
        {
            "status": "Terminated",
            "count": 1,
            "drug_type": "Small molecule",
            "drug_label": "GEFITINIB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 3,
            "disease_id": "EFO_0006859",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase III",
            "disease_name": "head and neck malignant neoplasia",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00088907%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL939"
        },
        {
            "status": "Terminated",
            "count": 1,
            "drug_type": "Antibody",
            "drug_label": "PANITUMUMAB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 3,
            "disease_id": "EFO_0000707",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase III",
            "disease_name": "squamous cell carcinoma",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT01627379%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL1201827"
        },
        {
            "status": "Terminated",
            "count": 1,
            "drug_type": "Small molecule",
            "drug_label": "ROCILETINIB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 3,
            "disease_id": "EFO_0003060",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase III",
            "disease_name": "non-small cell lung carcinoma",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT02322281%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL3545308"
        },
        {
            "status": "Unknown status",
            "count": 3,
            "drug_type": "Antibody",
            "drug_label": "CETUXIMAB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 3,
            "disease_id": "EFO_1001951",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase III",
            "disease_name": "colorectal carcinoma",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00182715%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00265850%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT01167725%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL1201577"
        },
        {
            "status": "Unknown status",
            "count": 1,
            "drug_type": "Small molecule",
            "drug_label": "ERLOTINIB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 3,
            "disease_id": "EFO_0000311",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase III",
            "disease_name": "cancer",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT02889692%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL553"
        },
        {
            "status": "Unknown status",
            "count": 1,
            "drug_type": "Small molecule",
            "drug_label": "ERLOTINIB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 3,
            "disease_id": "EFO_0000707",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase III",
            "disease_name": "squamous cell carcinoma",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT01752205%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL553"
        },
        {
            "status": "Unknown status",
            "count": 2,
            "drug_type": "Small molecule",
            "drug_label": "ERLOTINIB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 3,
            "disease_id": "EFO_0001071",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase III",
            "disease_name": "lung carcinoma",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00955695%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00989690%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL553"
        },
        {
            "status": "Unknown status",
            "count": 1,
            "drug_type": "Small molecule",
            "drug_label": "ERLOTINIB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 3,
            "disease_id": "EFO_0002618",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase III",
            "disease_name": "pancreatic carcinoma",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00440167%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL553"
        },
        {
            "status": "Unknown status",
            "count": 1,
            "drug_type": "Small molecule",
            "drug_label": "ERLOTINIB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 3,
            "disease_id": "EFO_0002916",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase III",
            "disease_name": "esophageal carcinoma",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00686114%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL553"
        },
        {
            "status": "Unknown status",
            "count": 4,
            "drug_type": "Small molecule",
            "drug_label": "ERLOTINIB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 3,
            "disease_id": "EFO_0003060",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase III",
            "disease_name": "non-small cell lung carcinoma",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00637910%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT01158170%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT02001896%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT02140333%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL553"
        },
        {
            "status": "Unknown status",
            "count": 1,
            "drug_type": "Small molecule",
            "drug_label": "GEFITINIB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 3,
            "disease_id": "EFO_0000311",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase III",
            "disease_name": "cancer",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT02889692%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL939"
        },
        {
            "status": "Unknown status",
            "count": 3,
            "drug_type": "Small molecule",
            "drug_label": "GEFITINIB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 3,
            "disease_id": "EFO_0001071",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase III",
            "disease_name": "lung carcinoma",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00006048%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00006049%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00955695%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL939"
        },
        {
            "status": "Unknown status",
            "count": 2,
            "drug_type": "Small molecule",
            "drug_label": "GEFITINIB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 3,
            "disease_id": "EFO_0003060",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase III",
            "disease_name": "non-small cell lung carcinoma",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT01066195%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT01158170%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL939"
        },
        {
            "status": "Unknown status",
            "count": 3,
            "drug_type": "Small molecule",
            "drug_label": "LAPATINIB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 3,
            "disease_id": "EFO_0000305",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase III",
            "disease_name": "breast carcinoma",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00486668%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00688194%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT02394496%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL554"
        },
        {
            "status": "Unknown status",
            "count": 1,
            "drug_type": "Antibody",
            "drug_label": "NIMOTUZUMAB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 3,
            "disease_id": "EFO_0002618",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase III",
            "disease_name": "pancreatic carcinoma",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT02395016%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL2108359"
        },
        {
            "status": "Unknown status",
            "count": 2,
            "drug_type": "Antibody",
            "drug_label": "NIMOTUZUMAB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 3,
            "disease_id": "EFO_0004252",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase III",
            "disease_name": "nasopharyngeal neoplasm",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT01074021%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT02012062%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL2108359"
        },
        {
            "status": "Unknown status",
            "count": 1,
            "drug_type": "Antibody",
            "drug_label": "PANITUMUMAB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 3,
            "disease_id": "EFO_0008528",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase III",
            "disease_name": "urothelial carcinoma",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT02818725%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL1201827"
        },
        {
            "status": "Unknown status",
            "count": 1,
            "drug_type": "Antibody",
            "drug_label": "PANITUMUMAB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 3,
            "disease_id": "EFO_1001951",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase III",
            "disease_name": "colorectal carcinoma",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00389870%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL1201827"
        },
        {
            "status": "Withdrawn",
            "count": 1,
            "drug_type": "Antibody",
            "drug_label": "CETUXIMAB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 3,
            "disease_id": "EFO_0006859",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase III",
            "disease_name": "head and neck malignant neoplasia",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT03342352%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL1201577"
        },
        {
            "status": "Withdrawn",
            "count": 1,
            "drug_type": "Antibody",
            "drug_label": "CETUXIMAB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 3,
            "disease_id": "EFO_1001951",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase III",
            "disease_name": "colorectal carcinoma",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT01338558%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL1201577"
        },
        {
            "status": "Withdrawn",
            "count": 2,
            "drug_type": "Small molecule",
            "drug_label": "ERLOTINIB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 3,
            "disease_id": "EFO_0003060",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase III",
            "disease_name": "non-small cell lung carcinoma",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT02795884%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT03529084%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL553"
        },
        {
            "status": "Withdrawn",
            "count": 2,
            "drug_type": "Small molecule",
            "drug_label": "GEFITINIB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 3,
            "disease_id": "EFO_0003060",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase III",
            "disease_name": "non-small cell lung carcinoma",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00090675%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT03529084%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL939"
        },
        {
            "status": "Withdrawn",
            "count": 1,
            "drug_type": "Antibody",
            "drug_label": "PANITUMUMAB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 3,
            "disease_id": "EFO_0006859",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase III",
            "disease_name": "head and neck malignant neoplasia",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT01142414%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL1201827"
        },
        {
            "status": "Active, not recruiting",
            "count": 1,
            "drug_type": "Small molecule",
            "drug_label": "AFATINIB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 4,
            "disease_id": "EFO_0003060",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase IV",
            "disease_name": "non-small cell lung carcinoma",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT02514174%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL1173655"
        },
        {
            "status": "Active, not recruiting",
            "count": 1,
            "drug_type": "Small molecule",
            "drug_label": "LAPATINIB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 4,
            "disease_id": "EFO_0003869",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase IV",
            "disease_name": "breast neoplasm",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00338247%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL554"
        },
        {
            "status": "Active, not recruiting",
            "count": 1,
            "drug_type": "Small molecule",
            "drug_label": "VANDETANIB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 4,
            "disease_id": "EFO_0002892",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor inhibitor"
            ],
            "clinical_trial_phase_label": "Phase IV",
            "disease_name": "thyroid carcinoma",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT01496313%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL24828"
        },
        {
            "status": "Completed",
            "count": 1,
            "drug_type": "Small molecule",
            "drug_label": "AFATINIB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 4,
            "disease_id": "EFO_0003060",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase IV",
            "disease_name": "non-small cell lung carcinoma",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT02208843%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL1173655"
        },
        {
            "status": "Completed",
            "count": 7,
            "drug_type": "Small molecule",
            "drug_label": "ERLOTINIB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 4,
            "disease_id": "EFO_0003060",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase IV",
            "disease_name": "non-small cell lung carcinoma",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00949910%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT01066884%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT01196078%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT01230710%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT01287754%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT01609543%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT02000531%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL553"
        },
        {
            "status": "Completed",
            "count": 3,
            "drug_type": "Small molecule",
            "drug_label": "GEFITINIB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 4,
            "disease_id": "EFO_0003060",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase IV",
            "disease_name": "non-small cell lung carcinoma",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00608868%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00770588%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT01203917%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL939"
        },
        {
            "status": "Completed",
            "count": 1,
            "drug_type": "Small molecule",
            "drug_label": "LAPATINIB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 4,
            "disease_id": "EFO_0000311",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase IV",
            "disease_name": "cancer",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT01328054%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL554"
        },
        {
            "status": "Not yet recruiting",
            "count": 1,
            "drug_type": "Small molecule",
            "drug_label": "GEFITINIB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 4,
            "disease_id": "EFO_0003060",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase IV",
            "disease_name": "non-small cell lung carcinoma",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT03264794%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL939"
        },
        {
            "status": "Not yet recruiting",
            "count": 1,
            "drug_type": "Antibody",
            "drug_label": "NIMOTUZUMAB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 4,
            "disease_id": "EFO_0002618",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase IV",
            "disease_name": "pancreatic carcinoma",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT02945267%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL2108359"
        },
        {
            "status": "Not yet recruiting",
            "count": 2,
            "drug_type": "Small molecule",
            "drug_label": "OSIMERTINIB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 4,
            "disease_id": "EFO_0003060",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor",
                "Epidermal growth factor receptor inhibitor"
            ],
            "clinical_trial_phase_label": "Phase IV",
            "disease_name": "non-small cell lung carcinoma",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT03853551%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT03853551%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL3353410"
        },
        {
            "status": "Recruiting",
            "count": 1,
            "drug_type": "Small molecule",
            "drug_label": "ERLOTINIB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 4,
            "disease_id": "EFO_0003060",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase IV",
            "disease_name": "non-small cell lung carcinoma",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT03460678%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL553"
        },
        {
            "status": "Recruiting",
            "count": 1,
            "drug_type": "Small molecule",
            "drug_label": "GEFITINIB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 4,
            "disease_id": "EFO_0003060",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase IV",
            "disease_name": "non-small cell lung carcinoma",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT02148380%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL939"
        },
        {
            "status": "Recruiting",
            "count": 1,
            "drug_type": "Antibody",
            "drug_label": "PANITUMUMAB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 4,
            "disease_id": "EFO_0000311",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase IV",
            "disease_name": "cancer",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT02301962%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL1201827"
        },
        {
            "status": "Suspended",
            "count": 1,
            "drug_type": "Small molecule",
            "drug_label": "ERLOTINIB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 4,
            "disease_id": "EFO_0003060",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase IV",
            "disease_name": "non-small cell lung carcinoma",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT01320501%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL553"
        },
        {
            "status": "Terminated",
            "count": 1,
            "drug_type": "Small molecule",
            "drug_label": "AFATINIB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 4,
            "disease_id": "EFO_0003060",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase IV",
            "disease_name": "non-small cell lung carcinoma",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT02695290%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL1173655"
        },
        {
            "status": "Terminated",
            "count": 1,
            "drug_type": "Small molecule",
            "drug_label": "ERLOTINIB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 4,
            "disease_id": "EFO_0002618",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase IV",
            "disease_name": "pancreatic carcinoma",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00642733%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL553"
        },
        {
            "status": "Terminated",
            "count": 2,
            "drug_type": "Small molecule",
            "drug_label": "GEFITINIB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 4,
            "disease_id": "EFO_0003060",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase IV",
            "disease_name": "non-small cell lung carcinoma",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT00536107%22",
                    "nice_name": "Clinical Trials Information"
                },
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT02299765%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL939"
        },
        {
            "status": "Unknown status",
            "count": 1,
            "drug_type": "Antibody",
            "drug_label": "CETUXIMAB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 4,
            "disease_id": "EFO_0004284",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase IV",
            "disease_name": "upper aerodigestive tract neoplasm",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT02015650%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL1201577"
        },
        {
            "status": "Unknown status",
            "count": 1,
            "drug_type": "Antibody",
            "drug_label": "CETUXIMAB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 4,
            "disease_id": "EFO_0006859",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase IV",
            "disease_name": "head and neck malignant neoplasia",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT01553032%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL1201577"
        },
        {
            "status": "Unknown status",
            "count": 1,
            "drug_type": "Antibody",
            "drug_label": "CETUXIMAB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 4,
            "disease_id": "EFO_1001480",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase IV",
            "disease_name": "metastatic colorectal cancer",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT01315990%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL1201577"
        },
        {
            "status": "Unknown status",
            "count": 1,
            "drug_type": "Small molecule",
            "drug_label": "ERLOTINIB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 4,
            "disease_id": "EFO_0000571",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase IV",
            "disease_name": "lung adenocarcinoma",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT02399566%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL553"
        },
        {
            "status": "Unknown status",
            "count": 1,
            "drug_type": "Small molecule",
            "drug_label": "ERLOTINIB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 4,
            "disease_id": "EFO_0003060",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase IV",
            "disease_name": "non-small cell lung carcinoma",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT02031601%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL553"
        },
        {
            "status": "Unknown status",
            "count": 1,
            "drug_type": "Small molecule",
            "drug_label": "GEFITINIB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 4,
            "disease_id": "EFO_0003060",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase IV",
            "disease_name": "non-small cell lung carcinoma",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT02031601%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL939"
        },
        {
            "status": "Unknown status",
            "count": 1,
            "drug_type": "Antibody",
            "drug_label": "NIMOTUZUMAB",
            "target_classes": [
                "Tyrosine protein kinase EGFR family"
            ],
            "target_id": "ENSG00000146648",
            "clinical_trial_phase_number": 4,
            "disease_id": "EFO_0004252",
            "mechanisms_of_action": [
                "Epidermal growth factor receptor erbB1 inhibitor"
            ],
            "clinical_trial_phase_label": "Phase IV",
            "disease_name": "nasopharyngeal neoplasm",
            "urls": [
                {
                    "url": "https://clinicaltrials.gov/search?id=%22NCT02293356%22",
                    "nice_name": "Clinical Trials Information"
                }
            ],
            "target_activity": "drug_negative_modulator",
            "target_symbol": "EGFR",
            "drug_id": "http://identifiers.org/chembl.compound/CHEMBL2108359"
        }
    ]
}